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Abstract
The cellular transcription factor E2F plays a critical role in co-ordinating 
the transcription of tai’get genes necessary for cell cycle progression. E2F 
interacts with important regulators of the cell cycle, such as the Rb tumour 
suppressor protein, related proteins p i07 and p i30 and cyclins and cyclin- 
dependent kinases. The cellular E2F activity is a heterodimer consisting of a DP 
family member, of which three members have been characterised and an E2F 
family member, of which six family members have been isolated.
Murine DP-3 differs from the other DP proteins due to striking 
complexity at the RNA level. RNA analysis has shown that extensive processing 
gives rise to four different DP-3 proteins, a , p, yD and 5. These variants arise via 
two open reading frame changes, including the insertion of the E region, a 16 
residue sequence within the DNA binding domain of DP-3 a  and 5, which forms 
part of a nuclear localisation signal. Additionally, the insertion of single 
glutamine codon has been noted in the DP-3y isoform. Extensive splicing within 
the 5’UTR of DP-3 results in translation initiation at two different methionine 
codons. Since DP-1 is the major component of the E2F DNA binding activity in 
mammalian cells and the role of DP-3 remains unclear, the aim of this study was 
to investigate the expression of DP-3 at the RNA and protein level, in an attempt 
to understand the role of DP-3 in the E2F heterodimer.
In an effort to understand the post-transcriptional control of DP-3, the 
murine DP-3 gene was isolated. Analysis of the exon/intron arrangement of the 
DP-3 gene and comparison of the DP-3 genomic and cDNA sequences provided 
insight into the post-transeriptional regulation of DP-3, in particular at sites such 
as the E region. Additionally, comparison with the murine DP-1 gene revealed 
striking conservation in genomic organisation, suggesting that they are 
ancestrally related.
Analysis of DP-3 RNA via Northern blotting was performed to study the 
expression pattern of the different DP-3 RNAs. A range of different mouse 
tissues and tissue cultui'e cell lines were tested for the presence of DP-3 RNA 
and DP-3 RNA abundance was analysed during cellular processes such as 
differentiation.
An investigation into the effects of the different DP-3 5’UTRs on 
translational regulation of DP-3 protein expression was performed using 
chimeric DP-3 5’UTR-luciferase reporter constructs. The translational potential 
of each 5’UTR was analysed by transient transfection in a range of mammalian 
cells and was found to be different for each 5’UTR. The translational ability of 
each 5’UTR was also analysed in vitro. The effect of the tumour suppressor p53 
on the translational ability of the DP-3 5’UTRs was also assessed. p53 is known 
to influence the translation of both its own RNA and that of cdk4. Analysis 
suggested that p53 might influence the translation of specific DP-3 isoforms.
To aid the detection of DP-3 protein, anti-peptide polyclonal antibodies 
were made. These were used to study DP-3 expression by western blotting in a 
range of different mammalian cells and by immunostaining.
These results imply that the expression of DP-3 is highly regulated at the 
post-transcriptional level. Although a definite role for DP-3 in E2F mediated 
processes has yet to be assigned, these results provide insight into the control of 
DP-3 expression, which may ultimately be linked to the role of DP-3 in cells.
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Chapter 1 
Introduction
The regulation of gene expression
The phenotype of a cell is dependent on the natnie of the genes expressed. 
Gene expression is controlled at a variety of levels, including transcription, 
messenger RNA processing, translation and protein modification and finally at the 
level of protein turnover.
1.1 Transcription
Transcription in eukaryotes is mediated hy three RNA polymerases (pol I, II 
and III), which transcribe three classes of genes. RNA pol I transcribes ribosomal 
RNAs (rRNA) whereas pol III transcribes transfer RNA and small nuclear RNA 
(snRNA). RNA pol II is responsible for the transcription of protein coding genes and 
will be discussed in the most detail.
1.1.1 RNA polymerase II basal transcription.
Transcription by RNA pol II is influenced by tlii'ce types of transcription 
factor; basal factors, DNA binding trans-aoXmg factors and coactivators. Initially 
basal transcription factors were identified termed, TFIIA, TFIIB, TFIID, TFIIE, 
TFIIH and TFIIF, which were necessary for basal transcription from TATA 
containing promoters (Zawel and Reinberg, 1993). Basal transcription factors have 
been shown to assemble on the TATA box in a sequential manner to initiate 
transcription (Figure 1.1). Thus, TFIID initially hinds directly to the TATA box, and 
under certain conditions this is stimulated hy TFIIA (Buratowski et al., 1989, 
Reinberg, 1996). However, in certain cases TFIIA is dispensable for basal 
transcription. Once TFIID has bound the TATA box, TFIIB binds and recruits RNA 
pol II to the complex, which is followed by the association TFIIE and TFIIH 
(summarised in Figure 1.1; Buratowski et al., 1989). Additional factors for basal 
transcription have also been identified for example; TFIIF may stimulate binding of 
pol II to TFIIB (Tschochner et al., 1992; Ha et al., 1993). Additionally, TFIIJ can 
bind to the final complex to form a fully primed pre-initiation complex, although 
ATP is required for transcription to begin (Reinberg, 1996).
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1.1.2 Transcription from TATA-less promoters
Not all polymerase II transcribed genes contain a TATA element, although 
TFIID is still required for transcriptional initiation (Pugh and Tijan, 1991). Several 
models have heen proposed to explain how transcription is initiated from these 
promoters. A novel sequence originally identified in the terminal 
deoxynucleotidyltransferase (TdT) promoter, termed an initiator element (Im*), was 
shown to be necessary to direct transcription (Smale and Baltimore, 1989). 
Subsequently many Im' elements have been Identified which fall into different 
families, but these elements are also found in TATA containing promoters (Zawel 
and Reinberg, 1993). It has been suggested that Pol II directs the assembly of a pre­
initiation complex though interacting weakly with Inr elements.
1.1.3 TFIID
The TFIID basal transcription factor is composed of several subunits; the 
TATA binding protein TBP and several TBP-associated factors (TAFs, Figure 1.1). 
TBP plays a role in transcription for all RNA polymerases and may also regulate 
transcription from TATA-less promoters.
TBP alone can only mediate basal levels of transcription, although when 
associated with TAFs, activated transcription can he induced by trans-diCXmg 
transcription factors (Hoey et a l, 1993). Originally TAFs were thought to act as 
“bridges” between ^rawj-acting factors and the basal machinery (Goodrich and 
Tjian, 1994). Further analysis has revealed that several TAFs are in fact structurally 
related to histones H2B, H3 and H4 (Burley and Roeder, 1996) suggesting a 
possible role for TAFs in modulating chromatin. Furthermore, TAFn250 has heen 
shown to possess histone acetyl-transferase (FIAT) activity (Mizzen et al., 1996). 
Histone acétylation is believed to be an important step in the generation of 
transcriptionally active chromatin and the regulation of chromatin structure is an 
important mechanism for regulating transcription (Grunstein, 1997).
1.1.4 Trans-^ciing factors for RNA polymerase II
Transcription factors that activate transcription consist of a heterogeneous 
group of proteins that can be cell type specific or ubiquitously expressed. They are 
usually modular in structure and can be separated into at least two domains; a DNA
18
binding domain and a transcriptional activation domain (Mitchell and Tjian, 1989). 
The DNA binding domain confers sequence specific DNA binding properties and 
usually contains basic residues that contact the DNA (Mitchell and Tjian, 1989).
Many transcription factors bind DNA as dimers through conserved 
interaction motifs. Often two different proteins bind to form heterodimeric 
transcription factors, for example AP-1, which is composed of the c-fos and c-jun 
proteins that dimerise via a leucine zipper motif (Neuberg et al., 1989). Likewise, 
the E box binding proteins E l2 and E47 dimerise via helix-loop-helix structure 
(Murre et a l,  1989).
The /‘rawi'activation domains of transcription factors can vary in structure. 
For example, Spl contains a glutamine rich region, whereas the ("rnwactivation 
domain of CTF is proline rich (Mitchell and Tjian, 1989). In general, trans-?iQ.ïm% 
factors induce transcription by binding to DNA sequences upstream of the 
transcriptional start site and contacting the basal transcription machinery (Figure 
1.2). Thus, the Spl 7m«,yactivation domain can bind to TAFul 10 part of the TFIID 
complex, and regulate transcription (Hoey et al., 1993). However, under some 
circumstances intermediate or coactivator proteins are required (Section 1.1.5; 
Figure 1.2).
1.1.5 Coactivators and the modulation of chromatin structure
A number of nuclear hormone receptors interact with the coactivator CBP 
(CREB-binding protein) and activate transcription. Other transcription factors such 
as p53 and MyoD, have been shown to use CBP or the related protein, p300 as 
coactivators of transcription (Eckner et ah, 1996; Lill et ah, 1996; Lee et ah, 1997). 
Coactivators may therefore function by aiding contact between the basal machinery 
and trans-diCXmg factors. Additionally, some coactivators have been shown to exhibit 
HAT activity (Hampsey, 1997; Hassig and Schreiber, 1997; Pazin and Kadonaga, 
1997). Therefore, like TAFn250 coactivators may have dual functions, promoting 
protein/protein interactions and also in regulating chi'omatin.
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1.2 Translational control of gene expression
The control of gene expression at the level of translation permits the direct 
and rapid expression of proteins in response to various cellular signals. When 
compared to the regulation of gene expression by transcription alone, translational 
regulation allows an immediate alteration in the level of a particular protein, whereas 
transcription, splicing, nuclear export and then translation can result in a delay in 
protein expression. Additionally, genes such as p53 are under hoth transcriptional 
and translation regulation, enabling the fine control of protein level. Some genes that 
are very large can take a considerable time to be transcribed, for example dystrophin 
mRNA is more than 2000 nucleotides long, therefore the protein needs to be 
expressed rapidly, this could be achieved via a translational mechanism, rather than 
by transcriptional control. A variety of mechanisms exist for translational control, 
including the regulation of translation by RNA/protein interaction and the regulation 
via structural or sequence elements in the untranslated regions (UTR) of an mRNA. 
Additionally, the regulation of activity of general protein factors of the translation 
machinery can also influence the level of translation in a cell.
1.2.1 The mechanism of eukaryotic protein synthesis
Translation in eukaryotes can be divided into three phases: initiation, 
elongation and termination. Most translational control mechanisms occur at the level 
of translation initiation, although some examples of regulation at the level of 
elongation have been observed.
1.2.1.1 The initiation phase
Translational initiation involves the selection of an mRNA and the formation 
of a rihosome initiation complex, in which the anti-codon of the initiator Met-tRNA 
interacts with the initiator eodon of the mRNA. It is this interaction that establishes 
the reading frame of the mRNA. The interaction of the Met-tRNA and mRNA to 
ribosomes is assisted by numerous initiation factors (elFs) and requires energy 
(Merrick and Hershey, 1996; Figure 1.3).
The translation efficiency of different mRNAs is different and is often 
dictated by the rate of initiation. Structural elements such as the m^G cap, the 
context of the initiator codon, the length of the 5’untranslated region (5’UTR) of the
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mRNA, secondary structure within the 5’UTR and the presence of multiple 
upstream AUGs (uAUGs) or open reading frames (uORFs) in the 5’UTR can all 
influence the initiation step of translation (Pain, 1996).
The initiation of translation can be divided into four major stages; 
dissociation of 80S ribosomes into subunits, recognition of Met-tRNAi to the 40S 
ribosomal subunit, binding of mRNA and recognition of the initiator codon and 
finally, association of the 60S ribosomal subunit (Figure 1.3).
1.2.1.1.a Dissociation of 80S ribosomes
Initiation of translation commences with the dissociation of the 80S 
ribosomes. The mechanism of ribosome dissociation is poorly understood, however 
three elFs are involved. elFlA  and eIF3 bind the 40S subunit and prevent 
association with the 60S subimit. eIF6 binds to the 60S subunit and inhibits 
association with the 40S subunit (Merrick and Hershey, 1996; Figure 1.3).
1.2.1.1.b Met-tRNAi binding to the 40S subunit
Before binding to the 40S subunit, the initiator Met-tRNAi forms a complex 
with eIF2 and GTP. This ternary complex then binds to the 40S ribosomal subunit to 
form a 43S preinitiation complex (Pain, 1996).
1.2.1.1.c mRNA binding and recognition of the initiator codon
Binding of the mRNA to ribosomes can occur via two methods. Firstly, the 
binding of the preinitiation complex to the 5’ end of the mRNA followed by 
‘scanning’ along the RNA until the initiator codon is reached, or internal ribosome 
entry, where the preinitation complex binds at the initiation codon (Sachs et a l, 
1997). Generally the ‘scanning’ mechanism of initiator codon recognition is thought 
to occur, this involves the recognition of the m^G cap by eIF4E, which forms the cap 
binding complex with eIF4A and eIF4G (eIF4F) (Merrick and Hershey, 1996; Sachs 
et al., 1997). eIF4A has RNA helicase activity and can disrupt mRNA secondary 
structuie to allow the binding of the 40S preinitiation complex (Pain, 1996; Sachs et 
a l, 1997).
The scanning model suggests that the most 5’ AUG will be the initiator 
codon, however if the context of the AUG does not match the consensus
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ACCAUGG, leaky scanning occurs (Kozak, 1991) and may result in an AUG being 
passed over and initiation taking place at another AUG.
1.2.1.l.d  Association of the 60S ribosomal subunit
After formation of the preinitiation complex and interaction of the AUG 
codon with Metj-tRNA, eIF5 recognises the complex and promotes the hydrolysis of 
the GTP bound to eIF2 (Pain, 1996). Once GTP hydrolysis has occurred eIF2 is 
released bound to GDP, which is then recycled (Figure 1.3). After the initiation 
factors have dissociated from the complex, the 60S ribosomal subunit combines with 
the 40S subunit to form the 80S initiation complex, which can then enter the 
elongation stage of translation (Pain, 1996).
1.2.1.2 Translational elongation
Translation elongation involves the addition of amino acids to the carboxy- 
terminal end of the emerging peptide. Elongation involves the binding of the 
aminoacyl-tRNA complex containing eEFlA and GTP (ternary complex), on the 
ribosomal surface. When codons are matching, GTP hydrolysis and guanine 
nucleotide exchange occurs on eEFl A and a peptide bond is formed and the stripped 
tRNA leaves the ribosome. The mRNA and the peptidyl-tRNA then move along on 
the surface of the rihosome, such that the next codon is exposed and ready for 
aminoacyl-tRNA binding and addition of the next amino acid (Menick and Hershey, 
1996).
1.2.1.3 Termination of translation
When a termination codon is reached on the ribosomal surface, no ternary 
complex can bind; in which case a release factor binds and promotes hydrolysis of 
the peptidyl-tRNA (Merrick and Hershey, 1996).
1.2.1.5 Reinitiation of translation following termination
After termination of translation the 80S ribosome is released and then 
dissociates into the 408 and 60S subunits and can then take part in ftirther protein 
synthesis. Reinitiation by the terminating ribosome is not thought to occur for most 
eukaryotic mRNAs (Merrick and Hershey, 1996). However the reinitiation after
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translational termination of short upstream ORFs can occur for example, the yeast 
GCN4 mRNA (Geballe and Morris, 1994; Section 1.5.2b).
1.2.2 The regulation of translation
The control of translation represents an important regulatory control point in 
gene expression. There are many mechanisms by which a cell can regulate 
translation and many involve sequence elements within the UTRs of transcripts and 
the influence these have on translation initiation. The sequence context of the AUG 
initiator codon, the presence of secondary structure, upstream AUG codons, internal 
rihosome entry sites and sequence elements recognised hy RNA binding proteins in 
the UTRs of an mRNA may all influence initiation of translation. Furthermore, 
translation may also be regulated via phosphorylation of translation factors, in 
response to changes in growth conditions.
1.2.2.a Translational regulation by structural features of the UTRs of mRNA.
Analysis of the sequence suirounding the AUG codon of many mRNAs from 
higher eukaryotes was found to conform to a consensus sequence, 
GCG^/nCCAUGG (Kozak, 1991). Although the full consensus sequence is rarely 
found, two highly conserved positions are observed and are critical for function, the 
purine at position -3 (usually an adenine) and the G at position +4 (the A of AUG is 
+1) (Kozak, 1991). Conformation to the consensus sequence results in efficient 
translation initiation. A few vertebrate mRNAs contain non-consensus nucleotides in 
the critical positions, such as genes encoding growth factors. Therefore, poor 
initiator context may act to restrain the expression of potentially harmful proteins.
The formation of stable stem-loop secondary structures within the 5’UTR of 
mRNA can influence translation and is thought to prevent binding of initiation 
factors, resulting in inefficient translation (Kozak, 1991; Pain, 1996). Analysis of 
mRNAs containing strong secondaiy structure revealed that, like those with poor 
initiator sequences, many mRNAs that have secondary structure code for proteins 
involved in cell growth (Kozak, 1991). The relief of translation repression is 
important to switch on protein expression when required. This may be achieved by 
activation of translation initiation factors. Indeed, several signalling pathways have 
been shown to phosphoiylate elements of the translation machinery in response to
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growth signals, an example being the control of translation by insulin. Insulin 
induces the phosphorylation of the eIF4E-binding proteins, the 4E-BPs. Once 
phosphorylated 4E-BPs cannot inhibit elF4E binding to the 5’ end of mRNAs 
(Section 1.2.1.1c) and translation proceeds (Proud and Denton, 1997).
1.2.2b Translational control by upstream AUG codons
The presence of uAUGs and uOREs can influence the translation of the 
major ORF. The presence of uORFs often has a suppressive influence on translation; 
however, translation can also be upregulated by uORFs (Geballe and Morris, 1994). 
An example of an mRNA with suppressive uORFs is the 5’UTR of the 
Saccharomyces cerevisae GCN4 mRNA, which is regulated by reinitiation and by 
phosphorylation of eIF2. GCN4 is a transcription factor required for amino acid 
biosynthesis. The GCN4 mRNA is constitutively expressed, however GCN4 protein 
is only produced during conditions of nutrient deprivation. The 5’UTR of GCN4 
mRNA contains four short uORFs. When amino acids are plentiful, the level of 
active eIF2 is high, since the kinase that phosphorylates eIF2 is activated only when 
the levels of amino acids are low. Translation of the GCN4 mRNA begins at ORFl 
and when complete, rapid reinitiation of translation occurs at 0RF4. The termination 
site of 0RF4 does not allow reinitiation and translation of this mRNA ceases and 
GCN4 is not produced. During amino acid deprivation eIF2 becomes 
phosphorylated slowing the rate of translation initiation. The rate of reinitiation is 
also slower and it takes longer for the reinitiation complex to form and scamiing 
continues past 0RF4 and initiation takes place at the GCN4 ORF (Kozak, 1992; 
Geballe and Morris, 1994).
The influence of uAUG codons can be overcome via the presence of internal 
ribosome entry sites (1RES). 1RES elements were first defined by construction of 
artificial dicistronic mRNAs containing a polio virus sequence which allowed 
translation of the second cistron, even when cap-mediated translation of the first 
cistron was blocked (Pelletier and Sonenberg, 1988; Mountford and Smith, 1995). 
The 1RES is thought to enable ribosomes to associate with the mRNA at the 1RES 
site and thereby avoid uAUG sites that could inhibit translation. This mechanism of 
translation has been observed in piconavirus RNAs and also occurs in some 
mammalian mRNAs such as the immunoglobulin heavy chain binding protein (BiP)
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(Macejak and Sarnow, 1991). It has been observed that those genes regulated by 
internal ribosome entry are often involved in cellular regulation, like many others 
regulated by structural features of the 5’UTR (Kozak, 1991; Pain, 1996). The 
5’UTRs of mammalian mRNAs with 1RES do not however resemble those of the 
picornaviruses and a different mechanism may exist in mammals (Pain, 1996). 
Additionally, eukaryotic 1RES sequences may be common since analysis of 
fimctionally defined 1RES elements does not reveal any sequence homology and 
conserved features and hence at present 1RES can only be identified by functional 
analysis (Mountford and Smith, 1995).
1.2.2c Regulation of translation by mRNA/protein interaction
Sequence elements within the UTRs of mRNAs may be binding sites for 
protein factors that can influence translation. The binding of proteins to the 5’UTR 
of an mRNA may prevent initiation or scanning by the translation machineiy. 
Alternatively, the binding of proteins to an mRNA may promote translation. In 
mammalian cells the synthesis of ferritin is regulated by the binding of a repressor 
protein, the iron regulatory factor (IRE) to the iron response element (IRE) in the 
5’UTR of the ferritin mRNA. The IRE has a stable secondary structure and a stem- 
loop structure forms, situated at the 5’ end of the fenitin 5’UTR. The binding of the 
IRF to the IRE under conditions of low iron results in repression of ferritin 
translation. It is thought that the presence of the IRF interferes with translational 
initiation and several models have been proposed (Melefors and Hentze, 1993). An 
inerease in cellular iron levels causes in a change in the affinity or availability of the 
IRF for the IRE and translation is de-repressed (Melefors and Hentze, 1993). RNA- 
binding proteins that promote translation have been characterised, however it is 
thought that these promote translation via an indirect mechanism rather than directly 
activating translation (Kozak, 1992).
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1.3 Cell Cycle Control
1.3.1 Cyclin-dependent kinases
The cell cycle in eukaryotic cells is divided into four distinct phases (Figure 
1.4). DNA synthesis (S-phase) and mitosis (M-phase) are separated by two gap 
phases termed G1 and G2. The G2 phase occurs before mitosis and allows 
assessment of the DNA replication process whereas G1 occurs after mitosis and is a 
major control point for entry into the cell cycle. Cell cycle progression is co­
ordinated by a family of related cyclin-dependent kinases (cdks) that phosphorylate 
substrates necessary for cellular proliferation. The cdk consists of a catalytic kinase 
subunit, a cyclin subunit and a regulatory subunit (cyclin-dependent kinase inhibitor 
cdkl). The importance of these kinases is reflected in their conservation thiough a 
variety of organisms ranging from yeast to humans. To date eight cdk subunits have 
been identified in mammalian cells termed cdkl-8. Furthermore thirteen cyclin 
subunits have been isolated (A-H) and seven cdk inhibitors have been identified 
(Pines, 1995).
The cyclins are related gene products containing a cdk binding domain and 
some contain a PEST sequence, necessary for ubiquitin-mediated degradation 
(Pines, 1995). As their name suggests cyclins undergo cyclical synthesis and 
destruction during cell cycle progression. Thus cyclin B is induced at the G2/M 
boundary whereas cyclin E is induced in G1 suggesting that each may be required 
for a different phase of the cell cycle. Indeed this appears to be the case since 
overexpression of cyclin E causes a reduction in length of G1 and entry into S-phase 
(Ohtsubo and Roberts, 1993; Ohtsubo et a i, 1995). In contrast cyclin B in 
association with cdc2 is necessary for cells to enter mitosis. Not all cyclins are cell 
cycle regulated, for example the D-type cyclins are only induced upon growth factor 
stimulation (Matsushime et al., 1991), although cyclin D1 will co-operate with 
cyclin E to promote G1 progression and S-phase entry (Resnitzky et aU, 1994). 
Other cyclins appear to be associated with specific cellular processes, such as cyclin 
H, which in combination with cdk7, is component of TFIIH and is also the cdk 
activating kinase (Fesquet et al., 1993; Poon et a l, 1993; Roy et al., 1994; Serizawa 
et al., 1995). For some cyclins such as cyclin C, a clear function remains to be 
assigned. Cyclin C was originally identified as a potential G1 cyclin; however, it 
does not appear to play a role in cell cycle progression (Lew et al., 1991).
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The cdks are also related gene products containing a cyclin binding domain, 
a catalytic domain and an ATP-binding motif. Cdks are activated when bound to a 
cyclin partner. Interestingly, the binding of cyclin to cdk results in a conformational 
change to allow ATP binding (Jeffery et a l, 1995). While cyclin binding has 
substantial influences on and is required for cdk activation, full activation also 
requires phosphorylation on cdk tlireonine-160 (Fisher and Morgan, 1994). 
Phosphorylation of Thr-160 is catalysed by another cyclin/cdk complex termed 
CAK (cdk activating kinase), which consists of cdk7 together with cyclin H (Fesquet 
et a l, 1993; Poon e? a/., 1993).
Unlike the cyclin component the cdks are generally more stable and are not 
subject to cell cycle mediated destruction. Therefore the timing of cdk activation is 
thought to be dictated by the availability of cyclins. As might be expected, specific 
cyclins associate with particular cdks to promote cell cycle progression. For 
example, cyclin E associates exclusively with cdk2 and therefore the cyclin E 
induced G1 acceleration is thought to be mediated by cdk2 (Sherr, 1993). In 
contrast, the D-type cyclins associate with cdk 2, 4 and 6, whereas cyclin B binds 
cdc2/cdkl (Xiong et aL, 1992; Sherr, 1993; Bates et al., 1994). Since cyclin E/cdk2 
kinase activity is required for G1 to S transition specific substrates must exist. One 
such substrate is the retinoblastoma protein (pRb). The pRb protein can be 
phosphorylated by cyclinE/cdk2 and the D-type cyclins (Ewen et a l, 1993), causing 
inactivation of growth suppressing functions and allows cell cycle progression from 
G1 to S-phase (Figure 1.4; Section 1.5). Similarly cyclin A/cdk2 is necessaiy for 
DNA synthesis (Girard et a l, 1991; Pagano et a l, 1992). The replication factor RF- 
A is a substrate for cyclin A/cdk2 and is phosphorylated in S-phase (Dutta and 
Stillman, 1992). Phosphorylation of RF-A enhances helicase activity, which may 
explain the basis for cyclin A/cdk2 mediated S phase progression (Dutta and 
Stillman, 1992).
1,3.2 Cdk inhibitor proteins
The identification of a family of cdk inhibitor polypeptides has proposed new 
mechanisms of cell cycle control. Two families of cdk inhibitors (cdkl) have been 
identified based on sequence similarity and mode of action, the p i6 and the p21 
family (Sherr and Roberts, 1999).
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The p i 6 family eonsists of p i 6 (INK4a), pi 5 (INK4b), p i 8 (INK4c) and pi 9 
(INK4d/ARF) (Serrano et aL, 1993; Guan et ah, 1994; Hannon and Beach, 1994; 
Kamb et aL, 1994; Chan et aL, 1995; Hirai et aL, 1995). The p l6  family can bind to 
either monomeric cdk4/6 or directly to the cyclin D/cdk4/6 complex to inhibit kinase 
activity. The importance of p i6 in growth control is underscored by the results 
obtained from transgenic knockout mice. Homozygous deletion of p i6 in mice 
results in increased susceptibility to tumours and mouse embryo fibroblasts (MEFs) 
derived from these mice grow faster with an increased S-phase population (Serrano 
et aL, 1996).
Unlike the p l6  family, the p21 family are general inhibitors of cdks. The p21 
family includes p21 (kip/wafl/cipl), p27 and p57 (Polyak et aL, 1994; Haiper et aL, 
1995; Lees et aL, 1995; Matuoka et aL, 1995). The p21 family bind to cyclin/cdk 
complexes and inhibit kinase activity partly by occupying the ATP binding site 
(DeBondt et aL, 1993; Jeffery et aL, 1995; Russo et aL, 1996). Interestingly, p21 
expression is induced by p53 and contributes to p53 mediated growth arrest. 
Transgenic mice lacking p21 and p27 have also been generated. Surprisingly p21 
null mice do not show increased malignancies, however the p53-dependent G1 arrest 
is impaired (Brugarolas et aL, 1995; Deng et aL, 1995). In contrast, mice lacking 
p27 are larger than normal mice, with bigger organs (Fero et aL, 1996; Kiokawa et 
aL, 1996; Nakayama et aL, 1996).
In conclusion, multiple related cdkl exist which function though regulating 
the activity of cdks. In general these inhibitors do not function during cell cycle 
progression but play a unique role in exit and entry into the cell cycle
1.4 The p53 tumour suppressor protein
The human tumour suppressor protein p53 is an important regulator of 
cellular proliferation. For example, the loss of p53 thi’ough mutation or inactivation 
by viral oncoproteins is observed in over half of all human cancers. Furthermore, the 
inheritance of a mutant p53 allele results in Li-Fraumenti syndrome and 
predisposition to various cancers (Malkin, 1993). The disruption of both p53 alleles 
in mice does not result in developmental defects but in a high predisposition to 
diverse tumours (Donehower et aL, 1992).
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Functional analysis of p53 has revealed a central role in the cellular response 
to DNA damage. The accumulation of p53 following DNA damage and other 
genotoxie stress, results in either arrest of the cell cycle at G1 or in cell death by 
apoptosis (Kastan et aL, 1992; Donehower and Bradley, 1993; Lu and Lane, 1993; 
Macleod et aL, 1995; Ko and Prives, 1996). Once detection of DNA damage and 
signalling to p53 have occurred, p53 functions to arrest cells at either the Gl/S phase 
or G2/M phase checkpoints of the cell cycle, allowing DNA repair to take place 
before DNA synthesis or division. If DNA repair is unsuccessful, p53 initiates 
apoptosis, thereby preventing the transmission of the genetic damage to the next and 
successive generations. However p53 is not required for all forms of apoptosis 
(Clarke et aL, 1993; Macleod et aL, 1996).
1.4.1 p53 is a transcription factor
The p53 protein is a sequenee specific transcription factor that can bind and 
activate promoters containing p53-binding sites. The DNA binding domain of p53 
has been mapped to the central region of the p53 protein. Since more than 90% of 
missense mutations in p53 are found in this region, the DNA binding and 
transcriptional functions of p53 are considered central to its biological fimctions (Ko 
and Prives, 1996). Mutation of residues such as R248 and R273 result in poor 
contacts with DNA and result in loss of transcriptional activity of p53 (Ko and 
Prives, 1996). Other mutations disrupt the structure of the DNA binding domain 
(Hupp et aL, 1992; Levine, 1997).
The N-terminus of p53 contains the transcriptional activation domain 
required for activation of p53 target genes. Numerous p53 target genes have been 
identified and are observed to be induced on activation of p53, for example after 
DNA damage. p53 responsive genes have functions linked to the known functions of 
p53, for instance cell cycle arrest. The p21 gene has been identified as a p53 target 
gene (El-Diery et aL, 1993; Harper et aL, 1993). p21 is a general cyclin-dependant 
kinase inhibitor (Pines, 1995; Section 1.3.2) and upregulation of p21 results in the 
inhibition of cyclin-dependant kinase phosphorylation of pRb. Consequently, 
hypophosphorylated pRb accumulates and the repression of E2F responsive genes 
results in cell cycle arrest at the Gl/S phase boundary (DeGregori et aL, 1995; 
Lukas et aL, 1995). p21 also inliibits other cyclin-dependant kinase complexes and
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can prevent the phoshorylation of other members of the pocket protein family, pi 07 
and p i30, thereby inhibiting the activity of E2F complexes (La Thangue, 1994). p21 
also interacts with PCNA (proliferating cell nuclear antigen) (Waga et aL, 1994; 
Gulbis et aL, 1996), this interaction blocks PCNA function in DNA replication and 
therefore, p21 can act via two mechanisms to inhibit S phase entry and DNA 
replication.
Other p53 responsive genes include the mdml proto-oncogene (Momand et 
aL, 1992; Oliner et aL, 1992). The MDM2 protein interacts directly with p53, 
inhibiting transcriptional activity by masking the transactvation domain (Momand et 
aL, 1992; Oliner et aL, 1992). Furthermore, MDM2 regulates the stability of p53 
and targets p53 protein for proteosome mediated degradation (Haupt et aL, 1997; 
Kubbutat et aL, 1997) and suggesting an autoregulatory feedback loop.
The GADD45 gene is another p53 transcriptional target that is induced in 
response to DNA damage (Kastan et aL, 1992; Lu and Lane, 1993). GADD45 
protein interacts with PCNA and inliibits the entry of cells into S phase (Smith et aL,
1994) and may contribute to p53 mediated cell cycle arrest.
The induction of apoptosis by p53 is thought to involve the activation of 
other transcriptional targets such as the bax gene. The Bax protein binds to the cell 
survival factor Bcl-2 and promotes apoptosis (Miyashita and Reed, 1995).
Other p53 responsive genes include the insulin-like growth factor binding 
protein 3 (IGF~BP~3) gene, the product of which inliihits mitotic signalling by 
insulin-like growth factor (Buckbinder et al., 1995) and cyclin G, a cyclin of 
unknown function (Okamoto and Beach, 1994).
p53 can also repress transcription of several genes which do not have p53 
binding sites in their promoters, including c-fos, c-jun, Rb, and Bcl-2 and it is 
thought that the functions of p53 as a repressor may be important in it’s role as a 
tumour suppressor (Ko and Prives, 1996). The N-terminal fra«.sactivation of domain 
of p53 interacts with basal transcription factors such as TBP (Florikoshi et aL, 1995), 
and TBP-associated factors including, TAF40, TAF60 and TAF31 (Lu and Levine, 
1995; Thut et aL, 1995). It is thought that these interactions may be involved in p53- 
mediated repression of transcription. Also, p53 has been shown to interact with 
components of TFllH, and thiough this interaction transcriptional inhibition by p53 
in the absence of a p53 DNA binding site is overcome (Levieillard et aL, 1996).
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1.4.2. p53-dependant apoptosis
p53 mediates apoptosis in many cell types and is an important mechanism 
for suppression of proliferation and tumour formation (Ko and Prives, 1996). The 
transcriptional functions of p53 are important for induction of cell cycle arrest and 
also for mediating apoptosis. However, some groups have shown that mutant p53 
proteins which cannot activate transcription can induce apoptosis, whilst others 
suggest that transcription defective p53 mutants camiot induce apoptosis (Haupt et 
ah, 1995; Sabbatini et ah, 1995; Ko and Prives, 1996). Such data suggests that p53 
may induce apoptosis via different transcription dependent and independent 
mechanisms and perhaps is influenced by cell or tissue specific differences. 
However, the expression of proteins that block p53-dependent apoptosis such as 
Bcl-2 or adenovirus ElB  19KD protein, have been observed to cause a decrease in 
p53 mediated transcriptional repression but have no effect on transcriptional 
activation (Shen and Shenk, 1994; Sabbatini et ah, 1995). In addition, the p53 
protein interacts with a range of cellular and viral proteins (Ko and Prives, 1996; 
Levine, 1997), and it is possible that these interactions may be involved in the 
induction of apoptosis.
How cells decide whether to arrest or apoptose in response to p53 activation 
appears to be dependent on several factors including cell type, growth factors, the 
presence of viral proteins, pRb function and overexpression of E2F (Ko and Prives,
1996). Loss of pRb fmiction results in failure to arrest in G1 and subsequent over 
expression of E2F-1 leads to apoptosis, which is enhanced in the presence of p53 
(Shan and Lee, 1994; Wu and Levine, 1994). The cellular status with respect to both 
pRb and E2F-1 may influence the balance between apoptosis and cell cycle arrest.
1.4.3 Regulation of p53 activity
The activation and accumulation of p53 protein in response to stimuli such as 
DNA damage, hypoxia, nutrient deprivation and other stresses are vital for induction 
of cell cycle arrest and apoptotic pathways. Wild-type p53 protein levels are low in 
cells due to a rapid turnover rate, and the activation of p53 results in an increase in 
protein levels, via post-transcriptional mechanisms (Kastan et ah, 1991). The 
stability and transcriptional activity of p53 is regulated by interaction with MDM2, 
which binds to the N-terminal region of p53 and prevents transcriptional activation
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by masking the transcriptional activation domain (Oliner et aL, 1993). MDM2 
targets p53 for proteosome-mediated degradation and indeed MDM2 can function as 
an E3 ubiqultin ligase (Haupt et aL, 1997; Honda et aL, 1997; Kubbutat et aL,
1997). Furthermore, MDM2 must bind to the transcriptional coactivator p300 to 
mediate p53 degradation (Grossman et aL, 1998) and shuttle from the nucleus to the 
cytoplasm to be degraded (Roth et aL, 1998). Since MDM2 is a transcriptional target 
of p53, the activation of p53 also induces MDM2 expression, which subsequently 
inliibits p53 function, thereby forming an autoregulatory feedback loop (Wu et aL, 
1993). Therefore, the disruption of the MDM2-p53 interaction is likely to be 
important in activating p53.
Recent work has revealed that p53 is induced on expression of p i 9^ '^ ’' 
(alternative reading frame, ARF), an alternative product of the lNK4a (p i6) locus 
(Kamijo et aL, 1998; Section 1.3.2). ARF binds to MDM2 and forms a trimeric 
complex with p53 in vivo; however, it is not clear how this leads to stabilisation of 
p53 (Kamijo et aL, 1998; Pomerantz et aL, 1998; Stott et aL, 1998; Zhang et aL,
1998). It is interesting to note that in cells that have a homozygous deletion of ARF, 
p53 is induced in response to DNA damage (Kamijo et aL, 1997), suggesting that 
other meehanisms exist to regulate p53 in conditions of DNA damage. ARF is 
thought to be induced by viral and cellular oncogenes and may represent another 
signalling pathway tlirough which p53 controls proliferation.
The p53 protein contains many phosphorylation sites. DNA damage can 
induce the phosphorylation of p53 on Ser-15 (Shieh et aL, 1997; Siliciano et aL,
1997). DNA-PK has been shown to phoshorylate Ser-15 and Ser-37 in vitro (Lees- 
Miller et aL, 1992) and in cells that lack DNA-PK, p53 cannot bind DNA, 
suggesting that DNA-PK may contribute to activation of p53 transcription (Woo el 
aL, 1998). p53 is also phosphorylated on Ser-15 by ATM, a kinase that is defective 
in patients with ataxia telangiectasia, a disorder resulting in extreme sensitivity to 
ionising radiation (Banin et aL, 1998; Canman et aL, 1998). In addition, the ATM 
related kinase ATR can phosphorylate Ser-15 and Ser-37 in vitro and a catalytically 
inactive form of ATR can inhibit Ser-15 phosphoiylation in vivo (Tibbetts et al.,
1999). Sueh data suggests that the phosphorylation of p53 at Ser-15 is important in 
the activation of p53 transcriptional activity. Phosphorylation of p53 at Ser-15 
weakens the interaction between MDM2 and p53 and the ability of MDM2 to
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repress p53 transcriptional activation (Shieh et ah, 1997). Therefore, multiple DNA 
damage induced protein kinases target the p53-MDM2 interaction to activate p53 
transcriptional activity.
Other sites in the N-terminus of p53 are also phosphorylated in response to 
DNA damage (Siliciano et ah, 1997; Sakaguchi et al, 1998). The C-terminus of p53 
is also modified in response to some forms of DNA damage, where both 
phosphorylation and acétylation have been reported to occur in response to DNA 
damage (Sakaguchi et ah, 1998), and also de-phosphorylation of a site has been 
observed after exposure to ionising radiation (Waterman et aL, 1998). The C- 
terminus of p53 can negatively regulate DNA binding and it is possible that these 
modifications de-repress p53 DNA binding. It is therefore likely that multiple 
kinases, phosphatases and acetylases modify p53 and influence function in response 
to various cellular stresses.
1.4.5 p53 can modulate translation
Analysis of p53 protein levels in human acute myelogenous leukemia (AML) 
cells revealed differences in the levels of p53 protein and p53 mRNA, and further 
analysis suggested that the 3’UTR of human p53 transcripts may repress p53 
translation (Fu et aL, 1996). In addition, the induction of p53 protein in response to 
y-radiation has been shown to be dependent on the 3’UTR of human p53 mRNA in 
AML cells (Fu and Benchimol, 1997). Murine p53 negatively regulates p53 
expression tlirough the 5’UTR of p53 transcripts and physically interacts with the 
5’UTR of p53 mRNA in vitro (Mosner et aL, 1995). Murine p53 has also been 
shown to be important in the repression of cyclin dependant kinase 4 (CDK4) 
translation in TGF-pl-induced G1 cell cycle arrest, an effect that is mediated by the 
5’UTR of the CDK4 transcript (Ewen et aL, 1995). Hence p53 may accumulate via 
mechanisms other than protein stabilisation, such as an increase in translation. 
Indeed, p53 may influence not only p53 protein levels, but also other targets by both 
transcriptional and translational mechanisms.
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1.5. The Retinoblastoma Gene
Retinoblastoma is a rare childhood cancer that arises ftom inactivating 
mutations on both alleles of the retinoblastoma (Rb) gene. Additionally, the Rb gene 
is often found to be mutated in cancers such as osteosarcomas, small-cell lung 
carcinomas, cervical and breast carcinomas and some types of leukaemia, suggesting 
that Rb has tumour suppressing function in many different cell types (Herwig and 
Strauss, 1997). The Rb gene product (pRb) acts as a tumour suppressor protein; an 
important function of pRb is to restrain uncontrolled growth by inhibiting 
progression tlirough G1 phase of the cell cycle. pRb is a member of a family of 
related proteins; p i07 and p i30 have similar growth suppressive functions to pRb, 
but not considered to be tumour suppressor genes, as they are not mutated in human 
tumours (Cobrinik et aL, 1993; Hannon et aL, 1993; Li et aL, 1993; Zhu et aL, 
1993).
1.5.1 The Rb protein
Human pRb is a 105 KD nuclear phosphoprotein that interacts with many 
cellular proteins including, E2F and the D-type cyclins, and in addition is targeted 
and inactivated by several viral oncoproteins such as adenovirus El a, human 
papilloma virus type 16 (HPV) E7 protein and simian virus 40 (SV40) T antigen. 
The regions of El a, E7 and T antigen required to bind pRb are also necessary for 
immortalisation and transformation (Whyte et aL, 1988; Dyson et aL, 1989). All of 
these proteins interact directly with pRb through a conserved region, named the 
pocket (Herwig and Strauss, 1997). The pocket region of pRb is frequently found 
mutated in human tumours and these mutants are unable to interact with ElA, T 
antigen, E7, E2F and the D-type cyclins. A comparison of the primary sequence of 
pRb and relatives, p i07 and p i30 revealed good sequence conservation in the pocket 
region and for this reason these proteins are often referred to as the pocket protein 
family. It is notable that no tumour derived mutants of p i07 and p i30 have been 
characterised that impair the functions of these two pRb related proteins, although 
the pocket region is still required to bind E2F (Cobrinik et aL, 1993; Hannon et aL, 
1993; Li et aL, 1993; Zhu a/., 1993).
34
1.5.2. pRb and tbe control of G l/S phase progression
In tumour cells lacking pRb, overexpression of wild-type pRb causes cell 
cycle arrest (Huang et aL, 1988; Bookstein et aL, 1989). pRb regulates the 
progression of cells from G1 to S phase of the cell cycle. The activity of pRb is 
influenced by phosphorylation state, where hypophosphorylated pRb can repress and 
control entry into S phase. Hyperphosphorylated pRb is unable to inhibit cell cycle 
progression and cells enter S phase and progress through the eell cycle (Mittnacht,
1998). Likewise, pl07 and pl30 ai'e also phosphorylated in a similar manner and 
like pRb, it is likely that phosphorylation influences function (Dyson, 1998).
The pocket proteins regulate the cell cycle through interaction with the E2F 
family of transcription factors (Bandara and La Thangue, 1991; Zamanian and La 
Thangue, 1992, 1993). The pocket proteins bind E2F via the pocket region and 
repress E2F transcriptional activity. E2F target genes include those required for S 
phase progression and DNA replication and repression of these genes prevents cells 
from entry into S phase (Section 1.6; Table 1.1). The oncogenic activity of ElA, E7 
and T antigen is considered to arise from the sequestration of pocket proteins, 
releasing active E2F and allowing uncontrolled cell cycle progression. Likewise, 
tumour derived mutant pRb camiot bind and inhibit E2F, resulting in uncontrolled 
proliferation (Bandara et aL, 1991).
The pocket proteins associate with specific members of the E2F family of 
proteins (Section 1.6.4). In addition, pocket protein-E2F complexes ai'e observed at 
different stages of the cell cycle. For example, and consistent with the role of pRb in 
regulating S phase entry, pRb complexes are observed in G1 phase. In contrast, 
pl30-E2F complexes are observed in quiescent cells (Dyson, 1998).
Homozygous disruption of the Rh gene in mice results in an embryonic lethal 
phenotype, with defects observed in the liver, central nervous system, lens and 
erythropoiesis (Clarke et aL, 1992; Jacks et aL, 1992; Lee et aL, 1992) which 
suggests that pRb may frmction in differentiation in some cell types. The disruption 
of either pl07 or p i 30 in mice results in no abnormalities (Cobrinik et aL, 1996; Lee 
et aL, 1996), although inactivation of both p i07 and p i30 results in neonatal 
lethality and defective bone development (Cobrinik et aL, 1996). The observation 
that disruption of pRb and pl07/pl30 result in different phenotypes suggests the 
pocket proteins may have different E2F target genes. This conelates with analysis of
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E2F targets in mouse embryo fibroblasts (MEFs) derived from knockout mice 
(Hurford et ah, 1997). The analysis of MEFs derived from pRb knockout mice 
revealed deregulation of a subset of E2F target genes, whereas either p i07 or pi 30 
knockouts did not reveal changes in E2F targets, although deregulation of E2F 
targets was observed in the MEFs from mice deficient for both p i07 and p i30. 
Interestingly, the target genes affected by the loss of pRb and by the loss of 
107/pl30 were different (Hurford et aL, 1997).
1.5.3. Phosphorylation of pocket proteins
The activity of pocket proteins is linked to the cell cycle via phosphorylation 
by cdks, which are activated by interaction with cyclins (Section 1.3). The G1 phase 
of the cell cycle is regulated by the D-type cyclins, which activate cdk4 and cdk6, 
and by cyclin E, which activates cdk2 in late G l. The D-type cyclins can interact 
with all pocket protein family members via the pocket region (Dowdy et aL, 1993; 
Ewen et aL, 1993). The cyclin D-dependent kinases can phosphorylate pRb, which 
results in dissociation of E2F/pRb complexes and loss of Gl arrest functions of pRb 
(Ewen et aL, 1993). Inhibition of cyclin D-dependent kinases by the expression of 
cdk inhibitors such as p i6 results in hypophosphoiylated pRb and Gl arrest (Lukas 
et aL, 1995b). However, cells that do not express pRh do not arrest when cyclin D- 
dependent kinase function is inhibited, suggesting that the phosphorylation of pRb 
by cyclin D-dependent kinases is important for cell cycle progression (Lukas et al, 
1994, 1995a). Similarly, the expression of cyclin E can induce the phosphorylation 
of pRb, and cyclin E can induce S phase in cells which lack functional pRb and 
therefore may phosphorylate other targets required for S phase entry (Ohtsubo et aL, 
1995; Hofmann and Livingstone, 1996).
The phosphorylation of p i07 and p i30 is also cell cycle regulated 
(Beijerbergen et aL, 1995; Mayol et aL, 1995), and the growth suppressing functions 
of p i07 and p i30 are overcome by cyclin D-dependent phosphorylation 
(Beijersbergen et aL, 1995; Zhu et aL, 1993).
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1.6 The E2F transcription factor
E2F was originally identified as a cellular transcription factor able to bind to 
a sequence in the adenovirus E2 promoter (Kovesdi et aL, 1987; La Thangue and 
Rigby, 1987). E2F DNA binding activity was found to be high in undifferentiated 
F9EC cells declining as cells differentiated to parietal endoderm-like cells, 
suggesting a role in embryo genesis. Furthermore, E2F was also implicated in 
adenovirus replication as a DNA binding activity, induced during infection.
The importance of E2F in the control of cellular proliferation was 
highlighted when it was identified as a target for pRb (Bandara and La Thangue, 
1991; Chellapan et aL, 1991). E2F forms complexes with pRb that can be disrupted 
by the adenovirus El a protein (Bandara and La Thangue, 1991). The regions of El a 
required for binding pRb coincide with that necessaiy for cell transformation 
suggesting that sequestration of pRb from E2F plays a role in Ela-mediated 
oncogenesis. In support of this hypothesis it has been shown that pRb can repress 
E2F-dependent transcription, which in turn can be alleviated by co-expression of 
E la  (Zamanian and La Thangue, 1992). The pl07 and pl30 proteins, like pRb, also 
form complexes with E2F and can repress E2F transcription (Zamanian and La 
Thangue, 1993; Vairo et aL, 1994)
The cellular E2F DNA binding activity is a heterodimer composed of an E2F 
family member and a DP family member. To date, six E2F genes and two DP genes 
have been isolated in mammals. E2F and DP family members have also been cloned 
in other species including Drosophila melanogaster, Xenopus laevis and chicken 
(Dynlacht et aL, 1994; Girling et aL, 1994; Ohtani and Nevins 1994; Philpot and 
Friend, 1994; Hao et aL, 1995; Pasteau et aL, 1995).
1.6.1 The E2F family
The first E2F family member isolated was E2F-1 (Helin et aL, 1992; Kaelin 
et aL, 1992; Shan et aL, 1992). Two further clones with significant homology to 
E2F-1 were also isolated, E2F-2 and E2F-3 (Ivey-Hoyle et aL, 1993; Lees et aL,
1993). E2F-1, 2 and 3 all have a highly conserved DNA binding and dimérisation 
domains, a C-terminal transactivation domain and an N-terminal domain, which 
contains a nuclear localisation signal and cyclin A binding domain (Figure 1.5). In 
addition, E2F-1, 2 and 3 all bind preferentially to pRb, through a C-terminal domain.
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Additional E2F family members, E2F-4 and E2F-5, have also been 
characterised (Beijersbergen et al 1994; Ginsberg et aL, 1994; Buck et aL, 1995; 
Hijmans et aL, 1995; Sai'det et aL, 1995). Although all the E2F family members 
share a similar domain structure, sequence compai'ison shows greater similarity 
between E2F-4 and 5 than with the other E2F family members and suggests they 
represent a subfamily of E2Fs. E2F-4 and 5 have a truncated N-terminus and 
therefore lack the cyclin A binding domain present in E2F-1, 2 and 3 (Figure 1.5). 
E2F-4 and 5 are regulated by interaction with p i07 and p i30 via a C-terminal 
domain (Figure 1.5), and E2F-4 can also associate with pRb under certain conditions 
(Beijersbergen et al 1994; Ginsberg et aL, 1994; Vairo et aL, 1994; Moberg et aL,
1995). E2F-5 preferentially interacts with p i30 (Hijmans et aL, 1995). In 
comparison to all the other E2Fs, the sixth E2F family member isolated E2F-6, lacks 
the N-terminus of E2F-1, 2 and 3 and consists of the DNA binding and dimérisation 
domains. Perhaps more importantly, E2F-6 lacks the C-terminal pocket protein 
binding and transactivation domains. Therefore, E2F-6 does not interact with any 
members of the pocket protein family and is thought to act as a repressor of E2F 
dependent transcription (Morkel et aL, 1997; Cartwiight et aL, 1998; Trimarchi et 
aL, 1998).
Presently, only a few differences have been observed between the individual 
E2F family members. Differences have been observed in the RNA expression 
patterns of mammalian E2Fs in a range of tissues and cell lines. For example in 
human tissues E2F-2 RNA is highly expressed in placenta, lung and kidney, and 
E2F-3 RNA levels aie higher in liver and muscle and absent in the brain (Lees et aL,
1993). E2F-1 is expressed in most tissues during mouse embryo development, and in 
some tissues is often co-localised with DP-1 (Tevosian et aL, 1996). Analysis of 
E2F-2 and 4 expression by in situ hybridisation during murine development suggests 
expression is highest in proliferating cells and in contrast, E2F-5 is expressed in 
differentiated cells such as the choroid plexus (Dagnino et aL, 1997; Lindeman et 
aL, 1998). Homozygous deletions of E2F-1 and E2F-5 in mice have resulted in 
different tissue specific effects and suggest that each E2F may have particular 
functions in tissues or cell types (Field et aL, 1996; Yamasaki et aL, 1996; 
Lindeman et aL, 1998).
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1.6.2 The DP Family
DP-1, the first DP family member to be isolated was identified as an E2F 
site-specific DNA binding polypeptide in murine F9EC cells (Girling et aL, 1993) 
and subsequently human DP-1 was also isolated (Helin et aL, 1993). Analysis of 
E2F DNA binding complexes has revealed that DP-1 is the most fi'equent 
component of the E2F DNA binding activity (Girling et aL, 1993; Bandara et aL,
1994). The isolation of related DP proteins, DP-2 in X. laevis and a second murine 
DP, named DP-3, suggest that not all E2F complexes will contain DP-1. All the DP 
family members isolated have a high level of conservation across the DNA binding 
domain and in the DEF box (region of DP and E2F similarity), a domain required 
for dimérisation with E2F family members (Girling et aL, 1993, 1994; Figure 1.6). 
The DEF box contains the region of greatest similarity with the E2F family. 
Additionally, all DP proteins show good eonservation in the DP-conserved boxes 1 
and 2 (DCB 1 and 2) and in an acidic C-terminal domain, the negatively charged 
box (NCB; Figure 1.6).
Analysis of the expression patterns of the DP family members revealed that 
human DP-1 and DP-2 are expressed in many different cell lines and tissues (Wu et 
aL, 1995; Zhang and Chellapan, 1995). In addition, in situ hybridisation analysis of 
DP-1 during mouse embiyogenesis revealed DP-1 to be expressed in most tissues, at 
a consistently higher level than E2F-1 (Tevosian et aL, 1996). Analysis of X. laevis 
DP expression suggested that DP genes might be tissue restricted (Girling et aL,
1994).
1.6.3 Murine DP-3
DP-3 differs from other DPs due to a striking complexity at the RNA level. 
RNA analysis has suggested that extensive processing of DP-3 RNA gives rise to 
four potentially different DP-3 proteins; a , (3, y, ô, which can all dimerise with E2F- 
1 and activate E2F-dependent transcription (Ormondroyd et aL, 1995). These 
variants arise via two changes in the ORF; namely the inclusion of a 16 residue 
sequence (named the E region) within the DNA binding domain in the DP-3 a  and ô 
isoforms, and a single a glutamine amino acid (Q) insertion in the DP-3 y isoform 
between the DNA binding domain and the E2F dimérisation domain (Ormondroyd
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et ah, 1995; Figure 1.7). Analysis of the E region revealed that it functions as part of 
a nuclear localisation signal (de la Luna et aL, 1996; Section 1.6.7b).
Extensive splicing in the 5’untranslated region (UTR) of DP-3 RNAs gives 
rise to several different 5’UTRs and results in the initiation of translation at two 
different translational start sites, named M l and M2 (Ormondroyd et aL, 1995) 
(Figure 1.8). Initiation at M l results in translation of the DP-3a isoform and an 
extended N-terminus, containing sequence homology to the N-terminus of DP-1 
(Ormondroyd et aL, 1995). All other DP-3 isoforms result from initiation at M2. To 
date, four different DP-3 5’UTRs have been characterised and RNase protection data 
suggests that the expression is tissue restricted (Ormondroyd et aL, 1995; Figure 
1.8). In addition, particular ORFs are found associated with specific 5’UTRs, 
suggesting another level of complexity (Ormondroyd et aL, 1995). Human clones 
with a high degree of homology to DP-3 have been found, named DP-2 and suggest 
that many of the variations observed for murine DP-3 are conserved in human DP-2 
(Wu et aL, 1995; Zhang and Chellapan, 1995, 1996; Rogers et aL, 1996).
1.6.4 Heterodimerisation and DNA binding of E2F and DP family members
Individual E2Fs or DPs can bind to DNA weakly (Helin et aL, 1992; Kaelin 
et aL, 1992; Shan et aL, 1992; Girling et aL, 1993). However, heterodimerisation of 
DP and E2F family member results in synergistic DNA binding and /raw^'activation 
of E2F-dependent transcription (Bandara et aL, 1993; Helin et aL, 1993). 
Heterodimerisation requires the DEF box of DP proteins and, in addition, residues 
outside this region contribute to dimérisation (Bandara et aL, 1993; Helin et aL, 
1993). The region of E2F-1 necessary for heterodimerisation with DP-1 has also 
been defined (Helin et aL, 1993). The relevance of E2F homodimerisation in vivo 
remains to be elucidated.
The crystallisation and subsequent structural analysis of E2F-4/DP-2 
heterodimer-DNA complex has been achieved and revealed that the E2F DNA 
binding domain is related to the winged-helix DNA binding motif, a motif that has 
been noted in several eukaryotic transcription factors. The structure also revealed 
that E2F-4/DP-2 heterodimers bind the major groove of DNA and that the residues 
that contact the DNA are well conserved in all E2F and DP family members (Zheng 
et aL, 1999). Furthermore, the DEF box and N-terminal sequences of DP-2 are
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required for heterodimerisation with E2F-4 and an extensive protein-protein 
interfaee is formed. The structines formed between E2F-4 and DP-2 are 
asymmetrical and it has been suggested that this contributes to DNA binding as a 
heterodimer rather than as homodimers (Zheng et al., 1999).
1.6.5 Binding of pRb family members regulates E2F activity
E2F heterodimers form stable complexes with members of the pRb family of 
proteins (pocket proteins) (Bagchi et aL, 1991; Bandara and La Thangue, 1991; Cao 
et aL, 1992; Cobrinik et aL, 1993; Figure 1.9). This is via direct interaction between 
the pocket protein and an E2F family member, however this interaction can be 
influenced by the contacts between the C-terminus of DP-1 and the pocket protein 
(Bandara et aL, 1994). The pocket protein binding domain of E2F family members 
is highly conserved and has been mapped to the C-terminus, overlapping with the 
frUM^-activation domain (Figure 1.5), suggesting that binding of a pRb family 
member to E2F masks the fraw^activation domain and prevents activation of 
transcription by E2F.
E2F/pocket protein complexes are observed at different stages of the cell 
cycle. pRb containing E2F complexes are present during Gl phase of the cell cycle, 
when pRb is hypophosphorylated (Buchkovich et aL, 1989; Chellapan et aL, 1991; 
Mittnacht, 1998) and decrease as cells enter S phase, correlating with increasing 
phosphorylation of pRb. E2F/pl07 complexes are observed during GO/Gl and 
increase in abundance as cells enter S phase. On the other hand, p i30 complexes are 
detected principally in quiescent or differentiated cells (GO cells), some complexes 
being observed in Gl phase (Dyson, 1998).
The phosphorylation state of pocket proteins is thought to regulate the 
formation of E2F complexes. The phosphorylation of pocket proteins disrupts 
E2F/pocket protein complexes, and the affinity of pocket proteins for E2F decreases 
as pocket proteins become hyperphosphorylated, releasing free E2F and resulting in 
an increase in E2F activity. The phosphorylation state of pocket proteins fluctuates 
as cells cycle and is regulated by the action of cdks. pRb, p i07 and pi 30 all have 
multiple cdk phosphorylation sites, and the regulation of pRb phosphorylation has 
been studied in the most detail. The phosphorylation of pRb occurs in stages, firstly 
in eai'ly Gl phase, via action of cyclin D-dependant kinases, followed by the cyclin
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E-dependant kinases at the Gl/S phase transition (Mittnacht, 1998). The conversion 
of pRb from a hypophosphorylated form to a hyperphosphorylated form at the Gl/S 
phase boundary correlates with an increase in E2F activity, p i07 and p i30 are also 
phosphorylated in a cell cycle-dependent fashion (Beijersbergen et aL, 1995; Mayol 
et aL, 1995) suggesting that E2F complexes containing pl07 and p i 30 may also be 
regulated by pocket protein phosphorylation. Indeed, p i07 complexes containing 
cyclin A/cdk2 and cyclin E/cdk2 have been noted (Faha et aL, 1992; Schwartz et aL, 
1993).
1.6.6 Transcriptional regulation by E2F
I.6.6.a E2F target genes
Analysis of cellular promoters identified E2F sites in genes involved in cell 
cycle regulation. These genes include those required for DNA replication such as 
DNA polymerase a, dihydrofolate reductase (DHFR), thymidine kinase and ORCl 
and genes involved in cell cycle control including, cyclin A, cyclin E, p i 07, E2F-1 
and 2 and B-myb (Herwig and Strauss, 1997; Helin, 1998; Table 1.1). The E2F sites 
in target genes can mediate either activation or repression of transcription; since 
mutation of E2F sites in target genes can result in either an increase or decrease in 
promoter activity when compared to the wild-type promoter. For example, activation 
of the DHFR promoter is lost when an E2F site is mutated (Means et aL, 1992), 
although mutation of an E2F site in the B-myb promoter results in loss of repression 
during GO (Lam and Watson, 1993). This suggests that E2F can target some genes 
for silencing during specific stages of the cell cycle whilst at the same time 
activating others. The E2F sites in these genes are neai'ly identical but act in 
opposing ways, suggesting that other sequence elements or factors involved in the 
complex cell cycle regulation of E2F target genes. For example, the CDC25C 
promoter has multiple sequence elements required for the observed cell cycle 
regulation of expression, A cell cycle-dependent element (CDE) and a cell cycle 
homology region (CHR) element are both present in the CDC25C promoter and are 
required for cell cycle-dependant expression (Zwicker and Müller, 1997). Mutation 
of these promoter elements abolishes cell cycle-dependent expression of this gene 
and suggests that proteins may bind to these elements. Indeed, in vivo footprinting 
analysis of the CDC25C promoter during GO/Gl phase of the cell cycle revealed the
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CDE to be occupied by an unknown repressor protein (named CDF; Lucibello et aL, 
1995a). In addition, footprinting analysis of other E2F target genes, such as CDC2 
and cyclin A revealed GO/Gl specific occupation of both the CDE and the CFIR. 
Mutation of the CDE and the CHR sites results in a reduction in the repression of 
these promoters in GO (Zwicker et al, 1995). Furthermore, it has been suggested that 
the CDF may compete with E2F for promoter binding (Lucibello et aL, 1995b; Liu 
et aL, 1998).
1.6.6.b rmrtsactivation of E2F target genes by E2F complexes
At present little information is available as to how individual E2F complexes 
mediate activation or repression of particular E2F target genes. However, different 
combinations of E2F and DP family members have been shown to bind specifically 
to particular' sequences using the CASTing method of selection of random 
oligonucleotides (Tao et aL, 1997). This suggests that subtle differences in E2F sites 
may influence which E2F heterodimers preferentially bind. The recruitment of 
pocket proteins to the DNA by E2F prevents activation of the target gene and results 
in the formation of a repressive complex on the DNA, therefore pocket proteins not 
only block E2F transcription by masking the transocFiYeAion domain but also 
actively repress transcription (Hamel et aL, 1992).
E2F may co-operate with other transcription factors to activate transcription. 
For example, it has been noted that E2F target promoters often have binding sites for 
the Spl transcription factor and that E2F-1, 2 and 3, but not E2F-4 or 5, can 
physically interact with Spl. It is notable that mutation of these Spl sites can 
decrease the cell cycle related activity of E2F target genes (Karlseder et aL, 1996; 
Lin et aL, 1996). In addition, the GBP transcriptional co-activator stimulates E2F 
activity and directly interacts with the activation domain of E2F-1 (Trouche et aL,
1996). Furthermore, in vitro binding of E2F-1 with TBP, TFIIB and TFIIH has been 
shown (Hagemeier et aL, 1993; Pearson and Greenblatt, 1997), suggesting that 
interaction between E2F-1/DP heterodimers and the basal transcription machinery 
may enhance activation of transcription. It is likely therefore that a combination of 
promoter elements, different E2F/pocket protein complexes and interactions with 
other transcription factors act in concert to confer the opposing regulation of E2F 
target genes.
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1.6.7 The regulation of E2F activity
1.6.7.a Regulation of E2F by phosphorylation
The DNA binding and framactivation functions of E2F heterodimers are 
compromised when DP and E2F partners are phosphorylated. Phosphorylation of 
E2F-1 and DP-1 has been shown to occur via interaction with cyclin A/cdk2, which 
forms a stable complex with an N-terminal domain of E2F-1 (Dynlacht et ah, 1994; 
Ki'ek et aL, 1994; Xu et aL, 1994). It is thought that both DP-1 and E2F-1 are 
phosphorylated tlii'ough the formation of this cdk complex. Mutation of either the 
cyclin A binding domain of E2F-1 or the phosphorylation sites of DP-1 causes the 
formation of stable E2F complexes and an S phase arrest in transfected cells (Ki'ek 
et al., 1995). The phosphorylation of E2F-4, which does not have the cyclin A 
binding domain, occurs through association with pl07/cyclin A/cdk2 or p i07/ cyclin 
E/cdk2 complexes (Zhu et aL, 1995).
The binding of pRb and E2F-1 may also be regulated by phosphorylation of 
E2F-1. E2F-1 is phosphorylated on Ser-332 and Ser-337 in vitro and mutation of 
these residues prevents the formation of E2F-l/pRb complexes (Fagan et aL, 1994). 
In addition, phosphorylation of E2F-1 on Ser-375 by cyclin A/cdk2 enhances 
association with pRb (Peeper et aL, 1995). It is possible therefore that 
phosphorylation of E2F-1 allows the disruption of E2F-l/pRb complexes without 
pRb phoshorylation.
1.6.7.b Regulation of E2F by subcellular location
The subcellular location of individual DP and E2F family members differs 
when overexpressed in transfected cells. E2F-1, 2 and 3 are all nuclear proteins, 
whereas B2F-4 and 5 are cytoplasmic (de la Lima et aL, 1996; Magae et aL, 1996; 
Allen et aL, 1997; Müller et aL, 1997; Verona et aL, 1997). Correspondingly, the 
subcellular location of the DP proteins differs when overexpressed; DP-1 is a 
cytoplasmic protein, although the subcellular location of DP-3 differs for the 
individual isoforms. DP-3 a  and DP-3Ô are located in the nucleus and, in contrast, 
DP-3p and DP-3y have a cytoplasmic location (de la Luna et aL, 1996). DP-3 a  and 
Ô differ from DP-3p and y due to the inclusion of the E region, a 16 residue sequence 
in the DNA binding domain of the DP-3a and Ô isoforms (Ormondroyd et aL,
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1995). Subsequent analysis of this region revealed that together with additional C- 
terminal residues (named NLS II; Figure 1.7), the E region functions as a nuclear 
localisation signal (NLS; de la Luna et a l, 1996). DP-1 does not contain a domain 
resembling the E region, although the cytoplasmic location of this protein is not due 
to the presenee of a cytoplasmic retention signal, since fusion of the NLS of the Bel 
1 protein resulted in nuclear accumulation (Ormondroyd et al., 1995; de la Luna et 
a l, 1996).
An NLS has also been identified for E2F-1, since an N-terminal deletion 
mutant of E2F-1, lacking amino acids 85-91, within the cyclin A binding domain, 
results in cytoplasmic staining when overexpressed in U20S cells (Muller et a l,
1997). Likewise, an NLS is located in the same N-terminal region of E2F-2 as for 
E2F-1 and it has been postulated that an NLS exists in same N-terminal region of 
E2F-3 due to high amino acid conservation (Verona et a l, 1997). E2F-4 and 5 lack 
the N-terminal cyclin-A binding domain and do not contain an NLS, and like DP-1, 
both E2F-4 and 5 can locate in the nucleus via the addition of an NLS (Müller et a l, 
1997; Verona et a l, 1997).
The expression of a nuclear E2F (E2F-1, 2 or 3) with a cytoplasmic DP 
protein (DP-1, DP-3p, or DP-3y) results in the nuclear localisation of both proteins 
(Figure 1.10). Likewise, the expression of E2F-4 or 5 with DP-3a or §, results in 
nuclear accumulation of both the E2F and the DP. However, the co-expression of 
E2F-4 with DP-1 results in cytoplasmic location of both proteins (de la Luna et a i, 
1996; Magae et a l, 1996; Allen et a l, 1997; Müller et a l, 1997; Verona et a l,
1997). Hence, an E2F or DP protein that contains an NLS can recruit a partner that 
does not contain an NLS to the nucleus (Figure 1.10).
It has been demonstrated that dimérisation is required for recruitment of DP- 
1 to the nucleus by E2F-1 (Magae et a l, 1996). DP-1 is a frequent component of the 
E2F heterodimer in many cell types and is often found complexed with E2F-4 or 5 
(Bandara et a l, 1993, 1994; Girling et a l, 1993; Wu et ah, 1995). Although these 
complexes do not enter the nucleus via an intrinsic NLS sequence on either protein, 
the subcellular location of endogenous E2F-4 and 5 does vary during the cell cycle 
(Allen et ah, 1997; Müller et al., 1997; Verona et a l, 1997), suggesting that 
mechanisms must exist for nuclear entry of DP-1/E2F-4 or 5 complexes. The co­
expression of DP-1 with E2F-4 or 5 with p i07 or p i30 results in nuclear
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accumulation of both DP-1 and E2F-4 or 5 and requires the pocket protein-binding 
domain (Allen et aL, 1997; Magae et aL, 1996; Verona et al., 1997). Therefore, two 
possible mechanisms regulate the nuclear entry of E2F-4 and 5, the formation of a 
heterodimer witli DP-3 a  or ô (NLS containing DP-3 isoforms) and formation of 
complexes with p i07 or p i30. The mechanism of nuclear entry can influence the 
cell cycle; nuclear accumulation of E2F-5 mediated by pocket proteins results in cell 
cycle aiTest and in contrast nuclear entry via dimérisation with DP-3 a  or 6 results in 
cell cycle progression (Allen et aL, 1997). Analysis of E2F-dependent transcription 
supports this data; expression of E2F complexes that contain an NLS in cells results 
in activation of transcription and pl07-mediated nuclear localisation of E2F-4 
complexes results in repression of E2F transcription (Müller et al., 1997; Verona el 
a l, 1997).
1.6.7.C Regulation of E2F activity by protein degradation
The ubiquitin-mediated degradation of E2F represents another level of 
control of E2F activity. When overexpressed E2F-1 and 4 are degraded by the 
ubiquitin-proteosome pathway (Hateboer et al., 1996; Hofmann et al., 1996). The 
stability of E2F-1 and 4 is increased when associated with members of the pocket 
protein family and loss of the transcription activation domain and pocket protein 
binding domain of E2F-1 and 4 also results in increased stability.
1.6.8 E2F and proliferation
It is thought that the growth suppressive properties of the pocket protein 
family members involves repression of E2F-dependent transcription and that 
deregulation of E2F activity promotes S phase entry and stimulates proliferation. 
The overexpression of E2F family members supports this model; the forced 
expression of E2F-1 promotes S phase entry, both alone and when DP-1 is co 
expressed (Johnson et al., 1993; Shan and Lee, 1994; Wu and Levine, 1994). Similar 
results have been observed for the other E2F family members, although E2F-4 and 5 
require co-expression of DP-1 (Lukas et ah, 1996). In addition, the expression of 
E2F-1 can overcome Gl aiTest imposed by expression of the CDK inhibitors p i6, 
p21 and p27 (DeGregori et al., 1995), and can also be overcome by the expression 
of E2F-2 and 3 alone, but E2F-4 and 5 require co-expression of DP-1 (Lukas et al..
46
1996). The ability of E2F-1 to promote S phase entry depends on the dimérisation, 
DNA binding and /ra^ ï.s’activation domains and therefore it is assumed that E2F-1 is 
involved in activating genes essential for S phase entry (Jolmson et al., 1993).
The ability of B2F to drive cells into S phase would suggest that E2F might 
have oncogenic activity. Indeed DP-1 can cooperate with activated ras to transform 
rat embryo fibroblasts (Jooss et al., 1995) and E2F-1 overexpression in rat embryo 
fibroblasts can induce neoplastic transformation (Singh et al., 1994). In addition, 
cooperation of E2F-4/DP-1 with activated ras can transform rat embryo fibroblasts 
(Beijersbergen et al., 1994). A mutant E2F-4 that cannot interact with pocket 
proteins can transform NIH 3T3 fibroblasts and cause tumour formation in nude 
mice (Ginsberg et al., 1994). It is therefore possible that E2F family members may 
function as oncogenes when deregulation is coupled with other mutations such as 
ras activation, in tumour cells.
1.6.9 Overexpression of E2F-1 leads to apoptosis
The overexpression of E2F-1 causes S phase entry and proliferation, 
although in many cell types overexpression of E2F-1 leads to apoptosis. In 
fibroblasts in which E2F-1 is inducible, E2F-1 expression results in apoptosis when 
cells are grown in low serum (Shan and Lee, 1994). The induction of apoptosis by 
E2F-1 is p53-dependent as co-expression of wild-type p53 but not mutant p53 with 
E2F-1 stimulates apoptosis (Wu and Levine, 1994). The induction of apoptosis by 
E2F-1 is unique, as over-expression of the other E2Fs does not result in apoptosis 
(DeGregori et ah, 1997). In addition, both E2F-1 and DP-1 physically interact with 
p53 and this interaction decreases E2F-dependant transcription (O’Connor et al., 
1995; Sorensen et al., 1996); E2F-1 also interacts with MDM2 (Martin et al., 1995). 
However, it is unclear how these interactions influence induction of apoptosis by 
E2F-1.
E2F-1 can also induce apoptosis in cells that lack p53 (Hsieh et al., 1997; 
Phillips et al., 1997), suggesting that a p53-independent mechanism exists. This 
apoptosis requires DNA binding but not ïrawi-activation, and the expression of pRb 
can inliibit E2F-1 induced apoptosis in the absence of p53 (Hsieh et al., 1997). In 
addition, p5 3-independent apoptosis by E2F-1 does not require S phase entry 
(Phillips et al., 1997). Since the DNA binding but not frawi'activation functions of
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E2F-1 are required for p53-independent apoptosis, E2F-1 may act to repress 
transcription of tai'get genes.
The analysis of mice with homozygous deletion of E2F-1 revealed defects in 
apoptosis in thymocytes (Field et ah, 1996) and in older mice, a high incidence of 
sporadic tumours was observed (Yamasaki et ah, 1996). Such data strongly supports 
a role for E2F-1 as a regulator of apoptosis and in suppression of proliferation. It has 
also been noted that in pRb-deficient embryos high levels of apoptosis are observed 
(Jacks et ah, 1992; Lee et ah, 1996). Analysis of embryos that lack both p53 and 
pRb revealed apoptosis in the lens and central nervous system is p53-dependent 
whereas, apoptosis in the peripheral nervous system was p53-independent 
(Morgenbesser et ah, 1994; Macleod et ah, 1996).
1.7 Aims
The aims of this project were to study the expression of murine DP-3 
isoforms at both the RNA and protein level. The identification of cellular 
cireumstances under which DP-3 is expressed would enable further investigation 
into the functions of DP-3 under physiological conditions and the elucidation of the 
role of DP-3 in the E2F heterodimer and in growth regulation.
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Figure 1.1
The assembly of RNA polymerase II transcription initiation complex on a 
TATA containing promoter
A schematic representation of the assembly of basal transcription factors on a TATA 
containing promoter.
a) Assembly of the TFIID complex on the TATA box. TFIID is composed of the 
TATA-binding protein (TBP, red) and TBP-associated factors (TAFs, orange).
b) TFIID targets other basal transcription factors to the transcriptional start site; 
TFIIB (green) binds and recruits RNA polymerase II (yellow), this interaction is 
thought to be stimulated by TFIIF (white).
c) TFIIE (lilac) and TFIIH (blue) then associate with the complex. In addition, TFIIJ 
(pink) may bind to the complex to form a fully primed initiation complex and 
transcription can proceed.
49
Figure 1.1
a)
Figure 1.2
7>u//5activation by DNA-binding transcription factors
A schematic representation of the activation of transcription by transcription factors.
a) Direct //‘««^activation. Transcription factor (TF, white) binds to the upstream 
activating sequence (UAS) and stimulates transcription by contacting the basal 
transcription machinery. The transcription factor contacts the TAFs (orange), 
components of TFIID (See Figure 1.1).
b) Transcription via co-activators. The transcription factor (white) stimulates 
transcription via the intermediate co-activator (blue). The co-activator forms a 
bridge between the TF and the basal transcription machinery.
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Figure 1.2
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Figure 1.3
The mechanism of translation initiation
Diagrammatic representation of the initiation phase of eukaryotic translation. 
(Adapted from Pain, 1996)
a) The 80S ribosome dissociates, the 40S subunit binds both elFlA  and eIF3 (43 S) 
and the 60S subunit binds to eIF6. Met-tRNAi binds to eIF2-GTP forming a ternary 
complex, which subsequently binds to the 40S ribosomal subunit. Thus, the 43S 
preinitiation complex is formed.
b) The 43 S preinitation complex binds to the mRNA, usually via the m^G cap 
structure, and scans along the RNA until the initiator codon is recognised. This 
process involves several initiation factors, required for the formation of the cap- 
binding complex and also to inhibit any mRNA secondary structure.
c) eIF5 recognises the preinitiation complex and promotes the hydrolysis of the GTP 
bound to elF2. eIF2-GDP is then released and recycled. Initiation factors dissociate 
from the 40S subunit and the 60S subunit joins, forming the 80S initiation complex 
and elongation proceeds.
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Figure 1.3 eIF2 + GTP
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Figure 1.4
The mammalian cell cycle
A schematic representation of the mammalian cell cycle.
The mammalian cell cycle is separated into distinct phases. G1 (Gap 1), S (S phase, 
DNA synthesis phase), G2 (Gap 2) and M (mitosis). GO represents a non-dividing or 
differentiated state. Cell cycle progression is coordinated by the cyclin-dependent 
kinases (cdk) and their cyclin partners, which phosphorylate important substrates 
such as the retinoblastoma gene product (pRb, orange), in a cell cycle dependent 
manner.
55
Figure 1.4
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Figure 1,5
The E2F family
A diagram summarising the members of the E2F family of proteins.
The conserved domains of the E2F family are indicated, including the pocket protein 
binding domain (pp binding, red), the region of similarity with the DP family 
(orange). The heptad (blue) and marked (green) boxes are also shown; these are 
regions of sequence similarity, however at present their functions are unknown. The 
DNA binding domain is also indicated (Adapted from Lam and La Thangue, 1994; 
Dyson, 1998).
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Figure 1.6
The DP family
A schematic summary of the DP family members.
The conserved domains DCBl (lilac), DCB2 (purple, DP conserved boxes 1 and 2) 
and NCB (pink, negatively-charged box) are indicated. The DBF box (blue, DP-E2F 
homology region) contains the region of greatest similarity to E2F family members. 
The positions of the DNA binding and dimérisation domains are indicated (Adapted 
from Lam and La Thangue, 1994).
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Figure 1.7
DP-3 protein isoforms
A schematic representation of the DP-3 protein isoforms, indicating the site of the E 
region (blue) and the glutamine (Q) insertion. The sequence required in addition to 
the E region, for nuclear localisation is also indicated (NLS II, yellow), this region is 
common to all DP proteins.
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Figure 1.8
The organisation of the 5’ untranslated regions of DP-3 RNA.
A diagrammatic representation of the 5”UTRs of DP-3 RNA
a) The 5’UTR arise from rearrangement of the five segments numbered 1-5. These 
sequences contain two different initiation signals (Ml and M2).
b) The 5’UTRs of DP-3. Arrows represent possible sites of translational initiation 
and X corresponds to the sites of translational termination. indicates sites of 
translational stop signals.
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Figure 1.9
The regulation of E2F heterodimers by stable binding to members of the pRb 
family
A diagrammatic representation of the regulation of E2F by interaction with members 
of the pRb family (pocket proteins).
a) DP (blue) and E2F (red) heterodimers bind to promoters containing E2F binding 
sites and activate transcription.
b) Members of the pocket protein family, exemplified by pRb, bind to E2F 
heterodimers and the transcription of genes containing E2F sites ceases. It is thought 
that the binding of pocket proteins to E2F result both in the formation of inhibited 
complexes, tlirough masking of the E2F /raMjactivation domain. Additionally, the 
recruitment of pocket proteins to the DNA may also result in the formation of a 
repressive complex.
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Figure 1.9
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Figure 1.10
The regulation of E2F by subcellular localisation
A schematic summary of the regulation of E2F by subcellular location and by 
heterodimer composition.
a) The formation of E2F heterodimers between E2F4/5, which do not contain an 
NLS and DP-3 E+ isoforms (a  and ô) which have an NLS, results in nuclear 
localisation of both the E2F and the DP partners.
b) E2F heterodimers composed of DP-3 isoforms that do not contain the E region 
and E2F4/5, which also do not have an NLS would not b able to accumulate in the 
nucleus. However, association with members of the pocket protein family results in 
the localisation of the E2F heterodimer to the nucleus. The formation of E2F pocket 
protein complexes localised to the nucleus results repression of E2F target genes.
c) The formation of heterodimers composed of E2F1, 2 or 3, which contain an NLS 
and DP proteins which lack an NLS (E minus DPs; DP-1, DP-3 p and 5), results in 
the accumulation of both partners in the nueleus. Such a complex would then able to 
activate E2F tai'get genes.
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Figure 1.10
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Table 1.1 E2F Target Genes
Genes involved in DNA replication and Sphase
DNA polymerase a  
Thymidine kinase 
Thymidylate synthase 
Dihydrofolate reductase (DHFR)
ORCl
CDC6
Hi stone H2A 
PCNA
Proto-oncogenes and transcription factors
E2F-1
E2F-2
pRb
pl07
c-myc
N-myc
B-myb
jun
Cyclins and CDKs
Cyclin-A 
Cyclin-E 
Cyclin D 
cdc2
Compiled from Helin, 1998; Herwig and Strauss, 1997.
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Chapter 2.
Materials and Methods. 
2.1 Mammalian cell culture
All tissue culture cell lines were cultured in Dulbecco’s modified Eagle’s 
Medium (DMEM) (Gibco BRL), supplemented with 10% fetal calf serum (Gibco 
BRL) and lOOU/ml penicillin, lOmg/ml streptomycin (Gibco BRL), at 37°C in a 5% 
CO2/ H2O saturated atmosphere. Cells were passaged by washing with sterile 
phosphate buffered saline (PBS) and treatment with trypsin/EDTA (Gibco BRL). 
Detached cells were resuspended in DMEM with PCS to arrest the trypsin and cells 
diluted and re-plated in tissue culture treated flasks. Alternatively, cells were 
pelleted by centrifugation at 900rpm at room temperature for 5 minutes, resuspended 
in fresh medium, counted in a haemocytometer and plated in tissue culture dishes. 
For immunostaining analysis (Section 2.12.4) sterile glass coverslips were 
introduced during the passage of cells and removed for staining before passage of 
cells.
2.1.1 Differentiation of F9 embryonic teratocarcinoma cells (F9EC).
F9EC cells were stimulated to differentiate to F9 parietal endoderm like cells (F9PE) 
by culture in DMEM with 10% fetal calf serum, supplemented with ImM N^,2’-0- 
dibutyladenosine 3’:5’ cyclic monophosphate (cAMP), 0.05pM trans retinoic acid 
and O.lmM 3- isobutyl-1 methyl-xanthine (IBMX). F9EC cells typically were 
seeded at 0.5x10^ cells per 10cm dish and harvested at 3, 5 and 7 days after addition 
of cAMP, retinoic acid and IB MX.
2.1.2 Transfection of mammalian ceils
Transient transfection of U20S, C33A, F9EC and SAOS-2 cells with 
expression vectors was performed using the calcium phosphate co-precipitation 
method (Maniatis et al., 1989). The transfection of NIH 3T3 was performed using 
lipofectamine (Gibco BRL) and COS-7 cells were transfected using lipofectin 
(Gibco BRL),
Cells for transfection by the calcium phosphate method were plated at 1x10^ 
cells per 100mm tissue culture dish or 5x10^ cells per 60mm tissue culture dish the
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day before transfection and left to attach overnight. Four hours prior to transfection, 
fresh medium was added. The DNA/calcium phosphate precipitates were made by 
mixing 7.5pg DP-3 5'UTR-luciferase expression vector, 0.5pg pCMVp-gal 
expression vector and high molecular weight DNA (Boehiinger Mamiheim) to a 
final concentration of lOpg. To this, 25pl of 2.5M CaCb was added and the volume 
made up to 250pl with dH20. The DNA solution was then added dropwise, with 
mixing to 250pl of sterile 2xHBS. The precipitates were allowed to form at room 
temperatme for 15-30 minutes and then added dropwise to the cells and left 
overnight. The following day the medium was removed and the cells washed twice 
with either sterile PBS or DMEM (no FCS) and fresh DMEM supplemented with 
FCS was added. The cells were harvested at 48 hour post-transfection by scraping in 
1ml PBS, 750pl of cell suspension was pelleted and used for RNA extraction, the 
remaining 250pl of cell suspension was pelleted and resuspended in Ix reporter lysis 
buffer (Promega Corporation) and used for reporter assays (Section 2.1.3) and 
protein analysis.
The transfection of SAOS-2 cells with p53 was performed using 12pg of DP- 
3 5'UTR-luciferase vector, Ipg pCMV|3-gal expression vector and variable amounts 
of p53 expression vector or the coiTesponding backbone vector. High molecular 
weight DNA was added to give a final concentration of 20pg DNA, 50pl 2.5M 
CaCl2 was then added and the volume made up to 500pl. The DNA solution was 
then added to 500pl 2xHBS as before. The preciptitate was then split between two 
60mm tissue culture dishes. Cells were harvested by scraping m i x  reporter lysis 
buffer and reporter assays performed.
NIH 3T3 cells were plated at 1x10^ cells per 100mm tissue culture dish and 
left to attach overnight. Lipofection was performed by mixing 20pi lipofectamine 
and 400pl of DMEM (no FCS) and incubation for 30 minutes at room temperature. 
The DNA, usually lOpg of DP-3 5'UTR-luciferase expression vector and Ipg 
pCMV(3-gal expression vector was mixed with 400pl DMEM (no FCS) and the 
added to the lipofectamine mix and incubated at room temperature for 10 minutes. 
The cells were then washed twice with DMEM to remove FCS. 6ml of DMEM was 
then added to the DNA and lipofectamine mixes and added to the cells (final volume 
medium, approximately 6.8ml). The following day the cells were washed and
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DMEM supplemented with FCS replaced. The lipofection of COS-7 cells was 
performed in the same maimer except the cells were plated onto 60mm dishes, 14pl 
of lipofectin was added to 200pl of DMEM and the DNA was mixed with 200pl 
DMEM. After the final incubation, 3ml of DMEM was added and this was then 
added to the cells. Cells were harvested the same manner as the other cell lines.
2.1.3 Reporter assays
Transfected cell lysates were pelleted briefly to remove cell debris and the 
supernatant used for luciferase and p-galactosidase reporter assays.
2.1.3.1 Luciferase reporter assay
Half the cell lysate was assayed for luciferase enzymatic activity using the 
luciferase substrate solution (Promega Corporation) in an automated luminometer. 
The luciferase activity for each sample was then divided by the p-galactosidase 
activity of the same sample to give the relative luciferase enzyme activity.
2.1.3.2 p“galactosidase reporter assay
The cell lysate was made up to 150pl with dHiO and mixed with 150pl 2x (3- 
gal assay buffer and incubated at 37°C until the yellow colour had fully developed. 
0.5ml of IM NaCO] was then added to stop the reaction and the optical density 
(OD) immediately measured at 420nm. The CD obtained was then used to normalise 
the luciferase enzyme activity.
2.2 Bacterial culture
Bacterial liquid cultures were prepared by inoculation of an appropriate 
volume of LB media containing ampicillin (50-100pg/ml) as required and 
incubation at 37°C, overnight, with shaking. Bacterial colonies were maintained on 
LB agar plates with ampicillin where necessary, stored at 4°C. For long term 
storage, an aliquot of an overnight liquid culture supplemented with 15% glycerol, 
was stored at -80°C.
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2.3 Manipulation of nucleic acids
2.3.1 Determination of nucleic acid concentration
The concentration of nucleic acid solutions was determined by absoiption at 
260nm. Concentration was calculated using the formulae:
An OD of hôonm = 50|ug/ml for double stranded DNA solutions 
An OD of l 260nm = lOpg/ml for DNA oligonucleotide solutions 
An OD of l 260nm = 40|ag/ml for RNA solutions.
2.3.2 DNA Preparation
Mini preparations of plasmid DNA were performed using SV Mini prep kits 
(Promega Corporation), using an appropriate volume of overnight culture of E. coli 
cells, according to the manufactui'er’s instructions. Alternatively, plasmid DNA was 
isolated from 1.5ml of overnight culture of E, coli cells by alkaline lysis, organic 
extraction and ethanol precipitation via standard protocols (Sambrook et aL, 1989). 
Plasmid DNA was resuspended in 50pl of TE or sterile distilled water (dH20).
Large scale preparations of plasmid DNA were performed using Qiagen maxi DNA 
preparation kits, from an appropriate volume of overnight culture of E. coli cells, 
according to the manufacturer’s instructions.
2.3.2a Preparation of murine brain genomic DNA.
One freshly dissected mouse brain was homogenized in PBS with a small 
Dounce homogeniser. The homogenate was pelleted and gently resuspended in 
0.5ml PBS and 10ml proteinase K buffer was added. 358pl proteinase K (lOmg/ml) 
was then added and gently mixed and incubated overnight at 37°C. An equal volume 
of phenol (pH8.0) was added and gently mixed for 1 hour and then centrifuged at 
3000rpm at room temperature for 10 minutes. The upper aqueous phase was then re­
extracted with an equal volume of phenol, mixed by hand for 5 minutes and 
centrifuged as before. The upper aqueous phase was re-extracted with an equal 
volume of chloroform as before. The DNA was precipitated by the addition of an 
equal volume of isopropanol and mixed gently by hand for 5 minutes. 0.25 volumes 
of 5M NaC104 were added and mixed gently, the DNA forms a ball from which the 
supernatant was removed by decanting. The DNA was then washed with 70%
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ethanol by gentle mixing and the supernatant removed by decanting. The genomic 
DNA was then briefly air dried and dissolved in 1ml sterile TE at 37°C for an hour.
2.3.2b Purification of phage DNA
A single plaque was picked using a sterile pasteur pipette and cultured in 
50ml LB media supplemented with lOmM MgS04, overnight at 37°C, with shaking. 
Once bacterial lysis was clearly observed 0.5ml chloroform was added and the 
culture incubated at 37°C, with shaking for 5 minutes. The culture was then 
centifuged at 4000ipm at room temperature for 20 minutes and the supernatant 
retained. Bacterial RNA and DNA was digested by the addition of DNase I and 
RNase to lOql/ml and incubated at room temperature for 30 minutes, or at 4°C 
overnight. Phage particles were pelleted at 16 OOOrpm, 4°C for 2 hours (Sorvall 
SS34). The supernatant was completely removed and the pellet resuspended in 0.5ml 
O.IM Tris (pH 7.9), 0.3 M NaCl and transferred to an eppendorf tube. The phage 
coat was digested by the addition of proteinase K to Iql/ml and incubated at 37°C 
for 30 minutes, the proteinase K was inactivated by the addition of EDTA to a final 
concentration of lOmM. The DNA was then extracted three times with 
phenol/chloroform/iso-amyl-alcohol (ratio 25:24:1, %), pre-equilibrated with IM 
NaCl, 20mM Tris/HCl (pH 8.0), ImM EDTA. DNA was then precipitated with 2 
volumes of ethanol at -20°C for at least 1 hour, and pelleted at 13OOOrpm at room 
temperature. The purified phage DNA briefly air dried and resuspended in 50pl T.E 
and stored at 4°C.
2.3.3 RNA Extraction
Total cellular' RNA was extracted from tissue culture cells using Tri Reagent 
(Molecular Research Center), following the manufacturer’s instructions.
All purified RNAs were solubilised in Formazol (Molecular Research Center) and 
stored at -80°C.
2.3.3a Extraction of nuclear and cytoplasmic RNAs.
NIH 3T3 cells were harvested PBS and pelleted at 3OOOrpm, 4°C. Cell 
pellets were resuspended in 0.5ml fractionation buffer per 6x10^ cells, incubated on
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ice for 5 minutes and centrifuged at 3OOOrpm for 2 minutes, 4°C. The supernatant 
was retained (cytosolic fraction) and stored on ice. The pellet (nuclear fraction) was 
washed with 0.5 ml fractionation buffer and incubated on ice for 5 minutes, 
centrifuged at 3OOOrpm at 4°C for 2 minutes, the supernatant was retained and added 
to the cytosolic fraction and stored on ice.
The cytosolic RNAs were purified using Tri Reagent LS (Molecular 
Research Center), following the manufacturer’s instructions. Nuclear RNAs were 
isolated from the pellets using Tri Reagent, following the manufacturer’s 
instructions. RNA was solubilised in Formazol (Molecular Research Centre) and 
stored at -80°C.
2.3.3b Isolation of polyadenylated mRNAs
Polyadenylated mRNA was purified from total RNA using an Oligotex 
mRNA mini kit (Qiagen) following manufacturer’s instructions and stored at -80°C.
2.3.4 Genomic library screening
A A.GEM12 genomic library prepared from embryonic stem cell line 
SV129D3 was kindly supplied by J.M. Gamier and P. Chambon. The phage titre 
was determined by serial dilution, plating and counting of phage plaques. The 
bacterial strain LE392 (Promega Coiporation) was used as the phage host strain and 
was cultured overnight in LB, the cells were then harvested by centrifugation at 
3000 rpm and resuspended in lOmM MgS04. The phage library was diluted in X 
diluent and gently mixed with plating bacteria and incubated at 37°C for 20 minutes. 
A solution of 0.7%agarose in LB was autoclaved and stored at 50°C, prior to use, 
MgS04 was added to a final concentration of lOmM. 50ml of top agarose was then 
added to the phage, mixed and then plated on LB agar plates, which has been dried 
and warmed to 45°C. Once the top agarose had set, the plates were inverted and 
incubated at 37°C until plaques had formed, after which plates were stored at 4°C.
Phage lifts were made in duplicate, using Hybond-N membrane (Amersham 
International) and each membrane denatured in denaturing solution for 1 minute. 
The membranes were then placed in neutralising solution for 5 minutes and rinsed in 
2xSSC, air dried and UV crosslinked using a UV crosslinker (Amersham
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International), set to autocrosslink mode and stored dry at room temperature. The 
filters were then hybridised using a DP-3 cDNA probe, washed (Section 2.8) and 
visualised by autoradiography (Section 2.9). Positive plaques were picked using a 
sterile pasteur pipette and phage eluted in X diluent. The phage were re-plated until 
pure and phage DNA then purified (Section 2.3.2b).
2.3.5 Restriction endonuclease digestion
Single enzyme digests were performed in Ix enzyme reaction buffer supplied 
with the restriction endonuclease, at the recommended temperature (usually 37°C). 
Double digests were performed in Ix reaction buffer suitable for both enzymes. 
Where no buffer was compatible with both enzymes, DNA was digested with one 
enzyme and then phenol/chloroform extracted and ethanol precipitated and digested 
with the other enzyme. The quantity of restriction endonuclease added to a digest 
varied depending on the source of DNA, however generally lunit of enyzme was 
added per pg of DNA in a 20pl reaction, at the appropriate temperature. When 
digesting genomic DNA an excess of enzyme was usually added to ensure adequate 
DNA restriction.
2.3.6 Polymerase chain reactions (PCR)
PCR reacts were all performed using the same conditions in a programmable 
thermal controller. A typical reaction contained lOng plasmid template, lOOng of 
each primer, lOmM of mixed dNTP and IxPCR reaction buffer (supplied with 
enzyme). To this, 2 units of Taq polymerase (Promega Corporation) was added and 
overlaid with paraffin oil. Typically, samples were initially heated to 94°C for 2 
minutes and then for another 30 seconds, then cooled to the annealing temperature 
for 30 seconds, and then incubated at 72°C for 1 min and then back to 94°C for 30 
seconds. This cycle was then repeated 30 times. The annealing temperatures were 
calculated using the formula for the Tm of an oligonucleotide, section 2 .8.
2.3.7 Phosphatase treatment of vector DNA
Vector DNA digested with a single enyzme was de-phosphorylated prior to 
ligation to prevent re-ligation of the vector. Calf intestinal alkaline phosphatase was
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added to digested DNA, approximately 0.1 units /pmol of DNA ends, was used per 
reaction. Reactions were performed in Ix alkaline phosphatase buffer, supplied with 
the enzyme (Boehringer Mannheim) at 37°C for 15 minutes. The vector DNA was 
purified by phenol/chloroform extraction and ethanol precipitation. The vector DNA 
was then checked on a gel and the concentration estimated.
2.3.8 Ligation reactions
Ligation reactions were performed in 10pi volume containing lxT4 DNA 
ligase buffer supplied with the enyzme and 10 units of T4 DNA ligase (Promega 
Corporation). Generally 50ng of vector DNA was used with a 3x molar excess of 
insert added. Reactions were performed either at 16°C overnight or at room 
temperatui'e for 2 hours.
2.3.9 Transformation of competent bacteria
Transformations were performed using purchased competent cells, generally 
E.coli strains XL-1 Blue (Stratagene) and DH5a (Gibco BRL) were used. 5pi of 
ligation reaction was transformed by mixing with 50pl competent cells and 
incubating on ice for 20 minutes. The bacteria were then heat shocked at 42°C for 20 
seconds and returned to ice for a further 2 minutes. 500- lOOOpl warmed LB was 
then added and the bacteria incubated at 37°C for 30 minutes with shaking. 200pi 
was plated on LB agar containing 50-100pg/ml ampicillin and incubated at 37°C.
2.3.10 DNA Sequencing
Plasmid DNA was sequenced using a Sequenase version 2.0 DNA 
sequencing kit (USB) following manufacturer's instructions. Alternatively, plasmid 
DNA was sequenced using an automated DNA sequencer. PCR reactions were 
performed as recommended (Applied Biosystems) and were analysed on ABI 
sequencers by the Glasgow University sequencing service.
2.3.11 Construction of genomic plasmid clones
Each genomic phage DNA was digested for four hours with Sad. The 
restriction digests were then phonol/chloroform extracted, precipitated and ligated
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into Sad digested and phosphatase treated pBluescript KS II (Stratagene). The 
dones were named by phage number (pi), restriction enzyme used and mini­
preparation number, for example p ll-S ad -3 . The inserts were the mapped by 
Southern blotting using oligonucleotides from the DP-3 ORF (Table 2.2) and 
sequenced (Table 2.1). The E exon clone pBKS 13-17, was constructed by digestion 
of phage 3 with Notl and Xhol, gel purification of the 5Kb fragment and ligation 
into pBluescript KS II (Stratagene) cut with Notl and Xhol.
2.3.12 Construction of DP-3 type IV 5’UTR-luciferase expression vector
DP-3 type IV 5'UTR-luciferase expression vector was constructed using 
PCR. The first round of PCR used a sense oligonucleotide primer from the 5' 
terminus of a type IV done, with a Hindlll restriction site (7.1 OH, Table 2.2) and an 
antisense oligonucleotide primer from exon 5 spanning the M2 ATG and fused to 
the 5' end of the luciferase ORF (Luc 3) with a type IV vector as template. The 
second round of PCR used a sense oligonucleotide primer from the 5'end of the 
luciferase ORF fused to the M2 region of DP-3 (Luc 1) and an antisense 
oligonucleotide primer from the EcoRI site of luciferase (Luc 2), using pGL2Control 
(Promega Corporation) as a template. The products of each PCR were purified by 
agarose gel electrophoresis and both used as templates in the third PCR reaction, 
using 7.1 OH and Luc 2 as primers. The product of this PCR was then chloroform 
extracted, precipitated and digested with Hindlll and EcoRI. The restricted DNA 
was gel purified and cloned into the Hindlll and EcoRI sites of pGL2Control 
(Promega Corporation) and sequenced. The type IV-luciferase was digested with 
Hindlll and BamHI, gel purified and subcloned into the Hindlll and BamHI sites of 
pBluecript KS II (Stratagene) for use in in vitro translation experiments.
Luc 1  ^GGACCCCAAATGATTGAAGACGCC AAAAAC- 
L uc2 ’ GTAGATCCAGAGGAATTC^'
Luc 3 ^'GTCTTCAATCATTTGGGGTCC^'
2.3.13 Vectors used
DP-3 5'UTR-luciferase constructs containing type I, type II and type III were 
prepaied as described in section 2.3.12 and kindly provided by S. de la Luna. The
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control vector was pGL2Control (Promega Corporation) and the mock vector used 
was pSG5.
The p53 expression vector contains BamHI fragment of p53 in pCMV-neo 
BAM vector, kindly supplied by D, Lane (Baker et al., 1990).
The DP-3 type I, type II and type III 5'UTR and control vectors in 
pBluescript KS II (Stratagene) were kindly supplied by S. de la Luna.
2.4 Agarose Gel Electrophoresis
2.4.1 Electrophoresis of DNA samples
Agai'ose gels were prepared for the analysis of DNA samples. Typically 1% 
gels were prepared for the analysis of plasmid DNAs, 0.8% gels were used to 
electrophorese genomic and phage DNA samples. Agarose gels were prepared by 
dissolving an appropriate amount of agarose in IxTBE by warming. Once cooled 
ethidium bromide was added to a final concentration of 0.2pg/ml. Gels were run in 
IxTBE and run at an appropriate voltage at room temperature. DNA samples were 
prepared by addition of DNA sample buffer to Ix. Electrophoresed DNA was 
visualised using an UV transilluminator with a digital imaging system.
2.4.2 Electrophoresis of RNA samples
Denaturing 1% agarose gels were prepared for the analysis of RNA samples. 
These were prepared by melting an appropriate amount of agarose in DEPC-treated 
water. Once cooled lOx MOPS and formaldehyde were added to final concentrations 
of Ix and 2.2M respectively. RNA was prepared by adding lOpl deionised 
formamide, 2pi lOxMOPS, 3.5pl 37% formaldehyde and Ipl ethidium bromide 
(2pg/pl). Prior to loading RNA was denatured at 65°C for 15 minutes and placed on 
ice. 2pl formaldehyde gel loading buffer was added and samples loaded 
immediately. Denaturing gels were run in IxMOPS/DEPC-HiO at 4°C, usually 
overnight at a low voltage. Electrophoresed RNA was visualised using an UV 
transilluminator. RNA gels for Northern blotting were then rinsed briefly in DEPC- 
H2O to remove excess formaldehyde and used for Northern blotting.
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2.4.3 Gel purification of DNA fragments
Fragments generated from restriction digests were purified by 
electrophoresis in low melting point agarose gels prepared in IxTAE as detailed 
(Section 2.4.1). The required fragments were excised using a scalpel and the DNA 
extracted by melting the agarose at 65°C for 5 minutes. EDTA and NaCl were added 
to 1 OmM and 1 OOmM respectively and the DNA was extracted with phenol (pH 8) 
and preciptated with 2 volumes of ethanol at -20°C. The DNA was then pelleted, 
washed with 70% ethanol and resuspended in TE. An aliquot of purified DNA was 
checked on an agarose gel to ensure extraction was successful and DNA 
concentration estimated.
2.5 Southern and Northern blots
Southern and Northern blots were prepared from agarose gels containing 
DNA and RNA samples. All blots were performed using Hybond-N (Amersham 
International) according to the manufacturer’s protocol. Blotting was usually 
performed overnight. Blots were then UV crosslinked using a UV crosslinker 
(Amersham International), set to autocrosslink mode.
2.6 Dot Blotting
RNA samples were prepared for dot blotting in Ix dot blotting solution and 
denatured at 65°C for 15 minutes and then placed on ice. Samples were blotted 
under vacuum onto Hybond N (Amersham International), soaked in 2x dot blotting 
solution, using Biorad dot blotting apparatus. Blotting samples were washed twice in 
200pl 2x dot blotting solution under vacuum. The blotting apparatus was then 
dismantled and the blot left to dry. The RNA was fixed by UV-crosslinking as 
before.
2.7 Probe preparation
2.7.1 Random priming
All DNA probes were prepared by random priming using 50-100ng gel 
purified template DNA, (a-^^P)dNTP (usually dCTP, Amersham International) and
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the Megaprime kit (Amersham International) according to the manufactui'er’s 
instructions.
2.7.2 5’ end labelling of oligonucleotides
Oligonucleotides were end labelled using (y-^T)ATP (Amersham 
International). Each labelling reaction consisted of lOpmol of oligonucleotide, 
lOpmol of (y-^^P) ATP, lOU of T4 polynucleotide kinase (Promega Corporation) and 
lxT4 polynucleotide kinase buffer (supplied with the enzyme) in a final reaction 
volume of lOpl. Reactions were incubated at 37°C for 30 minutes.
2.7.3 DP-3 E region probe
An E region probe was made using a primer to the 5’ end of the E region 
sequence (MB-E’^ ) and template DNA, pBKSDP-3a digested with BsrI. BsrI cuts 
DP-3 cDNA in several places including the 3’ end of the E region. 3pg pBKSDP-3a 
digested with BsrI (New England Biolabs) and 20pmol MB-E^ primer were mixed 
and denatured by boiling for 5 minutes. The primer and template were annealed by 
heating to 65°C for 2 minutes and leaving to cool gradually to 37°C. 3pi OLB 
(minus dCTP and dGTP), 12 pg BSA, 3pl (a-^¥) dCTP (3000Ci/mmol, Amersham 
International), 3pi (a-^^P) dGTP (3000Ci/mmol, Amersham International), lOU 
Klenow fragment was then added. The reaction was incubated at 37°C for 1 hour. 
MB-E'" ^TCGTTTACTTTCTGAGA^’
2.7.4 Probe Purification
Probes were purified using Quick Spin columns (Boehringer Mannlieim), 
DNA probes were purified thiough Sephadex G50 columns and oligonucleotide 
probes tlrrough G25 columns. On occasion, oligonucleotide probes were purified by 
phenol/chloroform extraction and precipitation.
2.8 Hybridisation of Southern, Northern and dot blots
Southern, Northern and dot blots were rinsed briefly in sterile H2O and 
hybridised in an appropriate volume of QuickHyb (Stratagene) in hybridisation 
bottles (Hybaid), in a hybridisation oven with shaking platform (Hybaid), at an
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appropriate temperatui’e. Typically DNA probes synthesised by random priming 
were hybridised at 65°C. End-labelled oligonucleotide probes were hybridised at 
temperatures determined by the melting temperature (Tm) of the oligonucleotide. 
The Tm was calculated by the formula:
Tm = [(G+C)x4] + [(A+T)x2] -5°C 
Blots were prehybridised for at least 1 hour and probes added. Ipl each probe was 
counted to determine the number of counts per minute (cpm) per pi of probe, 5x10^ 
cpm of probe was added per ml of hybridisation solution. Probes were hybridised 
overnight.
2.8.1 Southern, Northern and dot blot hybridisation washes
Blots hybridised with random primed labelled DNA probes were rinsed and 
then washed twice in 2xSSC/0.1%SDS for 10 minutes at 60°C, in roller bottles. The 
blot was then removed from the bottles and placed in a sandwich box. A high 
stringency wash was then performed in 0.1xSSC/0.1%SDS for 30 minutes at 60°C, 
on a shaking platform. Likewise, oligonucleotide probes were rinsed and washed 
twice in roller bottles in 6xSSC/0.1%SDS at 37°C. Higher stringency washes were 
performed at a temperature 5°C lower then the calculated Tm or the hybridisation 
temperature chosen, using 6xSSC/0.1%SDS for 30 minutes on a shaking platform.
2.9 Autoradiography
Washed blots were sealed in Saran wrap and exposed medical X-ray film 
(Fuji), in autoradiography cassettes with intensifying screens. Autoradiography was 
carried out at -80°C until satisfactory images were obtained.
2.10 Stripping Northern and Southern blots
Random primed generated DNA probes were removed from blots by 
washing in 50% formamide/1 OmM NaH2P04 (pH6.5), at 65°C for 30 minutes. 
Olignucleotide probes were stripped by washing in 0.1xSSC/0.1%SDS at 65°C for 
30 minutes. All blots were re-exposed to ensure all the probe had been removed.
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2.11 Protein analysis
2.11.1 Preparation of cellular protein extracts
Whole cell extracts of transfected tissue culture cells were prepared by 
harvesting in PBS and pelleting at 3OOOrpm, 4°C. Pellets were resuspended in Ix 
SDS gel loading buffer and stored at -20°C.
2.11.2 In vitro transcription/translation
Protein was translated in vitro from plasmid DNA templates using the TNT 
T3 coupled reticulocyte system (Promega Corporation), following manufacturer’s 
instructions. Ipg of plasmid DNA template was used in 50p,l reaction mixture with 
methionine (lOmCi/ml) and incubated at 30°C for 60-120 minutes, in vitro 
translated proteins were analysed by SDS PAGE (Section 2.11.3), vacuum dried and 
visualised by autoradiography (Section 2.9)
2.11.3 SDS PAGE
Protein samples were analysed by SDS PAGE (Laemmli, 1970). 10% 
denaturing polyacrylamide resolving gels with a low acrylamide/low pH stacking 
gel were prepared and electrophoresed in Ix SDS running buffer. Protein samples 
were prepared in Ix  SDS gel loading buffer and boiled prior to loading. Samples 
were electrophorised thiough the stacking gel at 80 volts, after which the voltage 
was increased to 110-130 volts, until the dye ft'ont had reached the bottom of the gel. 
Gels were immediately either vacuum dried or used for western blotting.
Resolving gel:
10% aerylamide/0.27% bis-acrylamide 
0.75M Tris-HCl (pH 8.8)
0.1% SDS 
Stacking gel:
5.1% aery lamide/0.186% bis-acrylamide 
O.IM Tris-HCl (pH 6.8)
0.1%SDS
Gels were polymerised by the addition of ammonium persulphate (APS) and 
TEMED (Sigma)
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2.11.4 Western blotting
Western blots were prepared from SDS polyacrylamide gels as described 
(Sambrook et al., 1989). Polypeptides were transferred onto 0.45pm pore 
nitrocellulose membrane (Biorad) at 400mA at 4°C, for 60-75 minutes, using a mini 
protein trans-blotter (Biorad). Transferred proteins were visualised by Ponceau-S 
(Sigma) staining of the membrane and destained by washing in PBS. The membrane 
was then blocked in 10% milk powder/PBS at room temperature for at least 30 
minutes, with shaking and incubated overnight in primary antibody, prepared in 5% 
milk powder/PBS. Where peptide competition was required, specific or non specific 
peptides were added to 25mg/ml final concentration. After incubation the membrane 
was washed three times for 15 minutes in PBS/0,25%Tween-20 (Sigma) and 
incubated in suitable secondary antibody, conjugated either to alkaline phosphatase 
(AP) (Promega Corporation) or horseradish peroxidase (HRP). Secondary antibody 
was incubated at room temperature for at least 30 minutes after which the membrane 
was washed three times for 15 minutes in PBS/0.25% Tween-20 and then developed 
for either AP or HRP activity.
Alkaline phosphatase activity was detected by incubating in NBT/BCIP solution 
prepared from an NBT/BCIP tablet (Sigma) dissolved in 10ml H2O.
Horseradish peroxidase activity was detected using the SuperSignal system (Pierce 
and Warriner) following the manufacturer’s instructions and visualised by 
autoradiography (Section 2.9).
2.12 Antibody production
2.12.1 Coupling of peptides to BSA.
1ml peptide 7.6 or 7.7 (5mg/ml) was mixed with 1ml bovine serum albumin 
(BSA) (5mg/ml in PBS), 2mls 0.2% glutaraldehyde/ PBS was added slowly whilst 
mixing at room temperature. The peptide was then mixed for 2 hours at room 
temperature. Glycine (pH 7.2, in PBS) was added to a final concentration of 200mM 
and mixed at room temperature for 1 hour. The peptide was then dialysed 
exhaustively in PBS at 4°C, and aliquoted and stored at -80°C.
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2.12.2 Rabbit immunisations
Antigen samples for immunisation were prepared by vortexing equal 
volumes of coupled peptide and Freunds complete adjuvant (Sigma) until 
thoroughly mixed. 1ml of antigen was prepared per rabbit. Rabbits were immunised 
and then boosted with antigen prepared in Freunds incomplete adjuvant (Sigma), 
four times at thi'ee week intervals. Test bleeds were taken and tested by western 
blotting. All the rabbits immunised elicited a response to DP-3 peptides and 
antibodies were therefore harvested by terminal bleed-out by cardiac puncture under 
general anaesthesia. Blood samples were left at room temperature to coagulate and 
then the coagulate was pelleted. The serum was removed, aliquoted and stored at - 
20°C.
2.12.3 Peptides used in this study
The following peptides were used in this study:
7.6 S D R K R A E F I D S D F S E
7.7 E A A Q  W V P S D R K R A
C D Y S T R R P L S P S N Q L Q E K H V
2.12.4 Antibody Reagents
Rabbit polyclonal anti-DP-3 antibody a7.2 has been described (Ormondroyd 
et aL, 1995; de la Luna et al., 1996). The rabbit polyclonal antibodies a7.6 ad a7.7 
were made as described in Chapter 7. The rabbit polyclonal anti-luciferase antibody 
was purchased from the Promega Coiporation and the anti-p-galactosidase 
monoclonal antibody pmchased from Boeliringer Mamilieim.
2.12.5 Immunofluoresence
Coverslips from transfected U20S cells were removed from culture dishes 
and washed in PBS. All washing of coverslips was performed by dipping each 
individual coverslip into a universal tube containing the wash solution, 10 times per 
wash. Cells were then fixed by treatment with 4% paraformaldehyde/PBS for 15 
minutes at room temperature and washed twice in PBS, coverslips were then 
transferred to a damp sponge, cell side facing upwards. The coverslips were then 
treated with l%TritonX-100/PBS for 10 minutes at room temperature and washed 
twice with PBS. Blocking was performed by the addition of lOOpl 5%FCS/PBS and
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incubation for 15 minutes at room temperature, followed by two washes in PBS. The 
primary antibody, either anti-7.2, (de la Luna et aL, 1996) or anti-7.6 (Chapter 7) 
was diluted 1:200 in 1%FCS/PBS, containing either peptide 7.6 or C at a 25mg/ml 
final concentration and cells treated for 30 minutes at room temperature, followed by 
four washes in PBS. Secondary antibody (anti-rabbit-FITC, Europath Ltd.) was 
diluted 1:200 in 1%FCS/PBS and cells treated for 15 minutes at room temperature. 
Coverslips were then washed four times in PBS, the final wash solution containing 
DAPI stain. Coverslips were then mounted in Citifiuor (Agar Scientific) on glass 
slides and analysed by fluorescence microscopy.
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Table 2.1
Summary of genomic plasmid clones and sequencing
Oligonucleotide Exon Phage Genomic plasmids
7.12A 6 3 p l3  SacI-1
7.16S 6 3 pl3  SacI-1
7.18S 6 3 pl3  SacI-1
El-S 7 3 pBK +13-17
E2-A 7 3 pBK +13-17
7.17A 8 3/5 pBK+ 13-17
7.17S 8 3/5 p l5  SacI-7, p l5  SacI-11
7.13A 8 5 p l5  SacI-2
7.13S 9 5 p l5  SacI-11, p l5  SacI-2
7.28A 9 5 pl5  SacI-2
7.27S 10 5 pl5  SacI-2, p l5  SacI-3
R7-A 10 5 pl5  SacI-3
7.31S 11 5 pl5  SacI-7
7.4S 12 1 p l l  SacI-3
7.30S 12 1 p l l  SacI-3
7.26S 13 1 p l l  S ad -8
7.26A 13 1/6 p l 6 Sad-3
7.5A 14 1/6 p l l  S ad-8, p l 6 Sad-3
7.9S 14 6 p l l  Sad-3, p l 6 Sad-3
7.9A 14 1 p l l  S ad -8
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Table 2.2
Oligonucleotides used
Oligonucleotide Sequence (5’-3’) Position (DP-3 type I 
E-Q+)
7.1 OH GCTGAAGAGAGAG 1-13
7.12A CCAATCAGAACACTTCCTG 268-286
7.16S CACCCGCAATGGTCACT 304-320
7.18S GCTGGCTGGGTTCCCAG 342-358
El-S GATAGAAAACGAGCTAGAG E Region
E2-A TTCTGAGAAATCAGAGTCTA E Region
7.17S/A GGGAAAGGCTTGAGACAT 387-404
7.7S CTGGCAGCTGATTCGCAG 507-524
7.13A CATCATAAACTCTTCGTCTA 545-564
7.13S CGAAGAGTTTATGATGC 549-565
7.28A CTGAGCAGAATTGGTAGG 633-650
7.27S TCGAGAAGCAGAGGCGG 670-686
R7S/A GAGCCCAGCTACAAGAACTTC 709-729
7.31S CCTGGTACAGAGAAATCGAC 755-774
7.4S GGCAAATGCTCTCTGGA 984-1000
7.30A CAGGGATCTTGCGATTTTC 1007-1025
7.26S/A GAACTCTACCCAATCAGT 1100-1117
7.5A TGCTAAGGCCACTTCAG 1188-1205
7.9A TCCTGTCTTTATTCTGGG 1337-1354
7.9S CAGAATAAAGACAGGAG 1339-1355
2.13 Buffers and solutions
IxL-Broth media (LB, per litre)
lOg bacto-tryptone 
5 g bacto-yeast extract 
lOgNaCl
Phosphate Buffered Saline (PBS)
136mM NaCl 
2.7mM KCl 
4mM Na2HP04  
1.8mM KH2PO4 
pH adjusted to 7.2
50 X TAE
2M Tris base 
IM glacial acetic acid 
50mM EDTA pH 8.0
10 X  TBE
IM Tris base 
IM boric acid 
20mM EDTA pH 8.0
5 X  SDS-PAGE Running Buffer
125mM Tris base 
1.25mM glycine 
17mM SDS 
pH adjusted to 8.3
lOx Blotting Buffer
250mM Tris base 
2M glycine 
17mM SDS 
pH adjusted to 8.3
6 X Agarose Gel Sample Buffer
0.25% (w/v)bromophenol blue 
0.25% (w/v)xylene cyanol FF 
50% (v/v)glycerol 
ImM EDTA pH 8.0
2 X  SDS Gel Loading Buffer
4% (w/v)SDS 
125mM Tris-HCl pH 6.8 
0.002% (w/v)bromophenol blue 
20% glycerol
10 X MOPS Running Buffer
0.2M MOPS buffer 
5 OmM sodium acetate 
lOmM EDTA 
(in DEPC-treated H2O) 
pH adjusted to 7.0
6 X F or maldehy de-Gel Sample Buffer
0.25% (w/v)bromophenol blue 
0.25% (w/v)xylene cyanol FF 
50% (v/v)glycerol 
ImM EDTA pH 8.0 
(in DEPC-treated H2O)
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DEPC-treated H2O
0.1% diethyl pyrocarbonate 
in H2O, treated overnight and 
autoclaved
20 X SSC
3M NaCl
3OOmM sodium citrate 
pH adjusted to 7.0
TE
1 OmM Tris-HCl pH 7.5 
ImM EDTA
1 Diluent
lOOmM Tris pH 7.5 
1 OmM MgS04
Denaturing Solution
1.5MNaCl
0.5MNaOH
Neutralising solution
1.5MNaCl
0.5M Tris-HCl pH 7.2 
ImM EDTA pH 8.0
RNA Cell Fractionation Buffer
150mMNaCl 
1 OmM Tris pH 8.5 
5mM MgCh 
0.5% IGPAL (Sigma) 
in DEPC-treated H2O
2x Dot Blot Solution
15% formaldehyde 
10 X SSC
in DEPC-treated H2O
2x p-galctosidase Assay Buffer 
200mM sodium phosphate buffer pH 7.3 
2mM MgCb
1 OOmM p-mercaptoethano 1
1.33mg/ml ONPG (o-nitrophenyl-p-D-
galactopyranoside)
2xHBS
280mMNaCl 
5 OmM Hepes 
1.5mM NaH2P04 
pH adjusted to 7.12 
Filter sterilised, stored -20°C
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Proteinase K Buffer
5OmM Tris pH 8.0 
lOOmMEDTApHS.O 
lOOmM NaCl 
1% SDS
OLB 
Solution A
625|uil 2M Tris-HCl pH 8.0 
125|l i 1 IM M gCb 
250pl H2O
18 pi p-mercaptoethanol 
5pi each dATP, dTTP, dGTP
Solution B
2M HEPES pH 6.6
Solution C
Random hexamers in 3mM Tris-HCl, 
0.2mM EDTA, pH 7.0
Solutions A, B and C were combined in the ratio 2:5:3 
Stored -20°C.
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Chapter 3
Analysis of the DP-3 Gene
3.1 Introduction
The isolation and analysis of genes at the genomic level can provide insight 
into the regulation of expression at several levels. The isolation and analysis of the 
5’ regulatory region of a gene permits study of the transcriptional regulation. In 
addition, post-transcriptional regulation can be investigated; the exon structure of a 
gene can contribute to the understanding of splicing and other RNA processing 
events and the isolation of these regulatory regions allows study and manipulation in 
vitro. Finally, genomic sequence can be used to generate transgenic and gene 
knockout animals for the study of genes in vivo.
The genomic sequence for several E2F family members has been 
determined. Analysis of the mouse E2F-1 gene revealed multiple promoter elements 
required for trancriptional regulation at the Gl/S phase boundary (Li et al., 1994; 
Hsiao et al., 1994; Neuman et al., 1994). Regulation of the E2F-1 gene is in part 
mediated via E2F binding sites suggesting that this gene may be subject to 
autoregulation. Likewise the isolation of the human E2F-2 gene has shown a similar 
pattern of regulation (Sears et al., 1997). In contrast, the murine DP-1 gene does not 
appear to be cell cycle regulated and contains a TATA-less promoter with multiple 
transcription initiation sites (Gopalkrishnan et ah, 1996), and is regulated by p53 
(Gopalkrishnan et al., 1998).
Extensive RNA analysis has suggested that DP-3 transcripts are highly 
processed and several different RNA species have been characterised. Sequence 
analysis suggests at least four different protein isoforms may exist (Figure 1.7) 
(Ormondroyd et aL, 1995). The DP-3 RNA variants arise from the inclusion or 
exclusion of two open reading frame changes. The insertion of a short 48 bp 
sequence within the DNA binding domain has been observed in some RNAs; this 
sequence, named the E region, has been shown to form part of a nuclear localisation 
signal in E+DP-3 proteins (de la Luna et aL, 1996). Furthermore, the presence or 
absence of a single glutamine residue (Q) has been noted between the DNA binding 
and E2F dimérisation domains of some DP-3 protein isoforms, (Ormondroyd et aL, 
1995; Zhang and Chellapan 1995). In addition, four different 5’ untranslated regions
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have been identified, which result from rearrangements of five different exons 
(Figm'e 1.8). This regulation in the 5’ region of RNA has the potential to result in 
translation intiation at one of two different initiating methionines and as a 
consequence one of the predicted protein isoforms, DP-3 a , has an N-terminal 
extension which, interestingly, shows some homology to the N terminus of DP-1 
(Girling et aL, 1993; Ormondroyd et aL, 1995). Two alternative 3’untranslated 
regions have also been characterised, which are likely to result in translational 
termination at the same translation termination signal.
The diverse and complex range of DP-3 RNAs could arise via several 
regulated events. The various different DP-3 RNAs may result from extensive post- 
transcriptional processing. It is also possible that different DP-3 RNAs result from 
the use of alternative transcriptional start sites and that there are several different 
promoter regions within the 5’ end of the DP-3 gene. Since the processes of 
transcription and mRNA splicing take place simultaneously and are structurally 
linked (Xing et aL, 1993), the regulation described for DP-3 RNA may be 
influenced by a combination of these events.
The aim of this study was to isolate and characterise the murine DP-3 gene in 
order to provide information that may be useful in understanding its regulation.
3.2 Results
3.2.1 The DP-3 gene is a single copy gene
Prior to screening a genomic library to isolate the DP-3 gene, Southern blot 
analysis of mouse genomic DNA was performed with DP-3 probes to establish how 
many copies of the DP-3 gene existed in the genome. Mouse brain genomic DNA 
was isolated, blotted and thereafter probed for DP-3. This analysis revealed a simple 
pattern of genomic fragments (Figure 3.1), suggesting that DP-3 was a single copy 
gene. The blots were reprobed with different probes. The DP-3 FL probe spans the 
complete open reading frame (ORF) of DP-3 a  and produced a seven of bands of 
similar intensity. Digestion with Kpnl yielded four bands of 14.1Kb, 9.8Kb, 7.6Kb 
and 5.2Kb, whereas Hindlll digestion revealed tliree bands of 9.8Kb, 7.1Kb and 
2.6Kb. These data suggest the ORF of DP-3 spans at least 36.7Kb of DNA. Analysis 
with a probe from the 5’untranslated region revealed a 14Kb Hindlll fragment and a 
Kpnl fragment of 4.1Kb. The 5’ end of the DP-3 gene might therefore span more
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than 14Kb. The DP-3 3’end probe revealed that the 9.4Kb Kpnl and the 2.6Kb 
Hindlll fragments observed with the flill length probe contain the 3’end of DP-3 
ORF. These results are consistent with DP-3 being a single copy gene. Hence, the 
DP-3 gene appears to be a large gene and is likely to be single copy, since a more 
complicated pattern would have been expected for a multi-copy gene.
3.2.2 The isolation and restriction enzyme mapping of the DP-3 gene
A ZGEM12 genomic libraiy, constructed from the mouse embryonic stem 
cell line SV129D3, was plated and 10  ^ plaques were screened with DP-3FL probe 
(Figure 3.1b). The DNA from seven phage was isolated and comparison of the 
restriction digestion with Sad suggested that two of the phage were identical; in 
total six different phage were isolated. Southern blotting of phage DNA and 
subsequent hybridisation with DP-3 cDNA oligonucleotides confirmed that the 
phage contained DP-3 genomic sequence and that they overlapped. From these data 
a Sad map was constructed (Figure 3.2) which contained the ORF and the 3’UTR of 
the DP-3 gene. Blotting analysis of restriction digests with oligonucleotide probes 
derived from both 5’UTR and ORF sequence indicated that the first exon after the 5’ 
UTR (exon 6) was the most 5’ exon isolated of the phage. The Sad  map of the 
phage DNAs (Figure 3.2) therefore implied that an intron of at least 8.9Kb existed 5’ 
of exon 6 and suggested that the 5’UTR and promoter regions of DP-3 had not been 
isolated.
3.2.3 The DP-3 genomic structure
The phage clones were shotgun cloned into pBluescript (Stratagene) as Sad 
fragments and then sequenced to determine the positions of the exon/intron junctions 
(Figure 3.3). Sequence analysis revealed the splice junction of the most 5’exon 
isolated was just after the second initiating methionine codon (M2) of DP-3 
(Ormondroyd et ah, 1995) (Figure 1.8). Hence, these data confirm that the second 
exon of the DP-3 ORF was the most 5’ exon isolated. Since five exons are predicted 
from analysis of the 5’ untranslated region (Ormondroyd et aL, 1995), this exon was 
designated as exon 6 (Figure 3.3a). All the splice junctions sequenced (Figure 3.3b) 
conformed to the ‘GT’ 5’splice donor and ‘AG’ 3’ splice acceptor consensus intron 
sequences.
94
3.2.4 The E region of DP-3a and ô is a discrete 48 bp alternatively spliced exon
The isolation of the DP-3 gene enabled a study of the relationship between 
mRNA and genomic sequence. Previous studies of the DP-3 cDNAs had predicted 
four different protein isoforms, named a , p, y and ô (Ormondroyd et aL, 1995) 
(Figure 1.7). DP-3a and 8 have an extra 16 residues inserted close to the DNA 
binding domain of the E region (Ormondroyd et aL, 1995). Subsequently, the E 
region has been shown to be part of a NTS and DP-3 a  and 8 accumulate in the 
nucleus. However, E minus DPs such as DP-3P, y and DP-1 are cytoplasmic (de la 
Luna et al., 1996; Magae et aL, 1996). Sequencing and PCR analysis of the DP-3 
gene revealed the E region to be a discrete 48 bp exon (exon 7, Figure 3.3a) 
surrounded by a 5’ intron of 2.6Kb and a 3’ intron of 3Kb (Figure 3.4a). 
Conventional splice donor and acceptor sites exist at the exon boundaries (Figure 
3.4b).
3.2.5 DP-3 Q+ arises via the use of an alternative 3’ splice acceptor site.
The DP-3y isoform differs from the other DP-3 isoforms due to the insertion 
of a single glutamine (Q) residue (Ormondroyd et aL, 1995). The Q insertion occurs 
between the DNA binding and dimérisation domains, in a region not conserved 
between DP family members. It is likely that the insertion in DP-3y arises through 
alternative selection of two adjacent 3’splice acceptor sequences at the 3’ end of the 
intron between exons 8 and 9 (Figure 3.3). The selection of the first AG, reading 5’- 
3’, results in a Q+DP-3, whereas selection of the second results in a Q-DP-3 (Figure 
3.5).
3.2.6 hDP-2 protein isoforms arise via alternative splicing of equivalent exons
The human homologue of DP-3, human DP-2, has been reported (Wu et aL, 
1995; Zhang and Chellapan, 1995; Rogers et aL, 1996). The cDNAs so far published 
include the additional E region and are therefore homologous to DP-3 a  and 8. 
Furthermore, the inclusion of the Q residue has also been reported (Zhang and 
Chellapan, 1995). The human dbest database (Altschul et aL, 1997) contains data 
generated from a sequencing project; cDNA is generated randomly from human 
mRNA and sequenced. The sequence data is entered into the database directly, with
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little or no analysis, the sequence data therefore may contain unidentified 
sequencing enors. Searches of the human dbest database with a DP-3 cDNA 
sequence have identified sequences that suggest other potential human DP-2 
isoforms may exist (Figme 3.6). These human DP-2 isoforms are different to those 
published and since all the sequences arise from combinations of the DP-3 exons 
described in Figure 3.3, it is likely that these are previously unidentified splice 
variants. When the translation products of these splice variants were predicted, it 
was interesting to note that some of the RNAs give rise to short N terminal 
polypeptides and, in addition, translational initiation at downstream methionines 
may occur. An example is sequence N23047 (Figure 3.6), where translation could 
initiate at methionine 1 in exon 2. However, the absence of exon 6 results in a 
frameshift resulting in a termination signal in exon 7, in which case translation could 
be re-initiated the next methionine (M4) in exon 8. Furthermore, a unique exon not 
found in mouse DP-3 transcripts was observed in one transcript (Figure 3.6, 
AA039977) between exons 5 and 6, that may represent a human specific sequence. 
An examination of the sequence suggests that it is not an intron that was not 
successfully spliced out, since the sequence does not contain splice donor and 
acceptor signals. This sequence, contains a termination signal, therefore, the 
insertion of this exon may result in early translational termination, resulting in a 
short N terminal polypeptide.
3.2.7 Murine DP-1 and DP-3 have identical exon structure
Comparison of DP-3 a  exon structui*e and the DP-1 exon structure 
(Gopalkrishnan et ah, 1996), revealed striking similarity, since all the exon/intron 
junctions are observed in exactly the same positions (Figure 3.7). The exon 
arrangement diverges at the V  end of the gene, which is the region of least similarity 
between DP-1 and DP-3 at the amino acid level (Girling et aL, 1993; Ormondroyd et 
aL, 1995). However the highly conserved domains, such as the DBF box, DCBl, 
DCB2 and the N-terminus (Lam and La Thangue 1994) ai*e all situated on exons of 
exactly the same size in both proteins. The 5’ regions of DP-3 were not present in 
the genomic phage isolated and exons 2, 3 and 5 were predicted from studies of 
splicing arrangements of the 5’ untranslated regions (Chapter 1; Ormondroyd et aL, 
1995).
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The strong conservation in exon structure between these two genes suggests 
a common evolutionary origin, perhaps one gene arising via duplication and 
subsequent divergence of the first gene. However, an assessment of DP gene 
evolution requires extensive analysis of a large number of family members, which so 
far are available from DP proteins cloned in humans (Helin et ah, 1993; Wu et aL, 
1995; Zhang and Chellapan, 1995; Rogers et aL, 1996) and mice (Girling et aL, 
1993; Ormondroyd et aL, 1995). DP homologues have also been characterised in 
Xenopus laevis (Girling et aL, 1994) and in Drosophila melanogaster (Dynlacht et 
aL, 1994; Hao et aL, 1995). More family members and more species are needed for 
comprehensive phylogenetic analysis of the sequences.
3.3 Discussion 
3.3.1 Alternative splicing of the E region influences cellular the location of DP-3
Analysis of the genomic organisation of the E region revealed an 
alternatively spliced 48 bp exon (exon 7, Figure 3.3). The inclusion of the protein 
sequence resulting from this exon generates an NLS in DP-3 a  and DP-3Ô (de la 
Luna et aL, 1996). In addition, DP-3 a  and 8 can recruit cytoplasmic E2F-4 and 5 to 
the nucleus and likewise, E2F-1, 2 and 3 can recruit E minus DPs such as DP-1 and 
DP-3p and y to the nucleus (de la Luna et aL, 1996; Magae et aL, 1996; Allen et aL, 
1997). It has been shown that the mechanism of nuclear localisation of the E2F 
heterodimer can have different functional consequences on the cell cycle (Allen et 
aL, 1997) and therefore, the functional consequence of the alternative splicing of the 
E region may be very important in the growth regulating functions of E2F.
3.3.2 The insertion of the glutamine residue (Q) may represent a site of post 
translational modification
DP-3y contains an extra Q residue. The most likely reason for this is because 
of an alternative 3’splice acceptor sequence at the 3’ end of the intron between 
exons 8 and 9 (Figure 3.3). The selection of either of two splice acceptor sites might 
result from random slippage by the splicing machinery (Padgett et aL, 1986). 
Alternatively, the selection process may be regulated and in this respect, only a 
subset of DP-3 RNA variants would select the first splice acceptor site (Ormondroyd 
et aL, 1995). Furthermore, when DP family members were compared, it was noticed
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that the Q residue resides in an unconserved region between two conserved helical 
domains, which may form a loop that represents a potential site of post-translational 
modification. Indeed, the insertion of this Q residue results in the destruction of a 
theoretical casein kinase II phosphorylation site and the creation of a putative DNA- 
PK phosphorylation site. It is possible that the glutamine insertion may therefore 
represent a site of importance, for example in post-translational modifications by 
DNA-PK.
The insertion or exclusion of a single glutamine has been observed in other 
genes such as the mouse obese gene (Zhang et aL, 1994) where a Q residue is 
located in a highly conserved region of the protein. However, the significance of the 
insertion is unknown. The insertion of Q residues in two different positions in the 
human brca 1 gene has also been observed (Miki et aL, 1994), where the insertion 
occurs at a splice junction and may therefore represent a similar situation to that in 
DP-3. Likewise, the functional relevance of the Q insertion in BRCA 1 protein has 
not been determined.
3.3.3 Murine and human DP-3 cDNAs suggest similar genomic organisations
The analysis of available human DP-2 sequences predicted several different 
protein isoforms, some of which aie homologous to the murine DP-3 protein 
isoforms (Figure 3.6). In addition, some cDNAs suggested that truncated hDP-2 
proteins exist (Figure 3.6). The comparison of the hDP-2 cDNAs and the DP-3 gene 
exons revealed all the hDP-2 sequence valiants arise from reai'rangements of exons 
equivalent to those characterised for the murine DP-3 gene (Figures 3.3 and 3.6). 
Therefore, it is likely that the exon structure of the hDP-2 gene will be similar to the 
mouse DP-3 gene.
The expression level of both hDP-2 sequence variants and the resultant 
truncated protein products might be low in cells. However, it is possible that these 
short polypeptides may represent as yet uncharacterised functional DP-3/DP-2 
proteins and it is conceivable that they could influence E2F activity. Truncated 
polypeptides that lack important regulatory domains could form repressive 
complexes with E2F family members, preventing activation of E2F dependant 
transcription. Indeed, an E2F family member, E2F-6, that lacks a transactivation 
domain, has been proposed to function as a transcriptional repressor (Morkel et aL,
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1997; Cartwiight et al., 1998; Trimai chi et a l, 1998). It is relevant to consider that 
truncated DP-3/DP-2 proteins may function in a similar manner.
During the analysis of liDP-2 sequences, a cDNA containing an extra exon 
sequence, not yet observed for either DP-3 or hDP-2, was identified (Figure 3.6). 
This short sequence may represent an artefact that arose during the cDNA 
production or a real exon. It is feasible that this exon also exists in the murine DP-3 
gene but has not yet been isolated, as hDP-2 sequence valiants arise from selection 
of exons equivalent to those characterised for the murine DP-3 gene. Furthennore, 
comparisions of DP-3 and hDP-2 cDNAs has revealed a striking level of similarity. 
Consequently, it would not be unexpected for future work to reveal that this exon 
exists in the murine DP-3 gene.
3.3.4 DP-1 and DP-3 have a common evolutionary origin
An interesting and important question is why did a second DP gene evolve? 
At present the role for DP-3 in cells is ill defined. In contrast, DP-1 has been well 
characterised and its regulation exhaustively studied. DP-1 is the major DP partner 
in the E2F heterodimer, and to date the role DP-3 in E2F regulation has not been 
clarified. Further analysis of DP-3 function is required before questions such as 
these can begin to be answered.
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Figure 3.1
Analysis of the DP-3 gene
a) A Southern blot was prepared with lOpg brain genomic DNA digested with Kpnl 
and with Hindlll was sequentially hybridised with different DP-3 specific probes as 
indicated. The blot was completely stripped between hybridisations.
b) The DP-3 probes used for Southern hybridisations in (a). The DP-3 full length 
(FL) probe was purified from pBKSDP-3a digested with EcoRI and Xhol. The DP- 
3 5’UTR probe was purified from pBKS-B5 (type II 5’UTR), digested with EcoRI. 
The DP-3 3’end probe was purified from digestion of a pBKSDP-3y with EcoRV 
and Xhol. The nucleotide numbers are given for a DP-3y cDNA.
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Figure 3.1
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Figure 3.2
A Sacl restriction map of DP-3 phage clones
a) Genomic digests of the DP-3 phage clones derived from data obtained from 
restriction analysis of the DP-3 and Southern blot analysis with oligonucleotide 
probes (Chapter 2, Table 2.2). S denotes Sad  restriction sites and M denotes an 
Mbol restriction site (Chapter 2).
b) The positions of the DP-3 exons on the phage clones are represented by black 
bars. The thin lines represent intron sequences (not to scale).
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Figure 3.3
The murine DP-3 genomic structure
a) The DP-3 gene exon arrangement. Exons are represented as open rectangles. The 
numbers denote the nucleotide position of the first base of the exons and correspond 
to the DP-3Ô cDNA (Ormondroyd et al., 1995).
b) The DP-3 genomic sequences at each exon/intron junction. The intron sequences 
are boxed; the nucleotide positions are given of the first and last nucleotides of the 
exon. The splice donor and acceptor sequences are coloured red. The black boxes 
denote the position of the alternative 3’splice acceptor sites at the 3’ end of the 
intron between exons 8 and 9.
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Figure 3.4
The E region of DP-3 is a single, alternatively spliced exon
a) Diagram summarising the genomic DP-3 E region. Exons are labelled and 
represented by boxes and intron sequence by a solid line.
b) Sequence of the splice junctions of the DP-3 genomic region together with the 
resulting protein sequences. The top sequence is E minus, the bottom E plus. Exon 
boundaries are indicated by •.
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Figure 3.5
The Q insertion of DP-3y arises from use of an alternative 3*acceptor site
A diagram summarising how Q+ and Q- DP-3 mRNAs arise. The sequence of the 3’ 
end of the intron between exons 8 and 9 is given, together with the resulting amino 
acid sequences, Q- at the top and Q+ at the bottom.
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Figure 3.6
Comparison of hDP-2 cDNA sequences and DP-3 genomic structure
Diagrammatic representation of cloned hDP-2 sequences compared to mDP-3 
genomic structure. The shaded box indicates the E region. Numbered boxes indicate 
the arrangement of DP-3 exons, corresponding to the hDP-2 sequences.
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Figure 3.7
Comparison of murine DP-1 and DP-3 genomic organisation
Alignment of DP-3 a  exons and protein sequence, compared with analogous 
aligmnent of DP-1. Amino acid positions of the exon boundaries are indicated. 
Arrows indicate homologous exons of the 5’end. Shaded areas denote domains 
conserved in DP family members and are labelled.
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Chapter 4
Analysis of DP-3 RNA Expression
4.1 Introduction
Analysis of cellular mRNA provides an indication of the regulation of the 
gene of interest. Analysis of mRNA levels can reflect the transcriptional activity of a 
gene and provide an indication of the potential expression level of the protein. The 
analysis of cellular RNA by Northern blotting aids determination of the size and 
abimdance of RNA transcripts. Although Northern blotting can detect changes in 
transcript abundance it does not indicate the mechanism of RNA accumulation. 
RNA can be regulated transcriptionally and by RNA processing and stability, and 
RNA detected by Northern blotting gives a representation of the steady state levels 
of RNA. Therefore, Northern blotting represents a useful tecluiique for study of 
RNA transcripts. The information obtained can contribute to the understanding of 
the regulation of a particulai' gene and additionally, used in subsequent protein 
studies.
Northern blotting analysis of RNA from cells at different stages of the cell 
cycle indicated that DP-1 transcript levels remained luichanged during the cell cycle, 
although E2F-1, 4 and 5 transcripts were induced at the Gl/S boundary (Jolinson et 
al., 1994; Li et ah, 1994; Sardet et ah, 1995). Analysis of other E2F family members 
has revealed some differences in RNA expression patterns. For example, in human 
tissues E2F-2 RNA is highly expressed in lung and kidney, whereas E2F-3 RNA is 
high in muscle and liver but absent in brain (Lees et ah, 1993). Analysis of DP-1 
and E2F-1 by in situ hybridisation during mouse embryo development indicated that 
E2F-1 is expressed in many tissues and is often expressed in the same tissues as DP- 
1 (Tevosian et ah, 1996).
DP-3 differs from the other DPs due to a striking complexity at the RNA 
level. RNA analysis duiing the cloning of DP-3 cDNAs suggested that extensive 
processing of DP-3 RNA may give rise to four different DP-3 protein isoforms, 
a,(3,y,ô (Ormondroyd et ah, 1995) . These variants arise thiough two ORF changes 
and include the insertion of a 48 bp sequence within DNA binding domain. In 
addition, extensive processing gives rise to several different 5’untranslated regions 
(5’UTRs). Furthermore, two different 3’UTRs have also been identified (Chapter 1).
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In an effort to study the expression of DP-3, an investigation of DP-3 RNA 
was instigated. The aim of this study was to identify physiological conditions under 
which DP-3 RNA levels change and therefore conditions under which DP-3 proteins 
could be analysed.
4.2 Results
4.2.1 DP-3 specific transcripts are expressed in a range of mouse tissues
Analysis of DP-3 RNA via Northern blotting revealed that DP-3 exists as 
three transcripts of different mobility, approximately 8Kb, 3Kb and 2Kb in size 
(Figure 4.1a). Similar' analysis of DP-3 on a Northern blot of mRNA prepared from 
mouse tissues showed that DP-3 mRNA varies in abundance between tissues, not 
only were the overall levels of DP-3 message variable but the abundance of the 
individual transcripts also fluctuated. Comparison with the p-actin transcript (Figure 
4.1c) indicated that the quantity of mRNA analysed from each tissue type was 
approximately the same, suggesting that DP-3 transcripts may therefore be regulated 
in a tissue specific manner. For example, liver contained the 3Kb and 2Kb transcript, 
whereas the 8Kb transcript was poorly expressed (Figure 4.1a, lane 5). In contrast, 
brain RNA contained more of the 8Kb transcript than 3Kb and 2Kb transcripts 
(Figure 4.1a, lane 2). It is interesting to note that the mobility of the 3Kb and 2Kb 
transcripts were altered in the spleen (Figure 4.1a, lane 3), however, the mobility of 
the p-actin transcript was not changed in spleen RNA, suggesting that it was not due 
to experimental differences in the RNA samples (Figure 4.1c, lane 3). This may, 
therefore, represent a particular' level of regulation unique to spleen DP-3 RNA.
The DP-1 gene gives rise to a single transcript of 3Kb (Figure 4.1b), which 
does not cross-hybridise with the DP-3 probe used, arguing that the multiple 
transcripts described for DP-3 were not influenced by cross-hybridisation with DP-1. 
The DP-3 transcripts were less abundant than the DP-1 and the p-actin transcripts. 
Overall, these results indicate that DP-3 transcripts are expressed in a wide range of 
mouse tissues and the levels of individual transcripts may be regulated in a tissue 
specific manner.
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4.2.2 DP-3 transcripts are expressed in different cell lines
The abimdance DP-3 transcripts were also investigated in a range of tissue 
culture cell lines (Figuie 4.2). The F9 embryonal carcinoma (F9EC) and NIH 3T3 
mouse cell lines clearly expressed DP-3 (Figure 4.2a, lanes 1 and 2). In the human 
tumour cell lines C33A, U20S and HeLa, DP-3 transcripts were of a different 
mobility to the transcripts detected in mouse cell lines, although three transcripts 
were still observed (Figure 4.2a, lanes 3, 4 and 5). HeLa cells differ from the other 
cell lines due to a unique transcript of 4.4Kb (Figure 4.2a, lane 5). Comparison of 
the control, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and DP-3 
transcript levels suggested that there was some variation in the levels of DP-3 RNA 
in the human and mouse cell lines (Figure 4.2a and b). However, DP-3 RNA is 
expressed in all the cell lines tested.
4.2.3 DP-3 transcripts are polyadenylated, cytoplasmic mRNAs
The Northern blot analysis of DP-3 revealed a complicated pattern of RNA 
transcripts. In order to characterise the DP-3 transcripts in greater detail, it was 
determined if they possessed the properties of mRNA, namely being cytoplasmic 
and polyadenylated. Thus, polyadenylated RNA was selected from total RNA, and 
nuclear and cytosolic fractions of RNA were isolated, the purified RNA analysed by 
Northern blotting (Figure 4.3). A DP-3 specific probe revealed that DP-3 transcripts 
were polyA+, cytoplasmic (Figure 4.3a). A comparison of the poly A- and poly A+ 
samples (Figure 4.3a, lanes 2 and 3) suggested that the 3Kb transcript might be a set 
of transcripts of similar size, since a subset of these appeared to either lack 
polyadenylation, or were polyadenylated less efficiently than the other DP-3 
messages. However, since some of the GAPDH mRNA were not completely 
selected it is possible that the selection of polyadenylated transcripts was not 
complete and this effect was observed on two occasions (Figure 4.3b). Hybridisation 
with histone 3 (H3, an unpolyadenylated, cytosolic RNA) and U6 RNA (an 
unpolyadenylated, nuclear RNA) indicated that the polyadenylated fraction had not 
been contaminated with unpolyadenylated RNA (Figure 4.3c and d). Likewise, the 
nuclear and cytosolic fractionation suggests that DP-3 transcripts are cytoplasmic 
transcripts and little contamination of fractions had occuiTed. In conclusion, the 
majority of DP-3 transcripts appear to be polyadenylated and cytoplasmic and
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therefore the DP-3 transcripts possess the properties of typical mRNA, derived from 
protein-encoding genes.
4.2.4 DP-3 RNA is expressed throughout differentiation of F9EC cells
DP-3 transcripts were expressed in all the cell lines and tissues tested. To 
explore the possibility that DP-3 mRNA levels may be regulated during specific 
cellular processes, F9 embryonal carcinoma (F9EC) cells were stimulated to 
differentiate into parietal endoderm-like cells via treatment with retinoic acid and 
cAMP (Strickland et ah, 1980). This system is thought to represent a tissue culture 
based model used widely for studying differentiation. Analysis of the DP-3 
transcripts in F9EC cells and F9 parietal endoderm-like cells (F9PE) at 3, 5 and 7 
days after addition of retinoic acid and cAMP, revealed little change in DP-3 
transcript abundance (Figure 4.4a). A decrease occurred at day five however, since 
this was reflected in the GAPDH transcript (Figure 4.4b, lane 3) it was likely to 
result from experimental variation. Consequently, it is probable that DP-3 transcript 
abundance does not change significantly in F9EC cells stimulated to differentiate to 
parietal endoderm-like cells.
4.2.5 DP-3 transcripts contain the E region
The earlier analysis of DP-3 (Figure 4.1) indicated that there was some 
variation in the expression pattern of DP-3 transcripts in different tissues. Since 
analysis of DP-3 cDNA suggested several protein isoforms (Ormondroyd et ah, 
1995), fluctuation in the level of a particular transcript might correlate with a change 
in DP-3 protein isoform. In an effort to relate transcript to cloned cDNAs, the F9EC 
blot (Figure 4.4) was stripped and re-probed with a probe specific for the E region, a 
48bp sequence observed in a subset of DP-3 cDNAs (Ormondroyd et al., 1995; 
Chapter 1). A probe for the E region suggested that all the transcripts contained the 
E region (Figure 4.5a). Since it was known that the DP-3 transcripts possess the 
properties of mRNA, it was likely that these transcripts represented mature RNA and 
not unspliced RNA. As suggested earlier (Section 4,2.3), the 3Kb transcript may be 
composed of a heterogeneous set of transcripts of very similar mobility. Indeed, a 
comparison of the hybridisation pattern with the E region and the DP-3 probes 
revealed a slight difference in size (Figure 4.4 and 4.5) and combined with the
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polyadenylation analysis of DP-3 transcripts (Figure 4.3) suggests that not all the 
DP-3 3 Kb transcripts contain the E region.
The 8Kb and 2Kb DP-3 transcripts also contain the E region, and the 
hybridisation pattern observed was similar for both the E region and DP-3 probes 
(Figure 4.4 and 4.5). Hence, some of the DP-3 transcripts contain the E region and 
the 3Kb DP-3 transcript may be a heterogeneous mixtui’e of E+ and E- transcripts. 
Further analysis of the var iation between transcripts has not been successful.
4.3 Discussion
4.3.1 DP-3 expression differs in different mouse tissues
The results indicate that the expression of DP-3 transcripts is different in 
different tissues since fluctuations were observed both in the overall levels and the 
abundance of the individual transcripts (Figure 4.1). It is likely that, as a result of 
these differences, the levels of the DP-3 protein isoforms will vary correspondingly, 
suggesting perhaps that they have specific roles in different tissues. In contrast to 
DP-3, the expression of DP-1 RNA was not found to be variable, as DP-1 was 
observed in all mouse tissues tested. Possibly, DP-1 and DP-3 have different roles in 
specific tissues and it is conceivable that they influence the function of E2F in 
distinct ways and in turn, perhaps cause subtle differences in E2F activity.
Although at present little is known about the expression and functions of 
individual E2F family members in different tissues, mice have been generated with 
homozygous deletions of the E2F-1 and 5 genes (Field et al., 1996; Yamasaki et al., 
1996; Lindeman et al., 1998). These mice have exhibited different tissue specific 
effects and suggested that some tissues may have specific E2F requirements; for 
example E2F-5 null mice displayed defects in the choroid plexus, implying an 
important role for E2F-5 in this tissue during development (Lindeman et ah, 1998). 
Analysis of E2F-5 RNA expression by in situ hybridisation revealed high levels in 
the choroid plexus, in addition, E2F-5 RNA levels were also high in other tissues, 
such as the bowel and skin, however these tissues were normal in E2F-5 null mice 
(Lindeman et al., 1998). Such data indicates that a high level of RNA in a particular 
tissue does not necessarily correlate with an essential role in that tissue. 
Additionally, although a high degree of similarity exists between family members,
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gene knockout data suggests that they do not necessarily have degenerate functions. 
Therefore, DP-1 and DP-3 may have distinct roles in specific tissues.
The human DP-3 homologue has been cloned and named hDP-2 (Wu et ah, 
1995; Zhang and Chellapan, 1995; Rogers et aL, 1996). Work published by several 
groups reaches similar conclusions. For example, an analysis of human tissues 
revealed five hDP-2 transcripts, ranging from 9.5Kb to 1.35Kb (Zhang and 
Chellapan, 1995), some of similar size to DP-3 transcripts presented here. Likewise, 
the variation in abundance of hDP-2 and DP-3 transcripts was similar in some 
tissues, for example, both human and murine brain RNA exhibited a similar pattern 
of DP-3 transcripts (Zhang and Chellapan, 1995). DP-1 expression was detected in 
all human tissues tested, with some variation in abundance (Wu et aL, 1995; Zhang 
and Chellapan, 1995). Interestingly, the levels of both liDP-1 and hDP-2 transcripts 
were low in some tissues, such as pancreas and lung (Wu et aL, 1995), perhaps 
reflecting differing roles for hDP-1, hDP-2 and the E2F activity in these tissues. It is 
interesting to note that analysis of the results suggests that the lower level of 
expression of one DP cannot be compensated by increased levels of the other DP 
transcript, implying the DPs may have functionally distinct roles.
Since DP-3 transcripts are expressed differently in tissues, different DP-3 
protein isoforms may correspondingly be expressed to different levels. In addition 
DP-1 is uniformly expressed in all the tissues, whereas DP-3 is not, and it is 
therefore possible that DP-3 has a unique function and this may have implications 
for the role of the E2F heterodimer in tissues.
4.3.2 DP-3 transcripts are expressed in a range of tissue culture cell lines
Analysis of DP-3 transcripts in tissue culture cell lines revealed that DP-3 
transcripts are expressed in all the lines tested. The mouse cell lines, F9EC and NIH 
3T3, both expressed similar levels of DP-3 RNAs. The human cell lines expressed 
lower levels of the human DP-3 transcripts (hDP-2) and in addition the human 
transcripts were of different mobility. Comparison with the published analyses of 
hDP-2 RNA transcripts revealed similarities; hDP-2 is expressed in a range of 
human cell lines and some variation in abundance was observed between cell lines 
and particular transcripts. Unlike analysis of hDP-2 in tissues, thiee hDP-2 
transcripts were observed in human cell lines (Wu et ah, 1995). The level of hDP-2
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RNA in the MLl cell line was extremely high (Wu et aL, 1995), and subsequent 
studies have shown ML-1 cells to express hDP-2 protein to a detectable level 
(Rogers et aL, 1996). DP-1 was found to be expressed in all the cell lines tested (Wu 
et aL, 1995; Zhang and Chellapan, 1995) whereas liDP-2 expression was variable. 
As discussed (Section 4.3.1), this may reflect different roles for DP-1 and DP-3 in 
E2F cellular activity.
4.3.3 DP-3 transcripts are cytoplasmic, poly A+ messenger RNAs
Analysis of DP-3 transcripts revealed that they are cytoplasmic RNAs and 
the majority of species are polyadenylated. DP-3 transcripts therefore possess the 
properties expected for mRNAs, with the potential to be translated into protein. 
Selection of polyadenylated RNAs suggested that a subset of the 3Kb message may 
not be polyadenylated or has a shorter poly A tail, which may have an influence on 
DP-3 expression. Since polyadenylation can influence nucleocytoplasmic transport, 
mRNA stability, decay and translation (Manley and Proudfoot, 1994; Huang and 
Carmichael, 1996; Wickens et aL, 1997), it is possible that regulated 
polyadenylation may influence DP-3 protein expression.
4.3.4 Multiple DP-3 transcripts are obseiwed by northern analysis
Analysis of hDP-2 in tissues revealed five transcripts of different mobility 
(Zhang and Chellapan, 1995). In contrast, northern blot analysis with a DP-3 
specific probe revealed only tliree transcripts. However, the analysis of DP-3 
transcripts suggested that there might indeed be more than three DP-3 transcripts. 
The selection of polyadenylated RNAs revealed that a subset of the 3Kb transcript 
contained either a short polyadenylated tail or lacked polyadenylation (Figure 4.3). 
In addition, the identification of E+ transcripts (Figui'e 4.5) suggested that a subset 
of the 3Kb transcripts were E+. Detection of all transcripts with the E region probe 
would not be expected, as some DP-3 transcripts should be E- since E- cDNAs have 
been cloned (Ormondroyd et aL, 1995). Consequently, it is possible that there are 
more than thi'ee DP-3 transcripts, which represent different splice forms of DP-3 that 
have yet to be resolved and are similar to the five transcripts observed in human 
tissue analysis (Zhang and Chellapan, 1995).
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4.3.5 RNA analysis suggests extensive processing of DP-3 RNA
The DP-3 cDNA analysis revealed a complex regulation at the RNA level, as 
at least four different 5’UTRs and two 3’UTRs, with variations in the open reading 
frame, have been described. A complicated pattern of RNA would have therefore 
been predicted by northern analysis.
Overall, the results have indicated that the DP-3 gene gives rise to a variety 
of transcripts that differ dramatically in size. This information, combined with the 
fact that DP-3 RNA is subject to alternative splicing both in the coding sequence and
the 5’UTR, suggests that DP-3 RNA is subject to complex regulation.
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Figure 4.1
Northern blot analysis of DP-3 and DP-1 transcripts in mouse tissues.
a) A northern blot containing 2pg polyA+ RNA per lane prepared from the indicated 
mouse tissues was probed with the DP-3 3’end probe (Chapter 2). The RNA markers 
are shown.
b) The northern blot from (a) was stripped and reprobed with the DP-1 3’end probe 
(Chapter 2).
c) The northern blot from (a) was stripped and reprobed with a p-actin control probe.
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Figure 4.2
Northern blot analysis of DP-3 in a range of cell lines
a) Analysis of a northern blot prepared from 25 pg total cellular RNA from the 
indicated tissue culture cell lines, probed with the DP-3 3’ end probe. The positions 
of the RNA markers are shown.
b) The northern blot from (a) was stripped and reprobed with a GAPDH control 
probe.
124
Figure 4.2
a)
9.5 Kb —
7.5 Kb —
4.4Kb—  
2.3Kb----
1.3Kb----
mh"
Sz £
< c/5 S3en O -1en (N (UU D X
- DP-3
b)
l.3Kb — GAPDH
Figure 4.3
Analysis of DP-3 transcripts
a) A northern blot was prepared with 25pg NIH 3T3 cell total RNA and 
polyadenylated and non-polyadenylated RNA fractions were isolated from NIH 3T3 
cell total RNA. Nuclear and cytosolic RNAs were extracted from NIH 3T3 cells. 
The total amount of polyadenylated and non-polyadenylated RNAs and nuclear and 
cytosolic RNAs loaded was 25pg. The northern blot was hybridised with the DP-3 
3’end probe (Chapter 2). The RNA size markers are indicated.
b) The northern blot from (a) was stripped and reprobed with a GAPDH probe.
c) The northern blot from (a) was stripped and reprobed with a histone 3 probe.
d) The northern blot from (a) was stripped and reprobed with a U6 probe.
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Figure 4.4
Analysis of DP-3 transcripts during F9EC cell differentiation
a) A northern blot was prepared from 25 pg of total RNA purified from F9EC cells 
and F9PE cells at days 3, 5 and 7 of differentiation. The blot was hybridised with the 
DP-3 3’end probe (Chapter 2). The positions of the RNA size markers are shown.
b) The northern blot from (a) was stripped and reprobed with a GAPDH probe and 
washed at high stringency.
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Figure 4.5
Analysis of E+ DP-3 transcripts
a) The northern blot of F9EC and F9PE cells from Figure 4.4 was stripped and 
hybridised with a probe specific for the E region (Chapter 2). The size markers are 
shown.
b) The hybridisation of the GAPDH probe, from figure 4.4b.
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Chapter 5
The regulation of DP-3 translation by the 5’ untranslated regions 
5.1 Introduction
The regulation of gene expression in eukaryotic cells occurs at many levels 
including transcription, mRNA processing, nuclear mRNA export, mRNA stability, 
translation and post-translational modifications of proteins. Several studies have 
shown that genes involved in cell cycle control are regulated via a translation 
mechanism. An example is p27, a cyclin-dependant kinase inhibitor; accumulation 
of this protein is regulated during the cell cycle at both at the level of translation and 
protein turnover (Hengst and Reed, 1996). The translation of specific mRNAs may 
be influenced by structural features of the mRNAs, for example, the translational 
regulation of cyclin-dependant kinase 4 (CDK4) by TGF-pl is p53-dependant and is 
mediated by the 5’UTR of the CDK4 mRNA (Ewen et al., 1995). In addition, 
murine p53 binds to the 5’UTR of its own mRNA and negatively regulates p53 
translation (Mosner et al., 1995).
The isolation and characterisation of DP-3 cDNAs revealed a complex 
5’UTR structure. DP-3 5’UTRs are both tissue restricted and associated with 
particular DP-3 protein isoforms (Ormondroyd et al., 1995). Since DP-3 transcripts 
are expressed in a range of tissues and cell lines and possess the properties of 
mRNAs with the potential to be translated (Chapter 4), it is possible that the 5’UTR 
of a transcript influences the translation of DP-3 isoforms. The aim of this study was 
to investigate the influence of the different DP-3 5’UTRs on translation of DP-3 
transcripts.
5.2 Results
5.2.1 Analysis of DP-3 translation by the different 5’UTRs
A set of mammalian expression vectors were constructed with the luciferase 
reporter gene fused to the fbui' different 5’UTRs of DP-3, (types I-IV) (Figure 5.1). 
Since thiee of the DP-3 protein isoforms are translated from the second methionine 
(M2, exon/segment 5), the DP-3 5’UTRs were fused at M2, in which case initiation 
of translation at M2 would result in active luciferase protein (Chapter 2). Initiation 
of translation at the first methionine (M l) of a type II 5’UTR would result in
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luciferase fused to the N-terminus of DP-3 a, which might influence the 
conformation of the luciferase protein and it was conceivable that the enzymatic 
activity of a fused luciferase protein might be impaired.
The measui ement of luciferase activity in cells transfected with the chimeric 
reporter constructs, combined with analysis of luciferase RNA, was extracted to 
provide an indication of the level of translation from each luciferase transcript. The 
backbone vector (pGL2Control), with a short 5’UTR of vector sequence, was 
included as a control for luciferase expression. A set of vectors under the control of 
the bacteriophage T3 promoter were also constructed for studying the translation of 
the DP-35’UTR-luciferase fusions in vitro (Chapter 2).
The 5’UTR-luciferase expression vectors were transiently transfected into 
several cell lines of different origins and the luciferase levels assayed. In each 
transfection a second reporter vector, pCMV|3-galactosidase (Tassios and La 
Thangue, 1991) was included to enable determination of transfection efficiency and 
identify any non-specific effects on gene expression. Furthermore, RNA was 
extracted from the transfected cells and the levels of luciferase and (3-galactosidase 
mRNA determined by dot blot analysis. Hence, the translational potential of each 
chimeric transcript was assessed by comparison of the luciferase activity and the 
level of luciferase transcript.
5.2.2 The DP-3 5’UTRs are equally translated in vitro
A  set of vectors under the control of the bacteriaophage T3 promoter, for 
studying the translation of the DP-3 5’UTR-luciferase transcripts in vitro were 
constructed from the mammalian expression vectors (Chapter 2). The in vitro 
translation of these vectors in a coupled transcription/translation system in a rabbit 
reticulocyte lysate resulted in an equal level of translation in from all the DP-3 
5’UTRs (Figure 5.2). Furthermore, all the in vitro translated luciferase proteins were 
enzymatically active (data not shown). In addition, translation was initiated at both 
M l and M2 of a type II 5’UTR and no apparent difference in the abundance of the 
luciferase protein initiated from either methionine was observed. Hence, the DP-3 
5’UTRs are translated equally in vitro and are all of similar enzymatic activity.
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5.2.3 The luciferase activity reflects the quantity of luciferase protein
It was assumed that the luciferase activity measured in cell extracts 
accurately reflects the amount of luciferase protein translated. Since the expression 
vectors had been constructed using PCR (Chapter 2) it was possible that mutations 
may have been introduced which could affect the enzymatic activity of the reporter 
gene. To ensure that the observed enzymatic activity is a true reflection of the levels 
of luciferase and p-galactosidase protein, extracts from transfected NIH 3T3 cells 
(Figure 5.6) were analysed by western blot (Figure 5.3). The levels of luciferase 
protein detected by an anti-luciferase antibody (Chapter 2) closely reflected changes 
in luciferase activity (Figure 5.3; Figure 5.6).
Luciferase protein levels were very high in the type I and IV 5’UTRs 
transfected cells and the level of luciferase was lower in cells transfected with 
pGL2Control (Figure 5.6). Luciferase protein was not detected in type III transfected 
cell extracts, and the level of luciferase activity was somewhat lower than that of the 
control, suggesting that the level of protein is too low to be detected by the antibody. 
Interestingly, luciferase protein was detected in type II transfected extracts, despite a 
very low level of luciferase activity. The luciferase protein appears to be of a slightly 
slower mobility than the luciferase protein in the in other lanes (Figure 5.3a, lane 4 
*). Translation initiation was possible at either M l or M2 of DP-3 type II 5’UTR 
RNA, where initiation at Ml would result in expression of a DP-3 N terminus- 
luciferase fusion protein, which would be larger in size than luciferase. It was 
possible that the protein detected is a DP-3 N-terminal-luciferase fusion protein. The 
levels of p-galactosidase protein also closely reflect the p-galactosidase activity 
(Figui'e 5.3c) and are similar in each lane suggesting that the efficiency of 
transfection is comparable.
5.2.4 DP-3 5’UTRs have translational activities
In most cell lines tested, the type I 5’UTR RNA had the highest translational 
activity, for example, in C33A cells (Figure 5.4) the type I 5’UTR was 
approximately 70% higher than the activity derived for the control. In the other cell 
lines tested, COS-7 cells and NIH 3T3 cells (Figures 5.5 and 5.6) the type I 5’UTR- 
luciferase exhibited greater than 90% higher activity than the pGL2control. In F9EC
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cells (Figure 5.7) the type I 5’UTR was over 200% translationally more active than 
the control.
The type II and III 5’UTRs RNAs were generally expressed at a much lower 
level than the control. In most cell lines type II 5’UTR translation was reduced, in 
comparison with the control expression revealed up to 99% reduction in luciferase 
activity (C33A cells, COS-7 cells, NIH 3T3 cells and F9EC cells, Figures 5.4, 5.5, 
5,6 and 5.7). More luciferase was expressed from type III 5’UTR RNA than type II 
5’UTR. However, in most experiments expression of type III 5’UTR RNA resulted 
in between 65% (F9EC cells, Figure 5.7) and 90% decrease in luciferase expression 
when compared to the control activity (C33A cells, COS-7 cells NIFI3T3 cells, 
Figures 5.4, 5.5 and 5,6).
The translation of the type IV 5’UTR RNA was the most variable of all the 
5’UTRs in the cell lines tested. Generally type IV was expressed approximately 30% 
higher than the control (COS-7 cells and NIH3T3 cells. Figures 5.5 and 5.6), 
however in F9EC cells (Figure 5.7) the type IV 5’UTR was over 50% higher than 
the control. In C33A cells (Figure 5.4) a type IV 5’UTR was translated 20% less 
than the control.
In the cell lines tested, the four DP-3 5’UTRs examined were all translated 
differently. The type I 5’UTR-luciferase was expressed to a higher level than the 
control, pGL2control. The type IV 5’UTR was usually translated to a similar level as 
the control. The type III 5’5’UTR was translated to a much lower level than the 
control, and the type II 5’UTR was only marginally active. In each cell line the 
analysis of luciferase and (3-galactosidase mRNA revealed little variation, 
suggesting the differences observed in protein level, were not due to differences in 
transcription or mRNA stability in each transfection. Hence, the expression of DP-3 
directed by the 5’UTRs may be cell type dependent. As observed with the other cell 
lines the levels of luciferase and (3-galactosidase mRNA remained constant in each 
transfection,
5.2.5 Translation of DP-3 type I and IV 5’UTRs was compromised in U20S  
cells
The translation of the different DP-3 5’UTR fused to luciferase was different 
in U20S cells, an osteosarcoma cell line in which the control exhibited the highest
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level of translation (Figure 5.8). The translational activity of type I and IV 5’UTRs 
was lower than the control and therefore reduced in these cells (Figure 5.8). Similar 
activity was noted for type II and type III as was observed in the other cell lines 
Hence, the expression of DP-3 directed by the 5’UTRs may be cell type dependent. 
However, analysis of mRNA was not successful in this cell line, therefore it is 
conceivable that the differences observed are attributable to non-translation 
mechanisms.
5.3 Discussion
5.3.1 DP-3 5’ untranslated regions influence protein expression by a post- 
transcriptional mechanism
The influence of the 5’untranslated regions of DP-3 on translation has been 
assessed both in vivo and in vitro. In vivo, in transfected mammalian cells, the 
expression of luciferase protein is dependent on the DP-3 5’UTR to which it was 
fused. Comparison of RNA levels suggests that there were few differences between 
5’UTR transcript levels; hence the differences observed in enzyme activity are not 
due to variation in transcription and mRNA stability of the different luciferase 
transcripts. Therefore, the DP-3 5’UTRs are regulated by a post-transcriptional 
mechanism, probably at the level of translation.
The DP-3 type I 5’UTR was translated most efficiently in the four cell lines, 
suggesting that the most abundant DP-3 isoforms in cultured cells may be translated 
from DP-3 transcripts with a type I 5’UTR. A type IV 5’UTR expression was 
variable, however, expression was generally lower than type I 5’UTR and at 
approximately the same level as the control. On occasion type IV 5’UTR was 
expressed at a very high level, higher than type I and it is possible that the 
translation of this 5’UTR is dependant on the cell state, for example the stage in the 
cell cycle. Type IV 5’UTR may therefore be regulated imder specific cellular 
conditions. The type II and III 5’UTRs were translated much less efficiently than 
either the control or types I and IV and therefore lower levels of DP-3 isoforms 
expression would be predicted from transcripts that possess types II and III 5’UTRs.
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5.3.2 DP-3 expression is cell type dependent and mediated by the 5’UTRs
Transfections in U20S cells revealed a strikingly different pattern of 
translation. The translation of types II and III were similar to that observed in other 
cell lines with respect to the control activity. In contrast, translation of types I and IV 
was lower than control in this cell type. It is therefore conceivable that specific cell 
or tissue types may express different levels of DP-3 via a specific translational 
control mechanism, mediated by the 5’ untranslated regions.
It is however possible that the observed expression pattern is not due to 
differences in translational ability but because of regulation at another level. Gene 
expression can be regulated at several instances both at the level of transcription and 
via post-transcriptional mechanisms. Analysis of RNA levels suggested that similar 
amounts of RNA was expressed in each experiment. Therefore, it was unlikely that 
differences in RNA stability resulted in the observed differences in protein level. 
Additionally, differences in polyadenylation could affect translation (Pain, 1996; 
Sachs et al., 1997) and regulation at the level of RNA nuclear transport could also 
influence translation. The RNA analysis undertaken in this study would not detect 
these subtle changes in RNA. However, the pGL2control contains a polyadenylation 
site and since the vector has not been manipulated in this region it is unlikely that 
the regulatory sequences in the 3’ region have been impaired.
5.3.3 M l of DP-3 type II 5’UTR may be used preferentially in vivo
The different DP-3 5’UTRs can direct the initiation of translation at either 
M l or M2. Initiation at M l results in an extended N-terminus, homologous to the N- 
terminus of DP-1. Initiation of translation at M l is possible in type I, II and IV 
5’UTRs, however in types I and IV, in frame stop codons terminate translation 
before M2 and subsequently translation can re-initiate at M2. Translation at Ml 
from a type II 5’UTR-luciferase transcript will result in a luciferase protein fused to 
the DP-3 N- terminus, which may affect the protein conformation and influence 
enzymatic activity. Type II 5’UTR had the lowest translational activity and it is 
feasible that a luciferase fusion protein would not be enzymatically active. 
Therefore, it is possible that M l, rather than M2 is used in vivo, since initiation at 
M2 would result in active luciferase protein. Hence Ml might be preferentially used 
in vivo. However, the absence of detectable M2 translated luciferase protein does not
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indicate that translation from M2 does not occur in vivo. Analysis of protein on 
western blots from transfected cells revealed the presence of a luciferase polypeptide 
that appeared slightly larger than the other luciferase proteins, suggesting an M l- 
luciferase protein, however the identity of this polypeptide must be frirther 
confirmed before any firm conclusions can be made. Therefore, further investigation 
into the translational activity of type II 5’UTR transcripts is required.
5.3.4 All DP-3 5’UTRs are translated equally in vitro
Analysis of the 5’UTRs in vitro revealed that all the 5’UTRs are translated 
equally, and that translation is initiated at both Ml and M2 in the type II end, in an 
equivalent mamier. Therefore, the difference in expression observed in vivo and in 
vitro suggests that cellular factors not present in rabbit reticulocyte lysates are 
required for the regulated expression observed in vivo.
5.3.5 DP-3 translation could be regulated via different mechanisms
There are multiple mechanisms for the regulated translation of mRNA in 
eukaryotes (Kozak, 1992; Pain, 1996). Structui'al features of an mRNA and the 
trans~2iCÏm% factors that interact with mRNA influence translation. The context of 
the AUG initiation signal can also influence translation (Kozak, 1989) and other 
sequence elements such as the presence of upstream AUG codons (uAUG) and 
ORPs (uORFs) can also affect the translational efficiency of an mRNA. For 
example, uORFs in the 5’UTR of the yeast GCN4 gene suppress the translation of 
GCN4 when nutrients are plentiful and only during amino acid staiwation is the 
translation of GCN4 de-repressed (Hinnebusch, 1996).
Secondary structure within the 5’UTR can also influence translational 
activity (Kozak, 1989) and additionally, RNA/protein interactions can regulate the 
translation of a few specific mRNAs, for example the synthesis of ferritin in 
mammalian cells is regulated by the secondary structure of the iron response 
element (IRE) within the 5’UTR of fenitin mRNA. The iron regulatory factor (IRF) 
binds to the IRE and represses translation (Melefors and Hentze, 1993).
DP-3 5’UTRs could be regulated by any of these mechanisms. DP-3 5’UTRs 
contain uORFs and uAUGs that may influence translation. Type I, II and IV 
transcripts all contain Ml (Figure 5.1) and initiation at M l from type I and IV
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transcripts results in translation of short uORFs that terminate before M2. 
Reinitiation at M2 may then occur resulting in translation of DP-3 M2 products. The 
distance between the stop codon of the uORF and M2 is different in type I and type 
IV and this intercistronic distance may influence reinitiation at M2 and could 
account for the differences observed in translation from transcripts with these 
5’UTRs. Therefore, the splicing arrangement of DP-3 5’ exons may determine the 
probability of reinitiation at M2.
The DP-3 type II 5’UTR contains two in frame initiation signals Ml and M2. 
A type II 5’UTR is only associated with an E+ Q- ORF, therefore translation at Ml 
or M2 would result in DP-3 a  or ô respectively. The differential use of in-frame 
initiation codons may have implications on DP-3 expression. The mRNA of LAP 
protein, a liver-eniiched transcription factor, contains two uAUG in-frame codons in 
the 5’UTR of the lap mRNA and results in synthesis of either LAP protein or an 
inhibitor of LAP called LIP (Descombes and Schibler, 1991). A change in the use of 
AUG codons results in a change in the ratio of LAP to LIP altering the 
transcriptional properties of the gene. Likewise, it is possible that initiation at Ml 
and M2 of type II may also he regulated and have a potentially dramatic influence 
on E2F formation and function.
Additionally, DP-3 a  and DP-35 have been shown to interact with a DP 
interacting protein (DIP), a POZ domain containing protein that influences the cell 
cycle (de la Luna et al., 1999). It is possible therefore that the interaction between 
DP-3 a  and DIP could be influenced by translational initiation, selection of M2 of 
type II 5’UTR transcripts would result in translation of DP-35 which only weakly 
interacts with DIP . A switch between translation initiation at M l and M2 may occur 
under specific cellular conditions and that this could influence the interaction of DP- 
3 with DIP or other cellular factors.
DP-3 expression could he regulated by RN A/protein interactions. DP-3 
5’UTRs are translated differently in vivo, however in vitro translation of each 
5’UTR is equal: this suggests that specific cellular factors may be required for the 
differences in translation observed in transfected mammalian cells. It is possible that 
repressor proteins bind to type II and III 5’UTR and inliibit translation, and that 
these proteins are unable to bind to type I or IV. Conversely activators may bind to 
type I 5’UTR and not to the other 5’UTRs. Therefore the variation in the level of
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type IV translation could be via altered affinity of a repressor or activator protein for 
type IV 5’UTR, perhaps in response to changes in cellular environment
5.3.6 A novel post-transcriptional mechanism may influence subunit 
composition of the E2F heterodimer
The translational regulation of DP-3 expression via the different 5’UTRs 
may have an impact upon E2F. Regulating of translation enables cells to rapidly 
‘turn on’ protein expression. DP-3 transcripts are detected in many tissues and cell 
lines, it is possible that these transcripts are present at all times and then in response 
to changes in cellular conditions for example in response to growth signals or stress, 
DP-3 protein is rapidly translated. The timely expression of DP-3 protein may be 
important for E2F function under such specific cellular conditions. Alternatively the 
5’UTRs of DP-3 may exist to maintain precise levels of each isoform. Each 
untranslated region is associated with different protein isoforms (Ormondroyd et al., 
1995) and the 5’UTRs aie translated to different levels in different cell lines. It is 
therefore possible that they are just translated differently to ensure that cells have the 
correct levels of each isoform. For example type I 5’UTR is found associated with 
DP-3 Y isoform and a type III 5’UTR with DP-3(3 isoform. Since a type I 5’UTR is 
highly expressed in cells and a type III 5’UTR is, on comparison, expressed to a 
much lower level, cells might require more DP-3y than DP-3 p. Such regulation may 
act to maintain the conect cellular levels of DP-3 and reflect its requirement as an 
E2F partner and ultimately, its physiological role.
The translational regulation of DP-3 via its 5’untranslated regions represents 
a level of regulation unique within the E2F family of transcription factors. Distinct 
cellular circumstances may dictate the expression of DP-3 isoforms and influence 
E2F heterodimer formation and activity.
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Figure 5.1
Translational analysis of DP-3 5’UTRs
Luciferase reporter constructs. Each of the DP-3 5’UTR sequences was fused to 
luciferase at methionine 2. Arrows represent possible sites of translation initiation. 
X represents sites of translational termination. * represents the site of a stop signal.
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Figure 5,2
The DP-3 5’UTRs are translated equally in vitro
1 pg of each plasmid DNA, as indicated, was in vitro translated in the presence of 
^^S-methionine. A tenth of each reaction was analysed by PAGE and 
autoradiography.
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Figure 5.3
The luciferase activity reflects luciferase protein
a) Extracts from transfected NIH 3T3 cells (figure 5.6) were immunoblotted with an 
a  luciferase antibody. The positions of M l and M2 initiating luciferase proteins are 
indicated. * denotes Ml-luciferase.
b) A shorter exposure of the immunoblot in a). The position of luciferase protein is 
given.
c) The immunoblot from a) was stripped and p-galactosidase protein detected with a  
p-galactosidase antisera.
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Figure 5.4
The expression of DP-3 5’UTRs in C33A Cells
a) C33A cells were transfected with 7.5pg 5’UTR-luciferase construct as indicated 
and 2.5pg pCMV-p-galactosidase by the calcium phosphate method. Cells were 
harvested at 48 hours post transfection, for both RNA and protein. The values 
plotted are based on the activity of luciferase relative to the activity of the control, P- 
gaiactosidase.
b) RNA was extracted from C33A cells from (a) and dot blotted. Dot blots were 
hybridised with a luciferase and a p-galactosidase probe.
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Figure 5.5
The expression of DP-3 5’UTRs in COS 7 Cells
a) COS-7 cells were transfected with 7.5pg 5’UTR-luciferase construct as indicated 
and 2.5jag pCMV-p-galactosidase. Cells were harvested at 48 hours post 
transfection, for both RNA and protein. The values plotted are based on the activity 
of luciferase relative to the activity of the control, p-galactosidase.
b) RNA was extracted from COS-7 cells from (a) and dot blotted. Dot blots were 
hybridised with luciferase and p-galactosidase probes.
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Figure 5.6
The expression of DP-3 5’UTRs in NIH 3T3 Cells
a) NIH 3T3 cells were transfected with lOpg 5’UTR-luciferase construct as 
indicated and 2|J,g pCMV-p-galactosidase. Cells were harvested at 48 hours post 
transfection, for both RNA and protein. The values plotted are based on the activity 
of luciferase relative to the activity of the control, p-galactosidase.
b) RNA was extracted from NIH 3T3 cells from (a) and dot blotted. Dot blots were 
hybridised with a luciferase and a p-galactosidase probe.
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Figure 5.7
The expression of DP-3 5’UTRs in F9EC Cells
a) F9EC cells were transfected with 7.5pg 5’UTR-luciferase construct as indicated 
and 2.5pg pCMV-p-galactosidase by the calcium phosphate method. Cells were 
harvested at 48 hours post transfection, for both RNA and protein. The values 
plotted are based on the activity of luciferase relative to the activity of the control, p- 
galactosidase.
b) RNA was extracted from F9EC cells from (a) and dot blotted. Dot blots were 
hybridised with both luciferase and p-galactosidase probes.
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Figure 5.8
The expression of DP-3 5’UTRs in U20S Cells
a ) U20S cells were transfected with 7.5pg 5’UTR-luciferase construct as indicated 
and 2.5jo,g pCMV-p-galactosidase by the calcium phosphate method. Cells were 
harvested at 48 hours post transfection, for both RNA and protein. The values 
plotted are based on the activity of luciferase relative to the activity of the control, P- 
galactosidase.
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Chapter 6
The effect of p53 on DP-3 translation
6.1 Introduction
The 5’ untranslated region of a transcript can influence translation of 
eukaryotic mRNAs. The level of translation can be influenced both by the 
mechanism of initiation site selection and by RNA-protein interactions within the 5 ’ 
untranslated regions (Jackson and Wickens, 1997). In addition, short upstream open 
reading frames can also influence translation of the major open reading frame (ORF) 
(Geballe and Morris, 1994). Therefore the 5’UTR of a transcript can have an impact 
on the expression of protein at a translation level.
The p53 tumour suppressor protein is an important regulator of the cellular 
response to DNA damage, the induction of active p53 protein resulting in either cell 
cycle arrest or apoptosis (Ko and Prives, 1996). The p53 protein is a sequence 
specific transcription factor, whose responsive genes are involved in apoptosis and 
cell cycle regulation. In addition, p53 interacts with a number of cellular and viral 
proteins (Ko and Prives, 1996). Genes regulated by p53 include p21 '^''^‘^ 'P', a cyclin- 
dependant kinase (cdk) inlribitor that induces cell cycle arrest (El-Deiry et al., 1993; 
Harper et al., 1993). The p21 protein modulates the activity of cdks by preventing 
phosphorylation of pRb. Hypophosphorylated pRb forms an inhibitory complex with 
E2F, thereby preventing progression into S phase of the cell cycle and aiTest in G1 
phase results (Dulic et al., 1994). Another transcriptional target of p53 is the mdm2 
gene (Moraand et al., 1992). MDM2 is an oncoprotein that interacts with p53, 
inliibiting the transactivation functions of p53 and also targeting p53 for 
proteosome-mediated degradation (Haupt et al., 1997; Kubbutat et al., 1997).
The pRb/E2F and p53 pathways appear to be linked, not only via induction 
of p21 and pRb induced cell cycle arrest but via p53 regulated apoptosis. High 
expression of E2F-1 can cause quiescent cells to enter S phase (Johnson et al., 1993) 
and subsequently apoptose, a process which is enlianced in the presence of p53 (Wu 
and Levine 1994). Furthermore, components of the E2F/pRb and p53 pathways 
physically interact, suggesting further integration of these pathways (Martin et al., 
1995; O’Connor 1995; Sorensen et ah, 1996).
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Murine p53 negatively regulates it’s own expression through the 5’UTR of 
p53 transcripts and physically interacts with the 5’UTR of p53 mRNA in vitro 
(Mosner et aL, 1995). Murine p53 has also been shown to be important in the 
repression of cyclin-dependent kinase 4 (CDK4) translation in TGF-pl-induced G1 
cell cycle ai’rest; this effect is mediated by the 5’UTR of the CDK4 transcript (Ewen 
et a i, 1995). In addition, the 3’UTR of human p53 mRNA inhibits the expression of 
p53 protein (Fu et aL, 1996) and participates in activation of p53 translation in 
response to y-irradiation (Fu and Benchimol, 1997). It is therefore apparent that p53 
may be able to exert its cell cycle regulatory effects both by transcriptional and 
translational mechanisms.
An investigation into the expression of the DP-3 5’UTR-luciferase vectors in 
SAOS-2 cells revealed striking differences in expression when compared with the 
results obtained in other cell lines tested (Chapter 5). SAOS-2 cells lack functional 
pRb and p53 (Shew et aL, 1990). Since the p53 and E2F pathways are integrated and 
p53 is involved in translational regulation of cell cycle related targets, an 
investigation into the effect of p53 on DP-3 5’UTR mediated translation was 
instigated.
6.2 Results
6.2.1 DP-3 5’UTRs are regulated in SAOS-2 cells
The chimeric DP-3 5’UTR luciferase reporter vectors (Chapter 5) were 
transiently transfected into SAOS-2 cells. The results (Figure 6.1) revealed 
differences in expression when compared to the other cell lines assayed (Chapter 5). 
The translation of the type I 5’UTR was observed to be 60% less than pGL2control. 
The type III 5’UTR was 95% lower than the control, similar to all other cell lines 
tested. However, a striking difference was observed for the type IV 5’UTR. The 
translation of this 5’UTR was 60% higher than the control, this elevated level of 
type IV activity was not observed in any other cell lines (Chapter 5). Such data 
suggests that the translation of DP-3 type IV 5’UTR is regulated in SAOS-2 cells.
6.2.2 p53 represses translation of DP-3 type IV 5’UTR transcripts
The expression of the chimeric DP-3 5’UTRs-luciferase was different in 
SAOS-2 cells when compared to the other cell types tested (Chapter 5). The high
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level of expression of type IV 5’UTR was unique to this cell line. All the other cell 
lines tested (Chapter 5) expressed pRb and p53, except C33A cells which lack pRb 
(Zhu et ah, 1993). On comparison with the other cell lines, the absence of pRb did 
not result in any differences in 5’UTR expression in C33A cells, since the 
expression of all the DP-3 5’UTRs was similar to that observed in the other cell lines 
(Chapter 5, Figure 5.4). Hence, it was possible that the absence of p53 in SAOS-2 
cells, resulted in the high level of luciferase expression from type IV transcripts. In 
an effort to further investigate the regulation of DP-3 translation via the DP-3 
5’UTRs, p53 was co-expressed with the chimeric DP-3 5’UTR-luciferase vectors in 
SAOS-2 cells.
Co-expression of p53 with the DP-3 5’UTR-luciferase vectors in SAOS-2 
cells resulted in several effects on DP-3 translation (Figure 6.2). Co-transfection of 
p53 did not effect the expression of type I 5’UTR. However co-transfection of p53 
resulted in a 65% reduction in type IV 5’UTR activity. The translation of type IV 
5’UTR in the presence of p53 was similar to the level of type I 5’UTR activity. 
Furthermore, expression of the type IV 5’UTR in SAOS-2 cells co-transfected with 
p53 was 50% less than the control and resembled the levels observed in other cell 
lines (Chapter 5). Such data suggests that p53 may repress the translation of DP-3 
transcripts with a type IV 5’UTR.
The translation of DP-3 type III 5’UTR transcripts was enhanced in the 
presence of p53 and resulted in a 60% increase in luciferase expression (Figure 6.2). 
However the level of type III translation was still 90% lower than the control value 
and therefore similar to the level observed in other cell lines (Chapter 5).
6.3 Discussion
6.3.1 The translation of DP-3 type IV 5’UTR is enhanced in SAOS-2 cells
The high level of translational of a DP-3 type IV transcript was unique to 
SAOS-2 cells, since all other cell lines tested revealed lower levels of type IV 
5’UTR translation (Chapter 5). Such data suggests that the translation of type IV 
5’UTR is regulated in a specific mamier in SAGS- 2 cells. The absence of pRb or 
p53 or both proteins in this cell line may be responsible for the phenotype observed. 
Transient transfection experiments in C33A cells, which lack functional pRb but 
express p53, revealed similar regulation to other cell lines tested, suggesting that the
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absence of functional pRb may not be solely responsible for the phenotype observed 
in SAOS-2 cells. Indeed, addition of p53 represses the expression of type IV 
transcripts to the levels observed in other cell lines (Chapter 5). It is conceivable that 
the absence of endogenous p53 in SAOS-2 cells prevents the repression of 
translation of type IV transcripts, and hence high levels of translation were observed. 
Alternatively, the expression pattern and regulation of translation factors in SAOS-2 
cells may dictate the level of translation.
6.3.2 p53 may influence DP-3 translation via direct RNA/protein interaction
There are several possible mechanisms through which p53 could exert its 
effects on DP-3 translation. p53 may directly regulate DP-3 translation by binding to 
the 5’UTR of a particular DP-3 transcript. A direct interaction between the DP-3 
type IV 5’UTR and p53 could prevent efficient translation. Since direct 
RNA/protein interactions can influence translation (Jackson and Wickens, 1997) and 
murine p53 protein has been shown to bind directly to p53 transcripts in vitro 
(Mosner et aL, 1995), p53 may specifically bind to type IV 5’UTR RNA and repress 
translation. In contrast, an interaction between p53 and type III RNA may result in 
the enliancement of type III translation observed in the presence of p53, however 
activators of translation are rare in eukaryotic translation (Kozak, 1992).
6.3.3 p53 dependent transcription activity may influence translation
p53 may influence translation indirectly by interaction with cellulai* proteins 
or via the transcriptional activation of a range target genes. Once such target is 
p2 iwaficipi, {increased levels of this cdk inhibitor induces cell cycle arrest (El-Deiry et 
aL, 1993; Harper et aL, 1993). It is conceivable that the translation of any of the DP- 
3 5’UTRs may be regulated during the cell cycle and that p53 mediated cell cycle 
arrest causes the change in translation of DP-3 5’UTRs observed. Thus, the effect of 
p53 on DP-3 5’UTR translation may be an indirect effect of p53 rather than a direct 
physical interaction between DP-3 RNA and p53 protein.
The mdm2 proto-oncogene is a target of p53 transcription. MDM2 protein 
has been implicated in translational regulation; thus, MDM2 interacts with the 
ribosomal L5 protein-5srRNA nucleoprotein complex, both in the presence and 
absence of p53 (Maréchal et aL, 1994). Furthermore, the RING finger domain of
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MDM2 binds specifically to RNA and this interaction is independent of the L5- 
MDM2 interaction (Elenbaas et aL, 1996). MDM2 may influence translation by the 
binding of specific RNAs and influence translation tlnough the L5-5srRNA 
interaction. If DP-3 5’UTRs were specifically bound and their translation influenced 
by MDM2, increased p53 expression could result in the modification of DP-3 
5’UTR translation observed. However, preliminary results in SAOS-2 cells suggest 
that over expression of MDM2 protein does not result in the changes observed in 
DP-3 5’UTR translation, when p53 is co-expressed (data not shown).
6.3.4 p53 may target the expression of specific DP-3 protein isoforms
The expression of p53 in SAOS-2 cells influenced the translation of specific 
DP-3 5’UTRs in opposing ways. Type I 5’UTR translation did not change in the 
presence or absence of p53. Type III translation was increased and in contrast, type 
IV translation was reduced in the presence of p53. Extensive analysis of DP-3 RNA 
has revealed that particular 5’UTRs are found associated with particular ORfs 
(Ormondroyd et aL, 1995). For example, type III 5’UTR is associated with an M2 E- 
Q- ORF and results in translation of DP-3(3 isoform (Ormondroyd et aL, 1995). 
Likewise, a type IV 5’UTR is associated with an M2 E-Q+ ORF and a DP-3y 
isoform would result from translation of such a transcript. Based upon the difference 
in response to p53 in SAOS-2 cells of the DP-3 5’UTR, it is likely that during a p53 
response the translation of DP-3p would be enhanced and that DP-3y translation 
would be reduced. It is interesting to note that the only difference between these two 
DP-3 protein isoforms is the inclusion of a single glutamine residue (Q) in the DP-3y 
isoform. This glutamine residue may represent a site of post-translational 
modification; the inclusion of the glutamine residue in DP-3y disrupts a putative 
casein kinase II phosphoiylation site in DP-3(3 and creates a putative DNA-PK 
phosphorylation site (Chapter 3; Figure 8.1). At present, comparisons of the 
transcriptional activity of DP-3p and DP-3y with different E2F partners and with 
various E2F responsive promoters is underway.
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6.3.5 DP-3 isforms may function during DNA damage or repair
p53 is induced and activated in response to a range of stimuli, including 
DNA damage. Several protein kinases phosphorylate p53, enhancing p53 
accumulation and functional activation in response to DNA damage. The kinases 
that phosphorylate p53 include DNA-PK, which has been shown to phosphorylate 
p53 in vitro (Lees-Miller et al., 1992) DNA-PK is also known to be active during 
DNA repair (Anderson and Carter, 1996). It is possible therefore that p53 decreases 
the expression of DP-3y (via type IV 5’UTR) and in addition, DNA-PK 
phosphorylates DP-3y, perhaps inhibiting any active DP-3y in the cell. Such 
regulation suggests that this DP-3 isoform needs to be switched off during DNA 
damage and repair.
The enliancement of DP-3 p expression in the presence of p53 suggests that 
this isoform may Rmction in cellular conditions where p53 levels are elevated, such 
as during DNA damage and repair. Subtle changes in the levels of DP-3 isoforms 
may serve to activate or repress particular E2F target genes. Many of the E2F target 
genes are required for DNA replication (He!in, 1998) and therefore, turning off E2F 
transcription would be expected, thereby allowing DNA repair before replication. 
This would imply that DP-3p expression might have a negative influence on E2F 
and reduce E2F-dependent transcription. Perhaps DP-3P dimerises with specific E2F 
partners and forms inhibitory complexes that cannot bind to DNA or that cannot 
activate transcription. Indeed, an E2F-4 or 5/DP-3 p complex would only accumulate 
in the nucleus via the action of pocket proteins and is thought repress E2F target 
genes (Allen et aL, 1997), therefore, expression of DP-Sp may indeed cause the 
formation of repressive E2F complexes. Alternatively, DP-3P may activate as yet 
undiscovered genes required for DNA repair. Additionally, phosphorylation of DP- 
3y by DNA-PK during DNA repair may modify the affinity of DP-3y for particular 
E2F partners or alter DNA binding ability and like DP-3P, influence E2F 
transcription. p53 functions as a sensor to cellular stresses, for example, DNA 
damage, metabolic changes and deregulated cell cycle progression, it is possible that 
p53 might target E2F activity by altering translation of particular DP-3 isoforms, 
potentially assisting growth arrest or apoptosis.
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At present no definite function has been found for DP-3. Endogenous DP-3 
protein is difficult to detect in cells and therefore, DP-3 isoforms may have a short 
protein half-life. It is possible that DP-3 is only required under specific 
circumstances, such as DNA damage or repair. The formation of specific E2F 
complexes dming conditions of DNA damage may be mediated by p53 dependant 
translational control of DP-3 isoforms and that rapid degradation of DP-3 prevents 
the maintenance of E2F complexes when no longer required.
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Figure 6.1
The expression of DP-3 5’UTRs in SAOS-2 Cells
a) SAOS-2 ceils were transfected with 7.5pg 5’UTR-luciferase construct as 
indicated and 2.5pg pCMV-p-galactosidase. Cells were harvested at 48 hours post 
transfection. The values plotted are based on the activity of luciferase relative to the 
activity of the control, p-galactosidase.
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Figure 6.2
The effect of co-expression of p53 on DP-3 5’UTRs activity in SAOS-2 cells
a) SAOS-2 cells were transfected with Spg 5’UTR-luciferase vector as indicated and 
0.5pg pCMV-p-galactosidase, in duplicate. Cells were harvested at 48 hours post 
transfection. The values plotted are based on the average activity of luciferase 
relative to the activity of the control, p-galactosidase.
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Chapter 7
Analysis of DP-3 protein
7.1 Introduction
Antisera have been important in the chai'acterisation of E2F. Antisera have 
been raised to the different E2F components and used to gain insight into the cellular 
E2F activity. For example, analysis of E2F DNA binding activity during the cell 
cycle, using E2F-1 and E2F-3 specific antisera has shown that E2F-3/DF-1 
heterodimers form the E2F activity as cycling cells enter S phase (Leone et a l, 
1998). Likewise E2F-4 and p i30 antisera have been used to characterise early cell 
cycle complexes (Vairo et a l, 1996), and antisera has been useful in the study of the 
sub cellular location of E2F and DP proteins (de la Luna et a l, 1996: Magae et a l, 
1996: Müller et a l, 1997). Antisera specific for DP-3 or a particular DP-3 isoform 
were therefore likely to be useful for the studying the role of DP-3 in E2F.
DP-3 cDNAs suggested four different protein isoforms may exist 
(Ormondroyd et a l, 1995). From the amino acid sequence, DP-3 a  was estimated to 
be approximately 50 KDa and DP-3 p,y and ô approximately 43 KDa in size. During 
the early analysis of DP-3 protein, several different rabbit anti-peptide antisera 
produced (S. de la Luna personal communication and Figure 7.1) Western blot 
analysis revealed that these polyclonal antisera all recognised bacterially expressed 
GST-DP-3 fusion proteins. In addition, the antisera detected exogenously expressed 
DP-3 proteins in transiently transfected mammalian cell extracts, in both 
immunoblots and immmiostaining studies, but did not react with exogenous or 
endogenous DP-1 in western analysis. However, detection of endogenous DP-3 
protein had proved difficult. Whilst competition experiments performed with 
specific and non-specific peptides in western blots found that all the anti-peptide 
polyclonal antisera react with polypeptides in whole cell extracts, none of the 
antisera detected the same polypeptides. Therefore confirmation that any of the 
polypeptides were indeed endogenous DP-3 protein was not possible.
The detection of DP-3 protein was essential for the characterisation of its 
role in the E2F heterodimer. Thus, in an attempt to analyse DP-3 protein expression, 
rabbit polyclonal antisera were raised to different regions of the DP-3 amino acid
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sequence. These antisera were characterised by western blotting and by 
immunostaining of transfected cells.
7.2 Results
7.2.1 Peptide design
Several peptides had been designed and made during the initial cloning of 
DP-3. In an effort to expand the repertoire immunochemical reagents available to 
study DP-3 proteins, new antisera were raised. The amino acid sequence of peptide
7.6 and 7.7 was taken from the E region of DP-3 a  and ô, 7.6 spans the entire 16 
residues of the E region (Figure 7.1). The peptide 7.7 sequence begins 8 residues 
before the E region and overlaps the 7.6 sequence (Figure 7.1c). These peptides 
were designed on the basis that the resultant antisera would react specifically with 
E+ DP-3s and permit a distinction between E+ and E- protein isoforms. It was 
predicted that antisera raised to 7.6 and 7.7 peptide sequences would not recognise 
DP-1, since the E region is absent (Figure 7.1b and c).
7.2.2 Analysis of a7.6 antisera
7.2.2.1 a7.6 antisera detects E+ DP-3 isoforms and not E- isoforms
Western analysis with extracts from COS-7 cells transiently transfected with 
DP-3 suggested that the a7.6 antisera could specifically distinguish between E+ and 
E- forms of DP-3 (Figure 7.2a). Antisera from both rabbits immunised with peptide
7.6 detected polypeptides in COS-7 cell extracts expressing DP-3a and ô (Figure 
7.2a, lanes 3 and 7, Figure 7.2b, lanes 11 and 15). However, extracts from cells 
transfected with DP-3|3 did not detect polypeptides with antisera from either rabbit 
(Figure 7.2a, lane 5 and Figure 7.2b, lane 13) showing a similar appearance to the 
negative control, (mock transfected extracts, Figure 7.2a, lanes 1 and 2, Figure 7.2b, 
lanes 9 and 10). As expected the positive control a7.2 antiserum specifically 
detected all DP-3 protein isoforms in both western blots of DP-3 transfected cells 
and bacterially expressed DP-3 proteins. The a l.2  antiserum recognised similar 
sized polypeptides in DP-3a transfected extracts (Figure 7.2b lane ) as a7.6 antisera 
from both rabbits (Figure 7.2a lane 3, Figui-e 7.2b lane 11).
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1.2.2.2 a7.6 antisera specifically recognises DP-3 E+ isoforms
The addition of peptide 7.6 to the binding reaction prevented detection of the 
DP-3 polypeptides (compare Figure 7.2a, lanes 3 and 4, 7 and 8, Figure 7.2b, lanes 
11 and 12, 15 and 16), suggesting that the antisera raised specifically recognises an 
epitope common to both DP-3 E+ proteins and contained within peptide 7.6. The 
addition of a peptide of similar size and of unrelated sequence (peptide C) to peptide
7.6 ensured that the effects observed were due to competition for a specific peptide 
epitope rather than a non-specific effect. Similarly, when the 7.2 peptide was 
included in the a7.2 antisera binding reactions detection of the same polypeptides in 
DP-3a expressing cells was prevented (Figure 7.2b, lanes 17 and 18). Polypeptides 
that were apparent on blots both in the presence and absence of specific peptides 
were non-specific detection of polypeptides by the antisera, and thus deemed of little 
relevance to the analysis of DP-3.
7.2.2.3 a7.6 antisera specifically detects DP-3 E+ isoforms by immunostaining
The DP-3 E region plus several C-terminal residues found in all DP proteins 
can act as an NLS (de la Luna et aL, 1996). To study the cellular location of DP 
proteins, the antisera were tested by immunostaining of transfected cells. 
Immunostaining with a7.6 antisera revealed specific recognition of DP-3a, a 
nuclear DP (de la Luna et aL, 1996), and the addition of peptide 7.6 abolished the 
nuclear staining in expressing cells (Figure 7.3a and b). Mock transfected cells, and 
those expressing DP-3(3 showed slight background fluorescence (Figure 7.3d, e, g 
and h). Immunostaining with the a7.2 antisera, which recognises all DP-3 isoforms, 
revealed that the cells had been transfected, since both DP-3 a  and p were expressed. 
Extracts from mock transfected cells did not express DP-3 protein (Figure 7.2 ).
7.2.3 a l . l  antisera specifically detected DP-3 E+ isoforms by western blotting
The antisera raised to peptide 7.7 were tested by western blotting with 
extracts from COS-7 cells transfected with DP-3. Only one of the two rabbits 
immunised with peptide 7.7 produced antiserum that could be used in 
immunoblotting analysis. The a l . l  antisera recognised the 53 KDa DP- 
3a polypeptide and the 50 KDa DP-36 polypeptide (Figure 7.4, lanes 3 and 4, lanes
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7 and 8). The detection of polypeptides was specific, since the addition of 7.7 
peptide abolished detection of these polypeptides. The same polypeptides were 
detected by the a7.6 and by a7.2 antisera (Figure 7.2). Likewise, a l . l  antisera 
failed to detect polypeptides in extracts from DP-3p transfected cells. The a l.2  
antisera revealed that DP-3P transfected extracts were indeed expressing a 50 KDa 
band which was effectively competed by addition of 7.2 peptide (Figure 7.4, lanes 9 
and 10).
7.2.4 Truncated DP-3 polypeptides are detected with a7.6 and a l . l  antisera
The results suggested that there were smaller DP-3 polypeptides since 
competition for the smaller polypeptides was apparent upon addition of specific 
peptide (Figure 7.2 and 7.4). The polypeptides were only observed in DP-3 
transfected cell extracts and not in the mock transfected cells, indicating that they 
were likely to be DP-3 polypeptides. These polypeptides could possibly result from 
initiation of translation at internal methionines in the DP-3 ORF, as several likely 
methionines exist in DP-3, some being in a favourable context for initiating 
translation (Kozak, 1989). Alternatively the polypeptides may just be products of 
proteolytic degradation. Since there was only one possible initiating methionine 
before the E region, the array of smaller bands seen may be the combination of 
products of internal translation initiation and degradation.
7.3 Discussion
7.3.1 DP-3 anti-peptide antisera detect exogenously expressed DP-3 proteins, 
but not endogenous DP-3
The antisera raised to peptides 7.6 and 7.7 react specifically with 
exogenously expressed DP-3 E+ protein isoforms, both by western blotting and 
immunostaining analysis. Flowever, the detection of endogenous DP-3 protein 
would have greatly advanced my studies into DP-3 expression and function. 
Although the anti-peptide antisera were tested with extracts from untransfected cells 
by western blotting (data not shown), I failed to detect any evidence that the antisera 
recognised endogenous DP-3, Hence, it has still not been possible to identify a 
polypeptide that reacts with two different DP-3 antisera, confirming that the 
polypeptide is indeed an endogenous DP-3 protein isoform.
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In conclusion, the anti-peptide antisera produced specifically detected 
exogenous DP-3 E+ proteins expressed in transfected cells, but failed to identify 
polypeptides which could be precisely ascribed to endogenous DP-3.
7.3.2 DP-3 protein is expressed at low levels in cells
The lack of detection of endogenous DP-3 protein could be due to several 
factors. The levels of DP-3 protein in cells may be extremely low and all the antisera 
so far made may not be sensitive enough to detect them. It is possible, however, that 
the antisera can indeed identify DP-3 polypeptides, but these epitopes recognised by 
each antibody were not available on all DP-3 isoforms. Although this is a 
conceivable idea, is unlikely since some anti-peptide antisera, such as a l.2  were 
made to regions common to all DP-3 isoforms (Figure 7.1).
Although many cell lines have been tested, a cell line expressing detectable 
levels of DP-3 protein, via western blot, has still to be identified. Studies on hDP-2 
protein expression has shown that ML-1 cells, a human myeloid leukemia cell line, 
express sufficient human DP-2 protein to be immunoprecipitated. Polypeptides of 
110, 55, 48 and 43 kDa in size were immunopreciptated from metabolically labelled 
ML-1 cells using a human DP-2 specific antibody (Rogers et al. 1996). However, 
western blot analysis of MLl cells extracts with the panel of anti-peptide DP-3 
antisera did not reveal the detection of DP-3 proteins (data not shown).
7.3.3 DP-3 protein levels may be influenced by post-transcriptional regulation
DP-3 is regulated by RNA processing (Chapter 4) and by translational 
control (Chapter 5). Consequently, the levels of DP-3 proteins may be controlled at 
several levels. The translation of DP-3 appears to be regulated by the nature of the 
5’UTR, some of which inlribit translation (Chapter 5), therefore, some DP-3 
isoforms may be expressed at very low levels and consequently detection of these 
iso forms might be difficult.
7.3.4 DP-3 protein expression may be regulated by degradation
DP-3 protein levels could also be regulated at the level of degradation. If DP- 
3 proteins were to be rapidly degraded, the levels of protein required for detection by 
western blotting may be insufficient. Both E2F-1 and E2F-4 are unstable proteins
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and are targeted for degradation by the ubiquitin-proteosome pathway (Hateboer et 
aL, 1996; Hofmann et aL, 1996), It is therefore possible that DP-3 protein 
expression may also be regulated by degradation. However, despite the degradation 
of E2F-1 and 4, several antisera have been developed which recognise the 
endogenous proteins by western analysis (Beijersbergen et aL, 1994; Ginsberg et aL, 
1994; Vairo et aL, 1996; Leone et aL, 1998).
7.3.5 Regulation of DP-3 protein may impact on E2F activity
Analysis of E2F complexes by gel retaidation assays has shown that DP-1 is 
the major DP component of the E2F heterodimer (Bandara et aL, 1993). It is 
possible that DP-3 has a very specific role in the context of the E2F DNA binding 
activity and possibly is expressed imder certain physiological conditions, such as in 
early embryonal development or during specific cellular processes such as during 
particular stages of the mitotic cell cycle or during meiosis. Perhaps translation of 
DP-3 transcripts is induced under such conditions, and the protein is rapidly 
degraded once DP-3 has performed its biological functions.
Overall, these anti-peptide antisera specifically detected exogenously 
expressed DP-3 E+ isoforms in mammalian cells by western blotting and 
immunostaining analysis. However, the antisera did not appear to detect endogenous 
DP-3 proteins in either assay system, probably because DP-3 protein expression is 
likely to be regulated at several levels.
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Figure 7.1
DP-3 peptides
a) Diagrammatic representation of DP-3a and DP-36 protein isoforms.
b) The sequence of the E region of DP-3 a  and 6 compared with the homologous 
region of DP-1
c) The sequences of peptides 7.6 and 7.7. The sequence of the control peptide C is 
also shown.
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Figure 7.2
Analysis of a7.6 antisera
a) Whole cell extracts from COS-7 cells transfected with expression vectors 
encoding the DP-3 isoforms, were immunoblotted with two different a7.6 antisera, 
with and without competing peptide, as indicated. M denotes mock transfected cell 
extracts. The positions of DP-3a and DP-36 polypeptides are shown. Positions of 
molecular weight markers are shown in KDa. As a control for expression of DP-3 a, 
a7.2 antisera, was used, as indicated (lanes 17 and 18).
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Figure 7.3
Immunostaining analysis with a7.6 antisera
U20S cells were transfected with 2jag DP-3a and |3 expression vector. 
Immunostaining was performed with a7.6 antisera (rabbit 267), in the presence of 
either specific or non-specific peptide, with an anti-rabbit FITC-conjugated 
secondary antibody. DAPI staining of nuclei was performed, 
a) exogenous DP-3a + a7.6 + peptide C, b) exogenous DP-3a + a7.6 + peptide 7.6
c) exogenous DP-3a + a7.2, d), DAPI stain of a), e) DAPI stain of b), f) DAPI stain 
of c), g) exogenous DP-Sp + a7.6 + peptide C, h) exogenous DP-3p + a7.6 + 
peptide 7.6, i) exogenous DP-3a + a7.2, j) DAPI stain of g) k) DAPI stain of h), 1) 
DAPI stain of i), m) Mock transfected +a7.6 + peptide C, n) Mock transfected 
+a7.6 + peptide 7.6, o) Mock transfected +a7.2, p) DAPI stain of m), q) DAPI stain 
of n), r) DAPI stain of o).
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Figure 7.4
Analysis of a7.7 antisera
Whole cell extracts from COS-7 cells transfected with DP-3 expression vectors as 
indicated, were immunoblotted with a7.7 antisera, with and without competing 
peptide. M denotes mock transfected cell extracts. The positions of DP-3 a  and DP- 
36 polypeptides are shown. Positions of molecular weight markers are shovm in 
KDa. Control immunoblotting with DP-3 a7.2 antisera, with and without competing 
peptide was included (lanes 9 and 10).
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Chapter 8 
General Discussion
8.1 Implications of DP-3 alternative splicing
The isolation and characterisation of the murine DP-3 gene revealed the exon 
structure of the DP-3 gene which when compared to the cDNA sequences known for 
this gene suggested complex post-transcriptional regulation. Analysis of DP-3 
mRNA sequences has suggested several splice variants existed. Variations in the 
open reading frame, combined with several different 5’UTR sequences and two 
possible initiating methionines, predicted four different protein isoforms, DP-3 
a , p,Y and 6 (Ormondroyd et a l, 1995).
The investigation of the genomic E region revealed that E+ DP-3 mRNAs 
arise via alternative splicing of a discrete 48 bp exon. The E region has been shown 
to form part of a NLS that can recruit E2F-4 and 5 to the nucleus and hence this 
splicing event has potentially important implications for E2F hetero dimer function 
(de la Luna et ah, 1996). Additionally, the mechanism of heterodimer localisation to 
the nucleus can have different functional consequences on the cell cycle, as nuclear 
localisation of E2F-5 by co-expression of an E+ DP-3 resulted in promotion of cell 
cycle progression and growth, whereas localisation via pocket protein expression 
resulted in growth arrest (Alien et ah, 1997). The localisation of proteins, in 
particular transcription factors, to the nucleus is often regulated (Vandromme et a l,
1996). However most examples involve regulation at the protein level, either by 
interaction with other proteins that either promote or prevent nuclear accumulation 
or by modifications such as phosphorylation, an example is the localisation of the 
transcription factor NFkB. NFkB is retained in the cytoplasm and target genes are 
repressed, when bound to an inhibitor protein, 1-kB. NFkB is only transported to the 
nucleus when 1-kB is phosphorylated in response to signalling from mitogens and 
cytokines (Vandromme et ah, 1996). The regulation of nuclear localisation by 
alternative splicing of part of a nuclear localisation signal is therefore rare.
The alternative splicing of the E region of DP-3 transcripts, combined with 
translational regulation via the 5’UTRs may serve to allow fine control of both cell
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cycle progression and the localisation of E2F family members. The regulation of 
translational, coupled with protein degradation processes, enables cells to rapidly 
alter levels of specific proteins, by both degrading existing proteins and translating 
new proteins. It may therefore be possible that when required the translation of E+ 
DP-3 transcripts is upregulated and E+ DP-3 isoforms are expressed, whilst at the 
same time E- DP-3s are degraded. Alternatively, by regulating transcription and 
splicing, E+ or E- transcripts are transcribed and translated as and when required. 
However, the ratios of E+ and E- DP-3 transcripts analysed by RNase protection 
suggested equal levels of E+ and E- transcripts, implying that either or even both 
mechanisms could have a role in regulating DP-3 and E2F cellular location.
The subnuclear location of the Wilm’s tumour protein WTl is regulated by 
alternative splicing (Larsson et a l, 1995). WTl is a tumour suppressor protein 
involved in the formation of Wilm’s tumour in the kidney and also in the generation 
of the Denys Drash and Frasier syndromes (Hastie, 1994; Barbaux et aL, 1997; 
Little and Wells, 1997). WTl is considered to be a transcription factor that contains 
four Ki’uppel-type zinc fingers and has been implicated in growth regulation. 
Alternative splicing of WTl results in numerous isoforms arising from the insertion 
of thiee amino acids (KTS) between the third and fourth zinc fingers and alternative 
splicing of the first exon. Additionally there are two alternative translational start 
sites and the pre-mRNA undergoes editing (Sharma et ah, 1994; Breuning and 
Pelletier, 1996). There are therefore several striking similarities between DP-3 and 
W Tl. Analysis of the subcellulai- localisation of WTl revealed that the localisation 
of the KTS- isoforms correlated with transcription factors, whereas the KTS+ 
isoforms associate with splicosomes and directly interact with U2AF65, a 
component of the splicing machinery (Larsson et al., 1995; Davies et ah, 1998). 
Such data suggested that not all forms of WTl functions as transcription factors. It is 
interesting to note that imbalance between the different isoforms is thought to be the 
basis of Frasier syndrome. This example suggests that although DP-3 isoforms can 
all bind E2F paitners and bind to DNA, they do not necessarily have to have similar 
roles in cells (Ormondroyd et ah, 1995). Isoforms of WTl which vary only by the 
insertion of thi'ee amino acids are implied to have very different and important roles 
in cells and in development.
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The DP-3 Y isoform differs from the other DP-3 isoforms due to the insertion 
of a single glutamine (Q) residue between the DNA binding and dimérisation 
domains (Ormondroyd et ah, 1995). Analysis of the DP-3 gene revealed that this 
variation arises from alternative seleetion of two adjacent 3’ splice acceptor sites in 
the intron between exons 8 and 9. This selection might arise from random selection 
between these two sites (named slippage) or a regulated process. Indeed, RNase 
protection analysis revealed that approximately 20% of DP-3 RNAs contain this 
glutamine residue. It is likely that if this process was a random event approximately 
equal amounts of Q+ and Q- RNAs might be predicted.
Examination of the amino acid sequence in the region of the insertion 
revealed theroretical phosphorylation sites. Therefore, this event may be regulated 
and suggests that DP-3 proteins could be regulated by post-translational 
modifications such as phosphorylation at this site. Insertion of the glutamine residue 
destroys a putative casein kinase II phosphorylation site and creates a hypothetical 
DNA PK site (Figure 8.1) (Bannister et aL, 1993; O’Reilly et aL, 1997). The 
implications of such regulation on E2F function have so far not been investigated. 
However, the regulation DP-3 y by DNA-PK may have implications in processes 
such as the cellular response to DNA damage. Additionally, the influence of p53 on 
the translational regulation of DP-3 RNAs via the 5’UTRs may also prove to be 
important; since the analysis suggested that translation of DP-3y is reduced when 
p53 is expressed. Thus, under conditions of DNA damage it may be necessary to 
reduce E2F activity to aid cell cycle arrest prior to DNA repair. It is possible that 
phosphorylation at the glutamine region by DNA-PK may act to reduce DP-3y 
activity or perhaps target it for degradation.
The insertion or exclusion of a single glutamine has been observed in other 
genes, such as the human brca 1 gene; two postions have been noted in which this 
insertion can occur. Analysis of the genomic organisation revealed that like DP-3, 
these insertions occur at exon/intron junctions (Miki et aL, 1994). The functional 
relevence of this event in BRCA 1 protein has not been determined. Likewise, the 
functional relevence of the insertion of a single glutamine residue in the mouse 
obese gene has also not been resolved (Zhang et aL, 1994).
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8.2 DP-3 RNA expression, regulation and functions
The 5’ regulatory regions of the DP-3 gene were not isolated and hence 
conclusions relating to the transcriptional regulation of DP-3 cannot be made. 
However, extensive analysis of RNA expression patterns via northern blotting 
revealed several transcripts of differing mobility, assumed to be alternatively spliced 
variants. Notably, differences in DP-3 and DP-1 RNA expression in adult mouse 
tissues were observed, suggesting that different tissues may have different E2F 
requirements.
The analysis of E2F-1 and 5 null mice revealed tissue specific abnormalities, 
suggesting particular E2F family members may be important for normal fonction in 
some tissues (Field et aL, 1996; Yamasaki et aL, 1996; Lindeman et aL, 1998). 
Analysis of E2F-5 mRNA levels in normal tissues showed that transcripts were 
highly expressed in some tissues, including the choroid plexus, skin and bowel, 
however E2F-5-null mice exhibited defects only in the choroid plexus, the other 
tissues appeared normal (Lindeman et aL, 1998). Such data implies that there may 
not be a simple correlation between level of mRNA and function in a particular cell 
type. Furthermore, although significant homology exists between the E2F family 
members, this gene knockout data indicates that E2F family members do not have 
degenerate roles. It is possible therefore that DP-1 and DP-3 have different roles and 
that DP-3 may have a specific, as yet undefined role, perhaps during specific cellular 
conditions such as the response to stress, DNA damage, apoptosis, at specific stages 
of the mitotic cell eycle or perhaps during meiosis. All of these are possible and 
further experiments including the generation and analysis of a DP-3 null mouse, are 
required to define the role of DP-3 in cells.
The intracellular location of specific mRNAs can vary in some cells and 
since mRNA are the templates for the translation of proteins; the localisation of 
mRNAs represents another level of regulation. RNA localisation enables the 
accumulation of high levels of proteins in specific locations and additionally, the 
regulation of the mRNA represents a more efficient way of localising proteins, 
rather than by protein tai’geting. For example, analysis of (3-actin mRNA revealed 
localisation to the leading edge of migrating fibroblasts, the site in the cell where (3- 
actin protein is required (Lawrence and Singer, 1986).
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Many localised RNAs exist as complexes with components of the translation 
machinery, and are thought to be transported in a translationally repressed state, 
suggesting that translation only occurs at the specified location. The localisation and 
translation of specific mRNAs also prevents the expression of proteins in 
inappropriate regions of the cell, an example being myelin basic protein (MBP). 
MBP interacts strongly with plasma membranes, causing compaction of the 
membrane. MBP mRNA is therefore localised and translated where it is needed, 
preventing damage to other cellular membranes (Trapp et aL, 1987). Analysis of 
localised RNAs revealed cw-acting signals, named zipcodes, which target RNAs to 
different cellular domains (Oleynikov and Singer, 1998). The RNA zipcodes are 
usually situated in the 3’UTR, although they can occur in the 5’UTR of transcripts 
where they are predicted to have strong secondary structure and may be linked to 
sequences that regulate translation, (St. Johnston, 1995; Hazelrigg, 1998). The 
Drosophila bicoid mRNA is an example, as it is localised to the anterior pole of the 
developing oocyte via c/.y-acting elements in the 3’UTR and furthermore, trans- 
acting faetors are involved in this localisation (Oleynikov and Singer, 1998).
DP-3 RNAs have a complex structure, as several 5’UTRs exist and these 
influence translation. The 5’UTRs of DP-3 may contain cA-acting elements that 
target the different mRNAs to different cellular destinations and novel proteins may 
bind these sequences and regulate localisation and/or translation. Alternative 
3’UTRs have been noted for DP-3 and hDP-2 mRNA (Zhang and Chellapan, 1995; 
unpublished data) and the influence of these 3’UTRs has yet to be investigated. The 
translation of Drosophila oskar mRNA is localisation-dependant and requires a 
functional interaction between elements in the 5’ and 3’UTRs. Once oskar RNA is 
localised to the posterior pole of the oocyte, translation is derepressed by a process 
requiring an element in the 5’UTR, a derepressor element. Activation of oskar 
translation requires an interaction between the derepressor element of the 5’UTR 
and the repressor element of the 3’UTR and additionally, RNA binding proteins are 
also thought to be involved (Gunkel et aL, 1998). Perhaps the different 5’UTRs or 
3’UTRs of DP-3 mRNA contain zipcodes or other localisation elements. The two 
alternative 3’UTRs are largely uncharacterised and at present it is not known 
whether these contain potential localisation elements.
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It is conceivable that the multiple DP-3 RNAs are located in specific regions 
of the cell and that fonction of the DP-3 protein isoforms is related to cellular 
location. In the developing nervous system of Drosophila melanogaster, neuroblasts 
undergo an asymmetric division into neuroblasts and ganglion mother eells (GMC), 
the localisation of the prospero transcription factor and prospero mRNA to the GMC 
is important in the determination of cell fate during this cell division. Staufen, a 
double stranded RNA binding protein is required for localisation of prospero mRNA 
and prospero protein to the GMC, after which prospero enters the nucleus 
(Oleynikov and Singer, 1998). Analysis of DP-3 RNA suggested that most DP-3 
transcripts are cytoplasmic, but DP-3 RNAs may have specific locations within the 
cytosol. To date, the analysis of endogenous DP-3 protein by immunostaining has 
been unsuccessful. Analysis of exogenously expressed DP-3 protein isoforms 
revealed E+ DP-3s (a  and ô) to be nuclear, as would be expected for a member of a 
transcription factor family, and that the E- DP-3s ((3 and y) to be cytoplasmic (de la 
Luna et aL, 1996). However these proteins were translated from transcripts that do 
not contain UTR sequences and therefore RNA localisation-dependent expression 
patterns would not be observed.
8,3 DP-3 translation maybe regulated by RNA/protein interactions
There are several mechanisms for the regulated translation of mRNA in 
eukaryotes (Kozak, 1992; Pain, 1996). Many of these result in modification of 
translation factors that have global impact on translation in the cell. However, a few 
instances of regulation of specific mRNAs do exist. In mammalian cells the 
synthesis of ferritin is regulated by the binding of a repressor protein, the iron 
regulatory factor (IRF) to the iron response element (IRE) in the 5’UTR of the 
ferritin mRNA, repressing ferritin translation. An increase in cellular iron levels 
causes a change in the affinity or availability of the IRF for the IRE and translation 
is de-repressed (Melefors and Hentze, 1993). In contrast few protein activators of 
translation have been characterised in eukaryotes, although activators of translation 
have been described for viral translation these aie not thought to be via a direct 
mechanism (Kozak, 1992). It is possible that DP-3 expression could be regulated by 
RNA/protein interactions. DP-3 5’UTRs ai'e translated differently in vivo, but in vitro 
translation is umegulated suggesting that specific cellular factors may be required
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for the differences in translation obsei-ved in transfected mammalian cells (Chapter 
5). Possibly, repressor proteins bind to type II and III 5’UTR and inhibit translation, 
these proteins may be unable to bind to type I or IV RNA. Conversely, activators 
may bind to type I 5’UTR and not to the other 5’UTRs. Therefore, the variation in 
the level of type IV translation could be via altered affinity of a repressor or 
activator protein for type IV 5’UTR, perhaps in response to growth signals. The 
regulation of translation by RNA/protein interactions provides a system whereby a 
rapid translational response to changes in cellular enviromnent can occur.
The observation that p53 can influence the translation of DP-3 type IV 
transcripts, coupled with the evidence that p53 can bind it RNA in vitro (Mosner et 
aL, 1995), suggests that p53 may influence translation of DP-3 directly (Chapter 6; 
Section 8.5). In addition, other proteins may also interact with DP-3 RNA and 
influence translation.
8.4 The potential regulation of DP-3 translation by reinitiation
Translation can be regulated by reinitiation. The presence of uORFs and 
uAUG in the 5’UTR of an mRNA can influence translation at downstream 
methionines. Usually uORFs have a suppressive influence on translation of a 
downstream cistron, although this suppression of translation can be regulated 
(Geballe and Morris, 1994), An example of an mRNA with suppressive uORFs is 
the 5’UTR of yeast GCN4 mRNA, which contains four short uORFs. GCN4 is a 
transcription factor required for amino acid biosynthesis. The suppressive influence 
of the uORFs is reduced dui'ing amino acid starvation and GCN4 translation is up 
regulated. Many cells limit the overall level of translation during nutrient 
deprivation by phosphorylating the a  subunit of eukaryotic initiation factor 2 (eIF2). 
The phosphorylation of eIF2 has been shown to reduce the suppressive influence of 
the uORFs of GCN4 mRNA, and GCN4 is translated even though the overall level 
of translation has been reduced (Hinnebusch, 1996). uORFs can also have a positive 
effect on downstream translation. Indeed it is uORFl of GCN4, which under low 
nutrient conditions enables the ribosomes to bypass the strongly repressive uORF4 
and translate GCN4 protein (Hinnebusch, 1996).
DP-3 5’UTRs contain uORFs that may influence translation. Type I, II and 
IV transcripts all contain M l and therefore the translation of type I and IV
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transcripts may result in translation of short peptides which terminate before M2, 
allowing reinitiation at M2 and translation of DP-3 M2 products. The distance 
between the stop signal of these short peptides and the uAUG of M2 is different in 
type I and type IV and this intercistronic distance may influence the likelihood of 
reinitiation at M2 and could account for the differences observed in translation from 
transcripts with these 5’UTRs. It is possible therefore that the regulation of splicing 
of the 5’UTRs may determine the probability of reinitiation at M2.
The 5’UTR of DP-3 type II contains two in frame initiation signals, Ml and 
M2 and since type II 5’UTR is only associated with an E+ Q- ORE, translation at 
M l or M2 would result in DP-3 a  or ô respectively. The differential use of in frame 
initiation codons has been noted in several genes including the mRNA of LAP 
protein, a liver-emiched transcription factor. uAUG in-frame codons in the 5’UTR 
of the lap mRNA result in synthesis of LAP protein and an inhibitor of LAP called 
LIP (Descombes and Schibler, 1991). A switch in the use of AUG codons during 
development produces a change in the ratio of LAP to LIP, causing an alteration in 
transcription. Similarly, it is possible that initiation at Ml and M2 of type II may 
also be regulated in particular tissues or in response to changes in cell conditions, 
such as stress, and could possibly have dramatic influence on E2F hetero dimer 
formation and influence E2F-dependent gene expression.
The N terminus of DP-3 a  has been shown to interact with a DP interacting 
protein (DIP), a POZ domain containing protein that influences the cell cycle, 
additionally DP-36, which lacks the N terminus of DP-3 a , also weakly interacts 
with DIP (de la Luna et aL, 1999). Consequently, it is possible that the interaction 
between DP-3 isoforms and DIP could be influenced by translational initiation, 
selection of M2 of a type II 5’UTR transcript would result in translation of DP- 
36 which only weakly interacts with DIP. Transfection data has suggested that 
translational initiation occurs at M l rather than at M2, however it may be possible 
that a switch to translation initiation at M2 may occur under as yet undefined 
cellular conditions and that this could influence the interaction of DP-3 and DIP and 
the functional outcome.
The translational regulation of DP-3 expression via the 5’UTRs may 
therefore influence E2F formation and function and additionally interactions with
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other cellular proteins. Translational regulation of protein expression is often 
associated with genes that are required rapidly under specific conditions, such as 
nutrient deprivation. Additionally, many genes with a role in cell growth or proto- 
oncogenes often have elements such as uORFs and uAUGs within the 5’UTR and 
also may have a poor initiator context or highly structured 5’UTRs and that 
expression is tightly regulated (Kozak, 1991, Pain, 1996). Likewise, it is therefore 
possible that DP-3 is required under specific conditions and that protein expression 
is also tightly controlled under normal cellular conditions. As discussed (Chapter 6; 
Section 8.5), the potential influence of p53 on DP-3 translation may provide an 
indication of the conditions under which DP-3 is required and ultimately, its 
physiological role.
8.5 The role of DP-3 during activation of p53
The p53 tumour suppresser protein is an important regulator of cellular 
proliferation and is induced in response to many different stimuli, including DNA 
damage and other genotoxic stress (Ko and Prives, 1996). Activation of p53 results 
in cell cycle arrest and in some cases cell death by apoptosis (Ko and Prives, 1996). 
The data presented suggests that p53 may influence the expression of DP-3 isoforms 
via the different 5’UTRs of DP-3 transcripts (Chapter 6). This data revealed the 
specific translational inhibition of transcripts with a type IV 5’UTR. DP-3 
transcripts with a type IV 5’UTR have only been observed in association with an M2 
E- Q+ ORE (DP-3y). It is interesting to note that the DP-3y isoform also contains a 
putative DNA-PK site, providing a second possible link with DNA damage. It can 
be speculated that DP-3y may be actively targeted during the cellular response to 
DNA damage, via a translational mechanism influenced by p53 and also by 
phosphorylation by DNA-PK (Figure 8.3). Since p53 inhibits translation of DP-3 
type IV transcripts, it is possible that phosphorylation by DNA-PK could 
correspondingly, have a negative influence on DP-3y function. Phosphorylation by 
DNA-PK in the glutamine region may prevent dimérisation with E2F partners or 
interaction with other cellular factors or perhaps influences transcription functions 
(Figure 8.3). Alternatively, phosphorylation by DNA-PK may act as a signal for 
rapid degradation of DP-3y protein.
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The aetivation of p53 results in cell cycle arrest and sometimes apoptosis, the 
inliibition of translation by p53 implies that DP-3y may have a role in promoting 
cell cycle progression and need to be rapidly inactivated to allow cell cycle arrest 
and DNA repair. Although at present one can only speculate the role of each 
different DP-3 isoform, this data does suggest a link between the DP-3y isoform and 
activation of the p53 pathway during DNA damage and the targeting of this 
particular isoform may be important in some circumstances. Additionally, this 
isoform may be targeted at two levels; p53 inhibits the translation of new DP-3y 
protein and DNA-PK may alter DP-3y function by post-translational modification. If 
both events do indeed occur in vivo, such targeting would imply an important role 
for DP-3y in growth regulation.
In contrast to type IV transcripts, this study suggested that p53 has no effect 
on the translation of the type I 5 ’UTR and that the other DP-3 isoforms may have 
different or even opposing roles during p53 activation, DNA damage or the cell 
cycle. The translation of type III transcripts, which correspond to an M2 E- Q- ORF 
(DP-3P), was enhanced in the presence of p53, suggesting a role during DNA 
damage and repair and perhaps in cell cycle arrest. It is conceivable that DP-3P has a 
negative influence on E2F transcription, perhaps forming repressive E2F 
heterodimers that cannot bind to DNA or activate transcription (Figure 8.2). 
Moreover, the formation of heterodimers such as E2F-5/DP-3P, ar e not able to enter 
the nucleus without binding to pocket proteins and are observed to have a growth 
suppressing function (Allen et aL, 1997, Figure 1.10). It is also possible that DP-3p 
may be important in the activation of genes involved with processes such as DNA 
repair.
It is notable that the only difference between DP-p and DP-3y is the presence 
of the extra glutamine residue in DP-3y that destroys the putative casein kinase II 
phosphorylation site and creates a theoretical DNA-PK site. The potential for post- 
translational modification of DP-3 isoforms by two different kinases and the many 
implications for regulation of protein activity by phosphorylation, combined with 
the likely translational regulation by an important tumour suppresser protein, 
emphasises the potential functional importance of DP-3 in regulating cell growth.
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8.6 A second DP family member, why?
Analysis of the genomic organisation of murine DP-1 and DP-3 revealed 
striking similarities in exon organisation, suggesting a common evolutionary origin 
for these genes (Chapter 3). Analysis has shown that DP-1 is the major DP 
component of the E2F hetero dimer in cells and that DP-3 is difficult to detect in 
cells (Bandara et ah, 1993; Ormondroyd et ah, 1995; Chapter 7). Additionally, other 
organisms such as flies function with a single DP protein, which although highly 
related to mammalian DP proteins performs functions similar to DP-1 (Dynlacht et 
aL, 1994; Hao et aL, 1995). This suggests conservation of not only the E2F 
regulatory pathway, but also the functions of DP-1 in different species. Hence, it can 
be speculated that a gene encoding a DP-1-like protein has been conserved tluough 
evolution and that via duplication and subsequent functional divergence of this first 
gene, a second DP protein evolved and was maintained in the genome. The 
differences between DP-1 and DP-3 might suggest that they may have different roles 
in cells, but perhaps maintain some level of functional degeneracy. Further analysis 
of the differences in function of DP-1 and DP-3 is required to answer these 
questions.
Many genes are found to be members of gene families with similar 
characteristics, some have distinct functions but family members can also have 
related functions. An example is the p53 gene family, which has several similarities 
with the DP family; indeed both p53 and DP-1 are important components of growth 
control pathways. RNA analysis of the p53 family members, p73 and p51 revealed 
obvious similarities with DP-3; multiple transcripts were observed, arising from 
alternative splicing and resulting in different protein isoforms (Ormondroyd et aL, 
1995; Kaghad et aL, 1997; Kaelin, 1999). Additionally, comparison of the p53 and 
p73 genes, like those presented for DP-1 and DP-3, revealed similar genomic 
organisations and suggested a eommon evolutionaiy origin (Kaghad et aL, 1997; 
Chapter 3). Both DP-1 and p53, are ubiquitously expressed, however p73 and p51, 
like DP-3, exhibit tissue specific distribution of both RNA and protein (Ormondroyd 
et aL, 1995; Kaelin, 1999; Chapter 4). Functional similarities may exist for family 
members; in vitro assays have shown that like p53, p73 and p51 ean bind to 
canonical p53 DNA binding sites, likewise, all DP-3 isoforms form heterodimers 
with E2F family members and bind to E2F sites (Ormondroyd et aL, 1995; Kaelin,
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1999). Further analysis of p73 and p51 has suggested a different role in cells from 
that of p53 and importantly, p73 and p51 may not act as tumour suppressers (Kaelin, 
1999). Similarly, DP-3 does not appear to have the same functions as DP-1 and may 
also function in a tissue specific manner. Therefore, clear similarities exist between 
these two families of proteins. The obvious question is why have these second 
family members evolved? p53 has important functions in cells, however, the p53 
family members are not thought to have overlapping functions. Nevertheless, 
analysis of p53-like DNA binding activities purified from p53-null cells have 
suggested that different family members may activate different p53-responsive 
promoters (Kaelin, 1999). It is also likely therefore, that p73 and p51 have evolved 
to have a more specialised function. The same may be tme for DP family members; 
DP-1 and each of the DP-3 isoforms may modulate the activity of different E2F- 
responsive promoters, perhaps during different cellular conditions, such as during 
the cell cycle or conditions of stress. Moreover, different E2F family members may 
further influence DP activity and adding another level of complexity to the 
regulation of E2F function.
Comparisons of DP-3 with other genes have also suggested that distinct 
isoforms may have a non-transcriptional role, as observed for particular WTl 
isoforms. Some WTl isoforms are thought to have a transcriptional role and others 
have been shown to interact with components of the splicing machinery and have a 
non-transcriptional role (Larsson et aL, 1995; Davies et aL, 1998). It is therefore 
possible that DP-3 isoforms may have very distinct, as yet unknown funetions in 
cells.
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8.7 Future Work
Although at present no definite functions have been assigned for DP-3 
isoforms, the data presented begins to provide some direction for future research.
8.7.1 Translational regulation of DP-3 expression
Further work is required to confirm the results presented (Chapters 5 and 6). 
Additionally, an investigation into the mechanism of translational regulation is 
required. Preliminary RNA binding assays suggested that cellular proteins may bind 
to the 5’UTRs of DP-3 (data not shown), however these experiments must repeated 
and extended before firm conclusions can be made. If protein factors are shown to 
directly interact with DP-3 5’UTR, several techniques are currently available to 
clone RNA binding proteins allowing further examination of the regulation of DP-3 
expression (Harada et ah, 1996; Putz et ah, 1996; Wang et ah, 1996; Sagesser et aL,
1997). Additionally, RNA binding assays can be employed to determine whether 
p53 directly interacts with DP-3 5’UTRs. Further experiments are required to 
investigate both the mode and functional importance of the translational regulation 
ofD P-3byp53.
8.7.2 The generation of DP-3 null mice
The generation of both DP-1 and DP-3-null mice and comparisons of the 
phenotypes would reveal valuable new data relating both to the role of DP-3 in vivo 
and the functional differences between DP-1 and DP-3. The isolation of the DP-3 
gene enables the construction of a DP-3 targeting construct and in theory, a DP-3 
null mouse could be generated. In addition, mice could be generated that can only 
express particular DP-3 isoforms, such as E+ or E- isoforms, enabling the study of 
the influence of DP-3 on subcellular localisation of E2F hetero dimers in vivo and 
perhaps some indication of the roles of the individual DP-3 isoforms may be 
obtained.
It is possible that the loss of DP-1 or DP-3 may result in a lethal phenotype. 
In such a case, the generation of mice in which the inactivation of the DP-3 gene can 
be induced in different cell types could be attempted. The use of the C ï g I I o x P  
recombination system would enable the homozygous deletion of DP-3 in specific 
cell types only (Gu, et aL, 1994; Kuhn, et aL, 1995; Rossant and Nagy, 1995). In
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this system, the gene targeting construct would contain the DP-3 gene flanked by 
recombination sites {loxP sites). Mice containing the DP-3 gene with the 
recombination sites are generated and then crossed with mice expressing the Cre 
recombinase under the control of cell type specific promoters. Thus, the deletion of 
the DP-3 gene can be restricted to the cells expressing Cre only. Using this system it 
may be possible to study the function of DP-3 in specific tissues or during 
development.
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Figure 8.1
The insertion of a glutamine residue disrupts a potential DP-3 phoshorylation 
site
a) The nucleotide and amino acid sequence of DP-3 a , (3 and ô in the region of the 
glutamine insertion. The casein kinase II consensus sequence is given and the 
corresponding DP-3 residues are highlighted.
b) The nucleotide and amino aeid sequence of DP-3y in the same region as a), 
showing the DNA-PK phosphorylation consensus sequence and the corresponding 
DP-3 residues. The insertion of a glutamine residue in the DP-3 y isoform disrupts 
the potential casein kinase II phosphorylation site and creates a theoretical DNA-PK 
phosphorylation site.
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Figure 8.2
The composition of E2F heterodimers may influence E2F activity
The formation of E2F heterodimers composed of different E2F and DP partners may 
influence E2F transcriptional activity. The creation of E2F complexes may result in 
E2F that can bind to E2F sites and initiate E2F-dependent transcription. 
Alternatively, some combinations of E2F family members with DP family members 
may result in the formation of E2F heterodimers that can bind to DNA but cannot 
activate transcription and thereby block E2F-dependent transcription. The formation 
of complexes that cannot bind to DNA prevents the activation of E2F target genes 
and may sequester E2F components and prevent the creation of other E2F 
complexes.
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Figure 8.3
Summary of the potential influence of p53 on DP-3
A schematic representation of how p53 may influence the expression of DP-3 
isoforms via the 5'UTRs. p53 influences the translation of DP-3 type IV 5'UTR 
transcripts. This influence may be exerted through a direct RNA/protein interaction. 
Alternatively, an indirect mechnism may result in the effects observed. p53 may 
interact with other proteins to exert its effects on type IV translation. p53 has several 
transcriptional targets and one of these may influence translation of DP-3. 
Additionally. Q+ DP-3 isoforms contain a DNA-PK site and may therefore be 
modified by DNA-PK in a DNA damage dependent manner. DP-3 isoforms are 
therefore potentially targeted by two members of the DNA damage pathway. Such 
targeting could result in an alteration in the levels of DP-3 isoforms and this may 
modify the levels of E2F heterodimers in the cell. A change in E2F heterodimers 
formation may in turn alter E2F activity in the cell and modify the expression of 
target genes.
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